Can These 4 MedTech Stocks Hit Targets This Earnings Season?
- Here is a sneak peek into how four MedTech bigshots, BSX, TMO, ALGN and EW, are expected to fare in their second-quarter results, slated to be released tomorrow.
- 07/23/2024
|
Watchman In Focus As Boston Scientific Reports Its Q2
- Boston Scientific (NYSE: BSX) is scheduled to report its Q2 2024 results on Wednesday, July 24. We expect the company to report revenues and earnings in line with the consensus estimates.
- 07/23/2024
|
HAE vs. BSX: Which Stock Is the Better Value Option?
- Investors looking for stocks in the Medical - Products sector might want to consider either Haemonetics (HAE) or Boston Scientific (BSX). But which of these two stocks offers value investors a better bang for their buck right now?
- 07/23/2024
|
HAE or BSX: Which Is the Better Value Stock Right Now?
- Investors interested in Medical - Products stocks are likely familiar with Haemonetics (HAE) and Boston Scientific (BSX). But which of these two stocks presents investors with the better value opportunity right now?
- 07/22/2024
|
Boston Scientific (BSX) Banks on Global Expansion, Innovation
- In EMEA, Boston Scientific (BSX) is successfully expanding its base, banking on its diverse portfolio, new launches and commercial execution with healthy underlying market demand.
- 07/22/2024
|
7 Robotics Stocks That Could Grow Your Wealth
- Robotics stocks are a good investment as the industry is rapidly progressing. Robotics stocks have great potential to increase their revenues in the future due to the increased usage of robots in different industries due to technological developments.
- 07/22/2024
|
Boston Scientific Q2 Earnings Preview: Can The Rally Continue?
- Boston Scientific is set to report Q2 earnings on July 24th. Growth is benefiting from the launch of recent FDA-approved medtech products. We highlight the themes to watch into the second half of the year, including an eye on what has become a lofty valuation.
- 07/17/2024
|
Boston Scientific (BSX) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
- Boston Scientific (BSX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- 07/17/2024
|
Are Medical Stocks Lagging Boston Scientific (BSX) This Year?
- Here is how Boston Scientific (BSX) and Novavax (NVAX) have performed compared to their sector so far this year.
- 07/17/2024
|
Will WATCHMAN Sales Aid Boston Scientific's (BSX) Q2 Earnings?
- In EMEA, Boston Scientific (BSX) is expected to have registered growth within structural heart, including Transcatheter aortic valve replacement, WATCHMAN and other interventional cardiology therapies.
- 07/16/2024
|
Boston Scientific (BSX) Exceeds Market Returns: Some Facts to Consider
- Boston Scientific (BSX) reachead $78.02 at the closing of the latest trading day, reflecting a +0.42% change compared to its last close.
- 07/15/2024
|
Boston Scientific Announces Conference Call Discussing Second Quarter 2024 Results
- MARLBOROUGH, Mass. , July 1, 2024 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) will webcast its conference call discussing financial results and business highlights for the second quarter ended June 30, 2024, on Wednesday, July 24, 2024, at 8:00 a.m.
- 07/01/2024
|
How Does The Current Fall In Abbott Stock Compare With The One During 2008 Recession?
- Abbott stock (NYSE: ABT) currently trades at $105 per share, 25% below its peak level of over $140 seen in December 2021. In comparison, its peer Boston Scientific stock (NYSE: BSX) has seen a nearly 90% rise over this period.
- 07/01/2024
|
Boston Scientific (BSX) Ascends While Market Falls: Some Facts to Note
- In the latest trading session, Boston Scientific (BSX) closed at $77.01, marking a +0.01% move from the previous day.
- 06/28/2024
|
7 Biotech Stocks to Boost Your Portfolio to Peak Health
- While innovations such as artificial intelligence have become all the rage, there's another type of technology – biotechnology – that deserves careful consideration for your portfolio. Indeed, if you haven't considered the sector, it's really time to focus on biotech stocks.
- 06/26/2024
|
Boston Scientific (BSX) DBS Programming Software Gets CE Mark
- Boston Scientific (BSX) secures CE Mark for the DBS image-guided programming software, Vercise Neural Navigator 5.
- 06/26/2024
|
3 Record-Breaking Stocks With More Room to Run
- U.S. markets continued to set all-time highs in June, with record-breaking stocks boosting major indices to new records last week. Even the traditionally slower DJIA logged two consecutive record peaks in two days.
- 06/25/2024
|
Why Boston Scientific (BSX) Dipped More Than Broader Market Today
- Boston Scientific (BSX) closed the most recent trading day at $76.71, moving -1.29% from the previous trading session.
- 06/24/2024
|
SILK ROAD MEDICAL INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Silk Road Medical, Inc. - SILK
- NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Silk Road Medical, Inc. (NasdaqGS: SILK) to Boston Scientific Corporation (NYSE: BSX). Under the terms of the proposed transaction, shareholders of Silk Road will receive $27.50 in cash for each share of Silk Road that they own. KSF is seeking to determine whether this consideration and the process that led to.
- 06/19/2024
|
Brokers Suggest Investing in Boston Scientific (BSX): Read This Before Placing a Bet
- The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side) analysts changing their ratings often affect a stock's price.
- 06/19/2024
|
Boston Scientific (BSX) to Buy Silk Road, Boost Cardiology
- This acquisition is expected to enhance Boston Scientific's (BSX) market position and revenue streams in North America and Europe.
- 06/19/2024
|
4 Medical Product Stocks to Buy From a Recovering Industry
- Despite the ongoing macro headwinds, recovering demand for medical procedures and cost-cutting initiatives should support the Zacks Medical-Products industry. BSX, RMD, LNTH and HAE are well-poised to gain from the favorable factors.
- 06/19/2024
|
Boston Scientific (BSX) Rises Yet Lags Behind Market: Some Facts Worth Knowing
- The latest trading day saw Boston Scientific (BSX) settling at $76.31, representing a +0.16% change from its previous close.
- 06/18/2024
|
ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of Silk Road Medical, Inc.
- NEW YORK , June 18, 2024 /PRNewswire/ -- Rowley Law PLLC is investigating potential securities law violations by Silk Road Medical, Inc. (NASDAQ: SILK) and its board of directors concerning the proposed acquisition of the company by Boston Scientific Corporation (NYSE: BSX). Stockholders will receive $27.50 for each share of Silk Road Medical stock that they hold.
- 06/18/2024
|
Boston Scientific Buys Silk Road Medical for $1.26 Billion
- Shares of Silk Road Medical (SILK) soared in intraday trading Tuesday after Boston Scientific (BSX) announced it was buying the medical device maker for about $1.26 billion.
- 06/18/2024
|
Boston Scientific Adds Stroke Prevention To Vascular Portfolio Via Silk Road Medical's $1.3B Deal
- Tuesday, Boston Scientific Corporation BSX agreed to acquire Silk Road Medical Inc SILK for $27.50 in cash per share, representing an equity value of approximately $1.26 billion.
- 06/18/2024
|
Breaking News: Is Silk Road Medical's $27.50 Per Share Sale Price a Fair Deal? Johnson Fistel, LLP Investigates Deal Terms
- SAN DIEGO, June 18, 2024 (GLOBE NEWSWIRE) -- Johnson Fistel, LLP, a leading shareholder rights law firm, announced today that it has initiated an investigation into the board members of Silk Road Medical, Inc. (NASDAQ: SILK) concerning potential breaches of fiduciary duties related to the proposed sale of the Company to Boston Scientific (NYSE:BSX).
- 06/18/2024
|
Silk Road Medical Stock Soars. It's Being Acquired by Boston Scientific.
- Boston Scientific will pay $27.50 a share, or $1.16 billion, for Silk Road Medical.
- 06/18/2024
|
Boston Scientific to buy Silk Road Medical in $1.16 billion deal
- Boston Scientific will acquire medical device maker Silk Road Medical in a $1.16 billion deal, the companies said on Tuesday.
- 06/18/2024
|
Silk Road Medical stock rallies on Boston Scientific acquisition deal
- Silk Road Medical Inc.'s stock SILK, +1.31% was up 22.6% in pre-market trades on Tuesday after it agreed to be acquired by Boston Scientific Corp. BSX, -0.74% for $27.50 a share. The deal values the medical device company at just under $1.2 billion.
- 06/18/2024
|
Boston Scientific Announces Agreement to Acquire Silk Road Medical, Inc.
- Acquisition adds innovative technology for stroke prevention to vascular portfolio MARLBOROUGH, Mass. , June 18, 2024 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) today announced it has entered into a definitive agreement to acquire Silk Road Medical, Inc. (Nasdaq: SILK), a medical device company that has developed an innovative platform of products to prevent stroke in patients with carotid artery disease through a minimally invasive procedure called transcarotid artery revascularization (TCAR).
- 06/18/2024
|
HAE vs. BSX: Which Stock Should Value Investors Buy Now?
- Investors looking for stocks in the Medical - Products sector might want to consider either Haemonetics (HAE) or Boston Scientific (BSX). But which of these two stocks offers value investors a better bang for their buck right now?
- 06/14/2024
|
Boston Scientific (BSX) Ascends But Remains Behind Market: Some Facts to Note
- In the most recent trading session, Boston Scientific (BSX) closed at $77.41, indicating a +0.34% shift from the previous trading day.
- 06/12/2024
|
VelocityEHS Congratulates Boston Scientific, A 2024 Verdantix EHS Innovation Excellence Award Winner
- VelocityEHS® celebrates Boston Scientific for being named the 2024 Verdantix EHS Innovation Excellence winner in the category Operational Risk Management.
- 06/11/2024
|
Boston Scientific (BSX) Rises Yet Lags Behind Market: Some Facts Worth Knowing
- In the latest trading session, Boston Scientific (BSX) closed at $75.57, marking a +0.76% move from the previous day.
- 05/31/2024
|
Here's Why You Should Buy Boston Scientific (BSX) Stock Now
- Investors continue to be optimistic about Boston Scientific (BSX) due to its geographical expansions and impressive acquisitions.
- 05/27/2024
|
Boston Scientific (BSX) Up 1.5% Since Last Earnings Report: Can It Continue?
- Boston Scientific (BSX) reported earnings 30 days ago. What's next for the stock?
- 05/24/2024
|
Boston Scientific (BSX) Rides on Emerging Markets, MedSurg
- Boston Scientific's (BSX) Endoscopy business within MedSurg is gaining from strong worldwide demand for its broad range of GI and pulmonary treatment options.
- 05/23/2024
|
What Drove A Nearly 2x Rise In Boston Scientific's Profits?
- Boston Scientific Boston Scientific (NYSE: BSX) saw its net income expand by $0.9 billion or 145% y-o-y to $1.6 billion in 2023. This can primarily be attributed to an expansion of its operating margin and lower taxes.
- 05/22/2024
|
Boston Scientific (BSX) Reaches 52-Week High: What's Aiding It?
- Investors are optimistic about Boston Scientific's (BSX) impressive market share gain in the MedSurg segment and continued geographical expansion.
- 05/20/2024
|
Boston Scientific (BSX) mCRM System Study Outcome Favorable
- Boston Scientific (BSX) mCRM System is designed to communicate wirelessly and coordinate painless intracardiac anti-tachycardia pacing (ATP) therapy.
- 05/20/2024
|
Boston Scientific (BSX) mCRM System Study Outcome Favorable
- Boston Scientific Corporation (BSX Quick QuoteBSX - Free Report) recently presented favorable six-month results from the ongoing pivotal MODULAR ATP clinical trial of the mCRM System — the first modular cardiac rhythm management system that consists of the EMBLEM Subcutaneous Implantable Defibrillator or S-ICD System and the EMPOWER Leadless Pacemaker. The findings were concurrently published in the New England Journal of Medicine and presented at the Heart Rhythm Society's annual meeting, Heart Rhythm 2024.The recent development will likely bolster Boston Scientific’s Cardiovascular business.About mCRM SystemThe device is designed to communicate wirelessly to coordinate painless intracardiac anti-tachycardia pacing (ATP) therapy, provide rate-responsive bradycardia pacing support and prevent sudden cardiac death without the use of leads in the heart or under the sternum.The company anticipates FDA approval of the mCRM System in 2025. Study DetailsThe trial assessed not only the safety and functionality of the EMPOWER LP as a stand-alone pacemaker but also the efficacy of the EMBLEM S-ICD System in wirelessly requesting the LP to administer ATP treatment. The trial's results satisfied all predetermined six-month safety and efficacy criteria.The trial's results met all pre-established six-month safety and effectiveness endpoints. They showed that the EMPOWER Leadless Pacemaker was implanted with a major complication-free rate of 97.5%, that communication between the EMBLEM S-ICD System and the EMPOWER Leadless Pacemaker was successful in 98.8% of cases, that anti-tachycardia pacing was successful in 61.3% of cases and that no patient requested that anti-tachycardia pacing or bradycardia pacing be turned off because of pain or discomfort.Study Outcome BenefitsBoston Scientific observed outstanding overall clinical performance of the mCRM System in this trial, including a high rate of successful communication from the S-ICD to the leadless pacemaker and a low rate of serious leadless pacemaker problems. These findings are significant because the high percentages of communication success and pain-free termination of spontaneous arrhythmia episodes suggest a potential upgrade pathway for patients currently implanted with an S-ICD who require ATP or pacing.Image Source: Zacks Investment ResearchInstead of exposing all patients to the risks of more invasive approaches, such as placing leads into the heart or tunneling them under the sternum to provide therapies they may not need, these findings suggest physicians may be able to tailor therapy to the patient's specific needs and health.Industry ProspectsPer a report by Grand View Research, the global cardiac rhythm management devices market size was estimated at $16.43 billion in 2023 and is expected to register a CAGR of 6.3% from 2024 to 2030. The growing prevalence of various cardiovascular diseases, such as arrhythmia and atrial fibrillation, among others.Other Notable HighlightsIn February 2024, Boston Scientific gained the FDA’s approval for the FARAPULSE Pulsed Field Ablation (PFA) system, which is indicated for the isolation of pulmonary veins in the treatment of drug-refractory, recurrent, symptomatic, paroxysmal (i.e., intermittent) atrial fibrillation. The system represents a unique new alternative to standard-of-care thermal ablation treatment.Earlier in 2023, Boston Scientific completed enrollment in the first phase of the ADVANTAGE AF clinical trial, which is studying the FARAPULSE PFA system for treating patients with drug-refractory, symptomatic, persistent AF. The company also commenced enrollment in a second phase of the study to evaluate the safety and effectiveness of the adjunctive use of the FARAPOINT PFA Catheter for cavotricuspid isthmus ablations — a procedure used to treat atrial flutter. Price PerformanceIn the past year, Boston Scientific shares have appreciated 39.1% compared with the industry’s rise of 1%.Zacks Rank and Other Key PicksBoston Scientific currently carries a Zacks Rank #2 (Buy).Some other top-ranked stocks from the broader medical space are Medpace (MEDP Quick QuoteMEDP - Free Report) , ResMed (RMD Quick QuoteRMD - Free Report) and Encompass Health Corporation (EHC Quick QuoteEHC - Free Report) .Medpace, sporting a Zacks Rank #1 (Strong Buy), reported first-quarter 2024 earnings per share (EPS) of $3.20. The figure beat the Zacks Consensus Estimate by 30.6%. Revenues of $511 million improved 17.7% from last year’s comparable figure. Medpace has an estimated 2024 earnings growth rate of 26.5% compared with the industry’s 12.3%. The company’s earnings surpassed estimates in each of the trailing four quarters, the average being 12.8%.ResMed, sporting a Zacks Rank #2, reported a first-quarter 2024 EPS of $2.13, which topped the Zacks Consensus Estimate by 10.9%. Revenues of $1.20 billion surpassed the Zacks Consensus Estimate by 1.9%.RMD has an estimated fiscal 2024 earnings growth rate of 17.9% compared with the industry’s 15.7%. In each of the trailing four quarters, the company delivered an average earnings surprise of 2.8%.Encompass Health, carrying a Zacks Rank #2, reported first-quarter 2024 adjusted EPS of $1.12, surpassing the Zacks Consensus Estimate by 20.4%. Net operating revenues of $1.3 billion topped the Zacks Consensus Estimate by 3.6%.EHC has an estimated long-term earnings growth rate of 15.6% compared with the industry’s 11.7% growth. The company’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 18.7%. Zacks Names "Single Best Pick to Double" From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all. It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time. This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.Free: See Our Top Stock and 4 Runners Up >>
- 05/20/2024
|
MODULAR ATP Study of the mCRM™ System Meets Primary Safety and Efficacy Endpoints
- Additional data from APPRAISE ATP trial reinforce modular therapy approach with EMBLEM™ Subcutaneous Implantable Defibrillator and EMPOWER™ Leadless Pacemaker MARLBOROUGH, Mass. , May 18, 2024 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) today announced positive six-month results from the ongoing pivotal MODULAR ATP clinical trial of the mCRM™ System,* the first modular cardiac rhythm management (CRM) system that consists of the EMBLEM™ Subcutaneous Implantable Defibrillator (S-ICD) System and the EMPOWER™ Leadless Pacemaker (LP).
- 05/18/2024
|
Levi & Korsinsky, LLP Notifies Shareholders of Boston Scientific Corporation (BSX) an Upcoming Claims Deadline in a Class Action Settlement
- NEW YORK, NY / ACCESSWIRE / May 16, 2024 / Levi & Korsinsky informs shareholders that a settlement has been reached in the pending class action lawsuit against Boston Scientific Corporation (NYSE:BSX). The settlement provides for a fund of $38,500,000 to benefit class members.
- 05/16/2024
|
3 Solid Buys From MedTech Following 2024 Guidance Raise
- Guidance hikes by BSX, ALGN and ALC for 2024 make them attractive investment bets.
- 05/15/2024
|
Wall Street Bulls Look Optimistic About Boston Scientific (BSX): Should You Buy?
- When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important?
- 05/15/2024
|
Boston Scientific (BSX) Gains From MedSurg Growth & Buyouts
- Within Neuromodulation, Boston Scientific's pain business is consistently gaining traction, banking on strength in the spinal cord stimulation (SCS) business.
- 05/14/2024
|
Levi & Korsinsky, LLP Notifies Shareholders of Boston Scientific Corporation (BSX) an Upcoming Claims Deadline in a Class Action Settlement
- NEW YORK, NY / ACCESSWIRE / May 14, 2024 / Levi & Korsinsky informs shareholders that a settlement has been reached in the pending class action lawsuit against Boston Scientific Corporation (NYSE:BSX). The settlement provides for a fund of $38,500,000 to benefit class members.
- 05/14/2024
|
Boston Scientific Elects Dr. Cheryl Pegus to Board of Directors
- MARLBOROUGH, Mass. , May 8, 2024 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) announced today the election of Dr. Cheryl Pegus to its board of directors, effective immediately.
- 05/08/2024
|
Levi & Korsinsky, LLP Notifies Shareholders of Boston Scientific Corporation (BSX) an Upcoming Claims Deadline in a Class Action Settlement
- NEW YORK, NY / ACCESSWIRE / May 7, 2024 / Levi & Korsinsky informs shareholders that a settlement has been reached in the pending class action lawsuit against Boston Scientific Corporation (NYSE:BSX). The settlement provides for a fund of $38,500,000 to benefit class members.
- 05/07/2024
|
A Golden Opportunity to Enter U.S. Stock Markets: 5 Top Picks
- We have narrowed our search to five U.S. corporate behemoths that have strong growth potential for 2024. These are: GOOGL, NFLX, AMZN, NOW, BSX.
- 05/06/2024
|
Citi Just Raised Its Price Target on These 3 Stocks
- Many Wall Street investors keep a close eye on the opinions of major brokerages, such as Citigroup (NYSE: C ). Therefore, today we'll explore three promising growth stocks that have recently received a vote of confidence by means of increases in Citi price targets.
- 05/04/2024
|
Levi & Korsinsky, LLP Notifies Shareholders of Boston Scientific Corporation (BSX) an Upcoming Claims Deadline in a Class Action Settlement
- NEW YORK, NY / ACCESSWIRE / May 2, 2024 / Levi & Korsinsky informs shareholders that a settlement has been reached in the pending class action lawsuit against Boston Scientific Corporation (NYSE:BSX). The settlement provides for a fund of $38,500,000 to benefit class members.
- 05/02/2024
|
Needham Just Boosted Its Price Target on These 3 Stocks
- It's not exactly an ideal time to be a stock market investor. The market is in correction territory, with many leading tech giants experiencing a pullback in prices.
- 05/02/2024
|
Boston Scientific Bucks the Medtech Slow Down and Raises Outlook
- Medical device maker Boston Scientific Co.'s NYSE: BDX product portfolio encompasses a wide range of therapeutic areas, from cardiovascular, urology, and neuromodulation to endoscopy instruments and rhythm management. The medical sector company is acquiring rhythm modulation device maker Axonics Inc. NASDAQ: AXNX in the second half of 2024 as the FTC requests additional information on the deal.
- 04/30/2024
|
Is Boston Scientific (BSX) Outperforming Other Medical Stocks This Year?
- Here is how Boston Scientific (BSX) and Canopy Growth Corporation (CGC) have performed compared to their sector so far this year.
- 04/29/2024
|
3 Medical Products Stocks Set to Beat This Earnings Season
- Here are three stocks, TXG, CAH and HOLX, which are expected to beat earnings estimates in the ongoing reporting cycle.
- 04/26/2024
|
Here's Why Boston Scientific (BSX) is a Strong Momentum Stock
- The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
- 04/26/2024
|
Why Boston Scientific (BSX) is a Top Growth Stock for the Long-Term
- Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
- 04/25/2024
|
Boston Scientific (BSX) Q1 Earnings Beat Estimates, View Raised
- Barring Neuromodulation, organic and operational revenues at Boston Scientific's (BSX) core business segments rise in the first quarter.
- 04/24/2024
|
AHCO vs. BSX: Which Stock Is the Better Value Option?
- Investors with an interest in Medical - Products stocks have likely encountered both AdaptHealth Corp. (AHCO) and Boston Scientific (BSX). But which of these two stocks presents investors with the better value opportunity right now?
- 04/24/2024
|
Boston Scientific Beats Forecasts, Boosts Outlook on Booming Heart Device Sales
- Shares of Boston Scientific (BSX) hit an all-time high Wednesday as the maker of medical equipment reported better-than-anticipated quarterly results and boosted its guidance on demand for its cardiovascular devices, including a newly approved product to treat irregular heartbeats.
- 04/24/2024
|
Boston Scientific Corporation (BSX) Q1 2024 Earnings Call Transcript
- Boston Scientific Corporation (NYSE:BSX ) Q1 2024 Earnings Conference Call April 24, 2024 8:00 AM ET Company Participants Jon Monson - Senior Vice President, Investor Relations Mike Mahoney - Chairman and Chief Executive Officer Dan Brennan - Executive Vice President and Chief Financial Officer Ken Stein - Chief Medical Officer Conference Call Participants Robbie Marcus - JPMorgan Larry Biegelsen - Wells Fargo Rick Wise - Stifel Joanne Wuensch - Citi Vijay Kumar - Evercore ISI Travis Steed - Bank of America Danielle Antalffy - UBS Josh Jennings - TD Cowen Chris Pasquale - Nephron Research Matthew O'Brien - Piper Sandler Matt Taylor - Jefferies Matt Miksic - Barclays Michael Polark - Wolfe Research Operator Good morning, and welcome to the Boston Scientific First Quarter 2024 Earnings Call. All participants will be in listen-only mode.
- 04/24/2024
|
Boston Scientific (BSX) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates
- Although the revenue and EPS for Boston Scientific (BSX) give a sense of how its business performed in the quarter ended March 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
- 04/24/2024
|
Boston Scientific (BSX) Q1 Earnings and Revenues Top Estimates
- Boston Scientific (BSX) came out with quarterly earnings of $0.56 per share, beating the Zacks Consensus Estimate of $0.51 per share. This compares to earnings of $0.47 per share a year ago.
- 04/24/2024
|
Boston Scientific Stock Rises on More Than Just an Earnings Beat
- The medical-device company tops first-quarter sales and profit estimates.
- 04/24/2024
|
Boston Scientific raises annual profit forecast on strong demand for heart devices
- Medical device maker Boston Scientific raised its annual profit forecast on Wednesday as the company banks on resilient demand for its heart devices, with post-pandemic elective surgical procedures picking up pace.
- 04/24/2024
|
Boston Scientific's stock jumps 2.7% after earnings top estimates
- Boston Scientific Corp.'s stock BSX, +1.43% rose 2.7% early Wednesday, after the medical tech company's first-quarter earnings beat analyst estimates. The company had net income of $495 million, or 33 cents a share, for the quarter, up from $300 million, or 21 cents a share, in the year-earlier period.
- 04/24/2024
|
What's in Store for These 4 Medical Products Stocks in Q1 Earnings?
- Medical Products companies' quarterly results are likely to reflect a year-over-year decline in earnings. Let's see how BSX, TMO, ALGN and ICLR fare this time.
- 04/23/2024
|
Unveiling Boston Scientific (BSX) Q1 Outlook: Wall Street Estimates for Key Metrics
- Beyond analysts' top -and-bottom-line estimates for Boston Scientific (BSX), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended March 2024.
- 04/19/2024
|
What's in Store for Boston Scientific (BSX) in Q1 Earnings?
- Boston Scientific (BSX) is expected to have registered strong growth in the Asia Pacific, led by strength in China, Japan and Latin America.
- 04/16/2024
|
Boston Scientific (BSX) Faces Rising Costs, Competition
- With Boston Scientific (BSX) recording 40% of its sales from the international market, it remains highly exposed to currency fluctuations.
- 04/10/2024
|
AHCO or BSX: Which Is the Better Value Stock Right Now?
- Investors with an interest in Medical - Products stocks have likely encountered both AdaptHealth Corp. (AHCO) and Boston Scientific (BSX). But which of these two stocks presents investors with the better value opportunity right now?
- 04/08/2024
|
Boston Scientific (BSX) and Scivita Medical Expand Partnership
- Boston Scientific (BSX) and Scivita Medical announce an expanded strategic cooperation arrangement.
- 03/28/2024
|
AHCO vs. BSX: Which Stock Is the Better Value Option?
- Investors looking for stocks in the Medical - Products sector might want to consider either AdaptHealth Corp. (AHCO) or Boston Scientific (BSX). But which of these two stocks is more attractive to value investors?
- 03/22/2024
|
Boston Scientific (BSX) Global Growth Robust, Macro Issues Ail
- Boston Scientific (BSX) is consistently registering fast recovery within its MedSurg segment in the post-pandemic period.
- 03/18/2024
|
Boston Scientific (BSX) Grows IC Business With New FDA Nod
- The AGENT DCB of Boston Scientific (BSX) is already available in Europe, parts of Asia Pacific and Latin America.
- 03/04/2024
|
Why Boston Scientific (BSX) is a Top Momentum Stock for the Long-Term
- Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
- 03/01/2024
|
US FDA approves Boston Scientific's heart device
- Boston Scientific said on Friday the U.S. Food and Drug Administration has approved its device to treat a complication of heart disease.
- 03/01/2024
|
Boston Scientific Corporation (BSX) Hits Fresh High: Is There Still Room to Run?
- Boston Scientific (BSX) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
- 02/27/2024
|
Should You Pick Boston Scientific Stock After A Solid Q4 And 13% Uptick This Year?
- Boston Scientific BSX (NYSE: BSX) reported its Q4 results last month, with revenues and earnings comfortably beating the street estimates. The company reported revenue of $3.7 billion and adjusted earnings of $0.55 per share, compared to the consensus estimates of $3.6 billion and $0.51, respectively.
- 02/23/2024
|
Boston Scientific (BSX) Surges 4.6%: Will the Rally Continue?
- Boston Scientific (BSX) is benefitting from an impressive gain in MedSurg market share and the strong adoption of WATCHMAN FLX.
- 02/21/2024
|
Boston Scientific (BSX) Completes First Case With Its PFA System
- Boston Scientific (BSX) announces the completion of its first commercial cases with its FDA-cleared Farapulse PFA System in the United States.
- 02/20/2024
|
Here's Why You Should Invest in Boston Scientific (BSX) Now
- Investors are optimistic about Boston Scientific (BSX) on strength across the target market and upbeat guidance.
- 02/08/2024
|
PBH vs. BSX: Which Stock Should Value Investors Buy Now?
- Investors interested in stocks from the Medical - Products sector have probably already heard of Prestige Consumer Healthcare (PBH) and Boston Scientific (BSX). But which of these two stocks offers value investors a better bang for their buck right now?
- 02/02/2024
|
Boston Scientific's (BSX) FARAPULSE PFA System Gets FDA Nod
- Boston Scientific (BSX) secures FDA approval for the FARAPULSE PFA system.
- 02/02/2024
|
Boston Scientific (BSX) Q4 Earnings Top, Operating Margin Falls
- Boston Scientific (BSX) sees an increase in organic and operational revenues in its core business segments and geographies in the reported quarter.
- 01/31/2024
|
Boston Scientific (BSX) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates
- The headline numbers for Boston Scientific (BSX) give insight into how the company performed in the quarter ended December 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
- 01/31/2024
|
Boston Scientific's stock jumps 5.8% after earnings beat and upbeat guidance
- Boston Scientific Corp.'s stock BSX, +0.18% jumped 5.8% early Wednesday, after it beat estimates for the fourth quarter and offered upbeat guidance for 2024. The Marlborough, Mass.
- 01/31/2024
|
Boston Scientific beats quarterly profit estimates on strong demand for heart devices
- Medical device maker Boston Scientific beat Wall Street expectations for fourth-quarter profit on Wednesday, helped by strength in its heart devices unit.
- 01/31/2024
|
FDA approves Boston Scientific's device for heart condition
- Boston Scientific said on Wednesday the U.S. Food and Drug Administration has approved the company's device for a type of heart condition.
- 01/31/2024
|
Boston Scientific (BSX) Q4 Earnings Preview: What You Should Know Beyond the Headline Estimates
- Looking beyond Wall Street's top -and-bottom-line estimate forecasts for Boston Scientific (BSX), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended December 2023.
- 01/26/2024
|
PBH or BSX: Which Is the Better Value Stock Right Now?
- Investors interested in Medical - Products stocks are likely familiar with Prestige Consumer Healthcare (PBH) and Boston Scientific (BSX). But which of these two companies is the best option for those looking for undervalued stocks?
- 01/17/2024
|
What's in Store for Boston Scientific (BSX) in Q4 Earnings?
- Boston Scientific (BSX) is expected to have witnessed strong growth of the WATCHMAN franchise in the fourth quarter, given the FDA approval of WATCHMAN FLX Pro in September.
- 01/17/2024
|
7 Healthcare Stocks Taking Medicine to the Next Level
- While the technology sector – especially regarding artificial intelligence – may have captured the spotlight, investors ought to consider adding healthcare stocks to their portfolio. If I had to boil it down to one phrase, it would be permanent relevance.
- 01/14/2024
|
Health care stocks are back in favor and these 3 names could lead the rally, according to the charts
- Here are three stocks in the health care sector that could provide further upside potential based on their improving technical characteristics.
- 01/11/2024
|
5 A-Rated Stocks to Buy ASAP in 2024
- Right around this time last year, InvestorPlace analyst Luke Lango made 10 big predictions for the stock market. His boldest included forecasting that 2023 would be one of the best years for stocks in history.
- 01/10/2024
|
10 Top Stocks With a Strong Buy Rating Right Now
- After rallying yesterday, financial markets are struggling to regain their recent momentum. Both the Dow Jones Industrial Average and the S&P 500 Global Index are in the red today.
- 01/09/2024
|
J&J, Merck, Boston Scientific Debut Trio Of Splashy Takeovers Topping $3 Billion In Value
- J&J, Merck and Boston Scientific kicked off the year's biggest medical conference with a trio of takeovers. AMAM stock and HARP stock soared.
- 01/08/2024
|
Axonics Stock Soars. It's Being Acquired By Boston Scientific In $3.7 Billion Deal.
- The move will expand Boston's product portfolio in its urology business.
- 01/08/2024
|
Axonic's stock soars after cash buyout deal with Boston Scientific valued at $3.7 billion
- Shares of Axonics Inc. AXNX, -0.84% soared 19.2% toward a 13-month high in premarket trading Monday, after the medical technology company focused on treating urinary and bowel dysfunction announced an agreement to be acquired by Boston Scientific Corp. BSX, -0.02% in a cash deal with an equity value of about $3.7 billion. Under terms of deal, Boston Scientific will pay $71 for each Axonics shares outstanding, which represents a 23.3% premium to Friday's closing price of $57.57.
- 01/08/2024
|
Boston Scientific to buy Axonics for $3.7 billion
- Boston Scientific said on Monday it had agreed to buy medtech company Axonics Inc for $3.7 billion.
- 01/08/2024
|
Boston Scientific (BSX) Rides on Global Growth Amid Macro Woes
- Within APAC, Boston Scientific (BSX) is registering strong growth in Japan and China.
- 01/05/2024
|
Boston Scientific (BSX) Initiates AVANT GUARD Clinical Trial
- Boston Scientific's (BSX) AVANT GUARD clinical trial is set to evaluate the FARAPULSE PFA System as the first-line treatment for persistent AF.
- 01/02/2024
|
PBH vs. BSX: Which Stock Is the Better Value Option?
- Investors with an interest in Medical - Products stocks have likely encountered both Prestige Consumer Healthcare (PBH) and Boston Scientific (BSX). But which of these two stocks presents investors with the better value opportunity right now?
- 01/01/2024
|
These Two Stocks Rocked During 2023 And Are Stretching To New Highs
- TJX stock hit a buy point and a new high on Friday as 2023 wraps up. A medical device stock also hit a buy point and a new high.
- 12/29/2023
|
Midday Movers: Boston Scientific Heart System, Tesla Cybertruck Accident
- U.S. equities were lower at midday on this last trading day of 2023. The Dow, S&P 500, and Nasdaq were down, although all three are likely to end of the year with solid gains.
- 12/29/2023
|
3 Medical-Device Stocks Could Click in 2024
- Baird is bullish on Boston Scientific, Insulet, and DexCom, stocks set to benefit as those companies ramp up sales.
- 12/26/2023
|
PBH or BSX: Which Is the Better Value Stock Right Now?
- Investors looking for stocks in the Medical - Products sector might want to consider either Prestige Consumer Healthcare (PBH) or Boston Scientific (BSX). But which of these two stocks presents investors with the better value opportunity right now?
- 12/15/2023
|
Boston Scientific (BSX) Hits 52-Week High: What's Aiding It?
- Investors are optimistic about Boston Scientific's (BSX) impressive market share gain in the MedSurg segment.
- 12/14/2023
|
12 Companies That Had IPOs in 1992: Best and Worst Performers
- In 1992, about 412 companies had an initial public offering (IPO) in the United States.
- 12/09/2023
|
Here's Why You Should Retain Boston Scientific (BSX) Now
- Investors are optimistic about Boston Scientific (BSX) on strong worldwide demand for its GI and pulmonary treatment options and traction in Europe for its next-generation WATCHMAN FLX.
- 12/07/2023
|
Boston Scientific (BSX) Gains From Global Expansion, FX Woe Ails
- Boston Scientific's (BSX) Endoscopy business within MedSurg benefits from strong worldwide demand for its broad range of GI and pulmonary treatment options.
- 12/05/2023
|
3 Healthcare Stocks to Pick Up Before the Year-End Rally
- With their robustness and growth potential, healthcare stocks are becoming a focal point in portfolios worldwide. Moreover, the U.S. stands out at the forefront of healthcare spending, allocating a staggering $4.3 trillion annually.
- 11/28/2023
|
Could Ozempic Harm These 3 Medical Device Stocks?
- Ozempic could make some medical devices less necessary than before. If that happens, it would lead to lower revenue for the device makers.
- 11/25/2023
|
3 Healthcare Stocks to Scoop Up as They Change the Medical Landscape
- The U.S. continues to spend more money on healthcare than any other country. Healthcare spending totaled $4.3 trillion, according to the American Medical Association.
- 11/22/2023
|
Boston Scientific (BSX) Closes the Relievant Medsystems Buyout
- Boston Scientific (BSX) expands the neuromodulation portfolio with the acquisition of Relievant Medsystems.
- 11/21/2023
|
PBH vs. BSX: Which Stock Is the Better Value Option?
- Investors with an interest in Medical - Products stocks have likely encountered both Prestige Consumer Healthcare (PBH) and Boston Scientific (BSX). But which of these two stocks is more attractive to value investors?
- 11/13/2023
|
Here's Why You Should Retain Boston Scientific (BSX) Now
- Investors are optimistic about Boston Scientific (BSX), led by growing demand for WATCHMAN FLX devices and upbeat guidance.
- 11/09/2023
|
Are Medical Stocks Lagging Boston Scientific (BSX) This Year?
- Here is how Boston Scientific (BSX) and Adagene Inc. Sponsored ADR (ADAG) have performed compared to their sector so far this year.
- 10/30/2023
|
Boston Scientific (BSX) Q3 Earnings Beat, Gross Margin Dips
- Boston Scientific's (BSX) organic and operational revenues at its respective core business segments and geographies rise in the third quarter.
- 10/26/2023
|
Boston Scientific (BSX) Tops Q3 Earnings and Revenue Estimates
- Boston Scientific (BSX) came out with quarterly earnings of $0.50 per share, beating the Zacks Consensus Estimate of $0.48 per share. This compares to earnings of $0.43 per share a year ago.
- 10/26/2023
|
Boston Scientific posts better-than-expected Q3 earnings
- Boston Scientific Corp. BSX, -1.90% posted better-than-expected third-quarter earnings early Thursday and raised its full-year guidance. The medical technology company had net income of $505 million, or 34 cents a share, for the quarter, up from $174 million, or 12 cents a share, in the year-earlier period.
- 10/26/2023
|
Boston Scientific beats quarterly profit estimates on strength in heart devices unit
- Medical device maker Boston Scientific topped Wall Street expectations for third-quarter profit on Thursday, helped by a resilient demand for its heart devices following the post-pandemic rebound in elective surgeries.
- 10/26/2023
|
Boston Scientific may be shielded from weight-loss drugs hit by procedure recovery
- Boston Scientific's quarterly results on Thursday are likely to show the benefits of a rebound in elective procedures and help ease fears that the medical device maker could take a hit from the surging popularity of weight-loss drugs.
- 10/25/2023
|
What's in Store for Boston Scientific (BSX) in Q3 Earnings?
- With global staffing issues and the supply situation gradually improving, Boston Scientific's (BSX) international business is expected to have improved further in the third quarter.
- 10/23/2023
|
The Pros Got It Wrong: 3 Stocks to Sell Despite Recent Upgrades
- One tool that investors can easily access for any stock is analyst ratings. These ratings point you in the direction of stocks to buy and stocks to sell.
- 10/18/2023
|
Boston Scientific's (BSX) Wavewriter Alpha SCS Gets FDA's Nod
- Boston Scientific (BSX) receives the FDA's nod for an expanded indication of Wavewriter SCS Systems.
- 10/16/2023
|
Is Boston Scientific (BSX) Stock Outpacing Its Medical Peers This Year?
- Here is how Boston Scientific (BSX) and Chugai Pharmaceutical Co., Ltd. Unsponsored ADR (CHGCY) have performed compared to their sector so far this year.
- 10/12/2023
|
5 Medical Product Stocks to Buy Amid Industry Recovery
- Despite the ongoing macro headwinds, recovering demand for medical procedures and cost-cutting initiatives should support the Zacks Medical-Products industry. SYK, BSX, ZBH, PODD and HAE are well-poised to gain from the favorable factors.
- 10/12/2023
|
7 Affordable Stocks to Invest in as America's Population Ages
- There's no doubt that America is aging. The numbers do not lie.
- 10/12/2023
|
What other industries could weight loss drugs disrupt?
- Jared Holz, Mizuho health care sector strategist, joins the ‘Fast Money' traders to discuss Novo Nordisj's kidney trial outcomes and the impact of weight loss drugs on the health care sector.
- 10/11/2023
|
Here's Why You Should Invest in Boston Scientific (BSX) Now
- Investors are optimistic about Boston Scientific (BSX) on consistent growth and upbeat guidance.
- 10/11/2023
|
PBH or BSX: Which Is the Better Value Stock Right Now?
- Investors interested in Medical - Products stocks are likely familiar with Prestige Consumer Healthcare (PBH) and Boston Scientific (BSX). But which of these two stocks offers value investors a better bang for their buck right now?
- 10/04/2023
|
Boston Scientific Announces Conference Call Discussing Third Quarter 2023 Results
- MARLBOROUGH, Mass. , Oct. 2, 2023 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) will webcast its conference call discussing financial results and business highlights for the third quarter ending September 30, 2023, on Thursday, October 26, 2023, at 8:00 a.m.
- 10/02/2023
|
Is Boston Scientific (BSX) Outperforming Other Medical Stocks This Year?
- Here is how Boston Scientific (BSX) and Conmed (CNMD) have performed compared to their sector so far this year.
- 09/26/2023
|
Boston Scientific (BSX) Set to Acquire Relievant Medsystems
- Boston Scientific's (BSX) new M&A deal is likely to broaden the Neuromodulation business portfolio.
- 09/25/2023
|
Boston Scientific to acquire Relievant Medsystems for $850 million upfront, plus milestone payments
- Boston Scientific Corp. BSX, +0.19% said Tuesday it has entered an agreement to acquire Relievant Medsystems Inc., a privately held medical tech company that has developed a treatment for a form of chronic low back pain. Boston Scientific will pay $850 million upfront and additional but undisclosed contingent payments based on reaching certain sales goals over the next three years.
- 09/19/2023
|
Boston Scientific to pay $850 mln upfront to buy Relievant Medsystems
- Boston Scientific said on Tuesday it would buy private medical tech company Relievant Medsystems for an upfront cash payment of $850 million.
- 09/19/2023
|
Investors should stick to the ‘late cycle playbook' and buy these sectors, says Morgan Stanley's Mike Wilson
- Investors stumped as to where the U.S. economy is situated in the current business cycle, should be focusing on late-cycle stock sectors, which includes one that has been heating up of late.
- 09/18/2023
|
PBH vs. BSX: Which Stock Is the Better Value Option?
- Investors interested in stocks from the Medical - Products sector have probably already heard of Prestige Consumer Healthcare (PBH) and Boston Scientific (BSX). But which of these two companies is the best option for those looking for undervalued stocks?
- 09/14/2023
|
Is Boston Scientific A Better Pick Over Altria Stock?
- We believe that Boston Scientific stock (NYSE: BSX) is a better pick over Altria stock (NYSE: MO), given its better prospects.
- 09/14/2023
|
Boston Scientific (BSX) WATCHMAN FLX Pro Gets FDA Approval
- Boston Scientific's (BSX) latest device features a polymer coating, visualization markers and a broader size matrix to treat a wider range of patients.
- 09/07/2023
|
Here's Why You Should Retain Boston Scientific (BSX) Now
- Investors are optimistic about Boston Scientific (BSX) on growth in the legacy business and upbeat guidance.
- 09/05/2023
|
Boston Scientific Announces 2023 Investor Day Meeting and Conference Call Discussing Third Quarter 2023 Results
- MARLBOROUGH, Mass. , Sept. 5, 2023 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) will host a meeting with the investor community to review its financial goals and long-term growth strategies on Wednesday, September 20, 2023, between 8:30 a.m.
- 09/05/2023
|
Boston Scientific's (BSX) FARAPULSE System Study Data Positive
- Boston Scientific's (BSX) FARAPULSE PFA System's performance in the trial is an encouraging sign of the potential utilization of the device in the United States.
- 09/01/2023
|
Beyond Pills: 3 Non-Pharma Healthcare Stocks for Healthy Gains
- When you consider healthcare stocks, do you automatically think of pharmaceutical companies? Most people do.
- 08/30/2023
|
PBH vs. BSX: Which Stock Should Value Investors Buy Now?
- Investors interested in stocks from the Medical - Products sector have probably already heard of Prestige Consumer Healthcare (PBH) and Boston Scientific (BSX). But which of these two stocks presents investors with the better value opportunity right now?
- 08/29/2023
|
ADVENT Offers Up An Early Present For Boston Scientific Investors
- Boston Scientific surprised the Street with better-than-expected ADVENT study results; Farapulse delivered better procedural success rates with good safety and lower procedure times. Farapulse will likely reach the U.S. market in mid-2024, giving Boston Scientific real momentum in an $8B market. Other drivers of growth for Boston Scientific include the Watchman device, new CRM products, and potential M&A opportunities.
- 08/28/2023
|
Boston Scientific Reports Positive Results from Atrial Fibrillation Device
- Boston Scientific (BSX) was the best-performing stock in the S&P 500 after the medical device maker reported positive results from a clinical trial for its system to treat patients with atrial fibrillation (AF).
- 08/28/2023
|
Boston Scientific shares propel higher on positive atrial fibrillation trial results
- Boston Scientific (NYSE:BSX) shares rose almost 5% after the biotechnology company reported positive results from its pivotal atrial fibrillation (AF) trial. The trial compared the company's FARAPULSE Pulsed Field Ablation (PFA) System against standard-of-care ablation for AF, a type of abnormal heartbeat.
- 08/28/2023
|
Boston Scientific (BSX) Expands Globally Amid FX Concerns
- Boston Scientific's (BSX) Endoscopy business within MedSurg is gaining from strong worldwide demand for its broad range of GI and pulmonary treatment options.
- 08/24/2023
|
Which Is A Better Buy – Boston Scientific Stock Or Abbott?
- Sharpe is a measure of return per unit of risk, and high-performance portfolios can provide the best of both worlds.
- 08/24/2023
|
Boston Scientific's (BSX) POLARx System Gets FDA Approval
- Boston Scientific's (BSX) POLARx enables doctors to expand and modify the new POLARx catheter to match a patient's unique anatomy during an ablation treatment.
- 08/15/2023
|
Stocks This Week: Hold Netflix And Sell Short Boston Scientific
- Over the near term, the indices are likely to move higher into the 14th. The autumn correction will not be hard on many stocks such as Netflix.
- 08/07/2023
|
Citadel Advisors LLC's Recent Transaction in Semper Paratus Acquisition Corp
- On July 17, 2023, Citadel Advisors LLC (Trades, Portfolio), a prominent investment firm, executed a transaction involving Semper Paratus Acquisition Corp ( LGSTU , Financial). This article provides an in-depth analysis of the transaction, the profiles of both Citadel Advisors LLC (Trades, Portfolio) and Semper Paratus Acquisition Corp, and the potential implications of the transaction on both entities.
- 07/27/2023
|
Boston Scientific (BSX) Q2 Earnings Beat, Margins Improve
- Boston Scientific's (BSX) organic and operational revenues at its respective core business segments and geographies rise in the second quarter.
- 07/27/2023
|
Boston Scientific (BSX) Q2 Earnings and Revenues Beat Estimates
- Boston Scientific (BSX) came out with quarterly earnings of $0.53 per share, beating the Zacks Consensus Estimate of $0.49 per share. This compares to earnings of $0.44 per share a year ago.
- 07/27/2023
|
Boston Scientific stock gets a boost from profit and sales beats, raised outloook
- Shares of Boston Scientific Corp. BSX, -0.02% rallied 1.9% in premarket trading Thursday, after the medical technology company beat expectations for both profit and sales, amid strength in its cardiovascular business, and raised its full-year outlook. Net income rose to $261 million, or 18 cents a share, from $246 million, or 17 cents a share, in the year-ago period.
- 07/27/2023
|
5 Must-Buy Stocks Ahead of Q2 Earnings Tomorrow
- We have narrowed our search to five stocks that are set to declare second-quarter earnings results on Jul 27, before market open. These are: HON, BSX, AOS, SPGI, ATHM.
- 07/26/2023
|
Are Medical Stocks Lagging Boston Scientific (BSX) This Year?
- Here is how Boston Scientific (BSX) and DexCom (DXCM) have performed compared to their sector so far this year.
- 07/24/2023
|
Will Boston Scientific (BSX) Beat Q2 Earnings Estimates?
- Boston Scientific (BSX) is expected to have registered strong growth in EMEA within structural heart, including TAVR, WATCHMAN and other interventional cardiology therapies.
- 07/20/2023
|
Boston Scientific (BSX) Gets FDA Nod for Vercise Software
- Boston Scientific's (BSX) Vercise Neural Navigator 5 Software has an improved user interface that presents patient data in an easier-to-understand style and enables better therapy delivery.
- 07/17/2023
|
VREX vs. BSX: Which Stock Is the Better Value Option?
- Investors with an interest in Medical - Products stocks have likely encountered both VAREX IMAGING (VREX) and Boston Scientific (BSX). But which of these two stocks offers value investors a better bang for their buck right now?
- 07/13/2023
|
Boston Scientific's (BSX) New Launches Aid Amid Cost Pressure
- Boston Scientific (BSX) remains excited about the rest of 2023 and expects to continue to outpace its peers within the EMEA market.
- 06/23/2023
|
Here's Why You Should Buy Boston Scientific (BSX) Stock
- Investors are optimistic about Boston Scientific's (BSX) strong improvement in organic sales, indicating a solid rebound in the legacy business.
- 06/20/2023
|
Surgical Centers, Med-Tech Stocks Up On Pent-Up Surgical Demand
- After a pandemic pause, hip and knee replacements are back. Long-postponed surgeries are being rescheduled, which is bad for business at insurance companies like UnitedHealth Group Inc. NYSE: UNH, but potentially good business for surgery centers like Surgery Partners Inc. NASDAQ: SGRY and companies like Zimmer Biomet Holdings Inc. NYSE: ZBH that manufacture joint-replacement technologies.
- 06/16/2023
|
What's Next For Boston Scientific Stock After Outperforming During The 2022 Inflation Shock?
- The notable rise in Boston Scientific's revenues in the recent past has also contributed to the stock's outperformance.
- 06/09/2023
|
Boston Scientific (BSX) Rises 26.4%: Will the Rally Continue?
- Boston Scientific (BSX) gains from strong improvement in organic sales, indicating a solid rebound in the legacy business.
- 05/31/2023
|
These Growth Stocks Seem Stalled. That May Be A Good Thing.
- Several IBD 50 stocks are forming bullishly tight chart patterns. The post These Growth Stocks Seem Stalled.
- 05/26/2023
|
Boston Scientific (BSX) Gains From Acquisitions, New Launches
- Boston Scientific (BSX) remains excited about 2023 performance and expects to continue to outpace its peers within the EMEA market.
- 05/24/2023
|
Are Medical Stocks Lagging Boston Scientific (BSX) This Year?
- Here is how Boston Scientific (BSX) and Aravive (ARAV) have performed compared to their sector so far this year.
- 05/15/2023
|
Shockwave Medical, Fast Grower, In Boston Scientific's Sights?
- Shockwave Medical Inc. NASDAQ: SWAV, the largest component within the iShares Russell 2000 ETF NYSEARCA: IWM, briefly cleared a cup-with-handle buy point on May 12, but reversed lower along with the broader market.
- 05/15/2023
|
Shockwave Tumbles As Boston Scientific Takeover Talk Reportedly Breaks Down
- The rumored matchup between Boston Scientific and Shockwave Medical reportedly broke down on Monday, leading SWAV stock into a dive. The post Shockwave Tumbles As Boston Scientific Takeover Talk Reportedly Breaks Down appeared first on Investor's Business Daily.
- 05/08/2023
|
Is Boston Scientific (BSX) Stock Outpacing Its Medical Peers This Year?
- Here is how Boston Scientific (BSX) and Cardinal Health (CAH) have performed compared to their sector so far this year.
- 04/28/2023
|
Can Boston Scientific Set Another Net High?
- MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis.
- 04/27/2023
|
Boston Scientific (BSX) Q1 Earnings Beat, 2023 View Raised
- Reported and organic revenues at each of Boston Scientific's (BSX) core business segments and geographies increase in the reported quarter.
- 04/26/2023
|
Boston Scientific (BSX) Q1 Earnings: How Key Metrics Compare to Wall Street Estimates
- The headline numbers for Boston Scientific (BSX) give insight into how the company performed in the quarter ended March 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
- 04/26/2023
|
Boston Scientific (BSX) Q1 Earnings and Revenues Surpass Estimates
- Boston Scientific (BSX) came out with quarterly earnings of $0.47 per share, beating the Zacks Consensus Estimate of $0.43 per share. This compares to earnings of $0.39 per share a year ago.
- 04/26/2023
|
Boston Scientific Approaches A Profit-Taking Zone On First-Quarter Beat
- Boston Scientific reported better-than-expected first-quarter growth on Tuesday, pushing BSX stock closer to a profit-taking zone. The post Boston Scientific Approaches A Profit-Taking Zone On First-Quarter Beat appeared first on Investor's Business Daily.
- 04/26/2023
|
Boston Scientific reports 1Q sales and earnings above guidance
- Boston Scientific (NYSE:BSX) has reported first-quarter revenue and earnings that beat its own guidance as well as Wall Street's expectations due to strong growth at its MedSurg and Cardiovascular units, sending its shares higher in pre-market trading. The Marlborough, Massachusetts-based medical products company said net sales increased 12% to $3.39 billion on a reported basis for the three months to March 31, 2023, above its guidance range of 3% to 5%.
- 04/26/2023
|
Boston Scientific stock jumps into record territory after earnings beat, raised outlook
- Shares of Boston Scientific Corp. BSX jumped 2.8% into record territory in premarket trading Wednesday, after the medical technology company reported first-quarter results that beat expectations and raised its full-year outlook, citing a “robust pipeline” in 2023 and beyond. Net income jumped to $300 million, or 21 cents a share, from $97 million, or 7 cents a share, in the year-ago period.
- 04/26/2023
|
New Product Launches To Aid Boston Scientific's Q1
- A rise in elective surgeries performed and market share gains for some of its products will likely aid the company's top-line growth.
- 04/25/2023
|
Shockwave Rockets As Boston Scientific Reportedly Mulls A Takeover
- Boston Scientific is considering a takeover of Shockwave Medical, according to a report Friday that sent SWAV stock soaring. The post Shockwave Rockets As Boston Scientific Reportedly Mulls A Takeover appeared first on Investor's Business Daily.
- 04/21/2023
|
Here's Why You Should Buy Boston Scientific (BSX) Stock
- Investors are optimistic about Boston Scientific (BSX) owing to impressive growth in MedSurg market share.
- 04/19/2023
|
Healthcare Innovation Drives Medical Device Makers To New Highs
- The healthcare sector has been looking fit in the past month, with medical products makers Stryker Corp. (NYSE: SYK) and Boston Scientific Corp. (NYSE: BSX) rallying to all-time highs, while sector peer DexCom Inc. (NASDAQ: DXCM) is forming a constructive base.
- 04/17/2023
|
Boston Scientific (BSX) Hits 52-Week High: What's Driving It?
- Boston Scientific (BSX) outperforms the industry and the S&P 500 due to several new acquisitions and the long-term growth prospects of the WATCHMAN device.
- 04/06/2023
|
Boston Scientific Announces Conference Call Discussing First Quarter 2023 Results
- MARLBOROUGH, Mass. , April 3, 2023 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) will webcast its conference call discussing financial results and business highlights for the first quarter ended March 31, 2023 on Wednesday, April 26, 2023 at 8:00 a.m.
- 04/03/2023
|
Pro reveals healthcare stocks that are worth buying right now
- “XLV” – the Health Care Select Sector SPDR Fund has been a disappointment for investors since the start of the year but a portfolio manager says it'll likely be a different story moving forward.
- 03/30/2023
|
Investment in procedural medical devices is safer for valuation, says E Squared's Les Funtleyder
- Les Funtleyder, portfolio manager for E Squared Capital Management, joins 'The Exchange' to discuss big cap pharma's Q1 performance, the dollar weakness contributing to biotech gains, and investment opportunities in the pharma space.
- 03/30/2023
|
VREX or BSX: Which Is the Better Value Stock Right Now?
- VREX vs. BSX: Which Stock Is the Better Value Option?
- 03/29/2023
|
Here's Why You Should Retain Boston Scientific (BSX) Now
- Investors are optimistic about Boston Scientific (BSX), led by impressive value-added acquisitions.
- 03/20/2023
|
Will Boston Scientific Stock See Higher Levels?
- Boston Scientific stock (NYSE: BSX) has seen a fall of 3% in a month, compared with -5% returns for the broader S&P500 index.
- 03/03/2023
|
Boston Scientific (BSX) Gains From New Buyouts, Cost Woes Stay
- Boston Scientific's (BSX) EMEA business grows above market, supported by the company's ongoing investments in emerging markets.
- 02/16/2023
|
Boston Scientific Stands Out With Strong, Diversified Growth Profile
- Boston Scientific came up short on margins in the fourth quarter, but reassuring guidance on revenue and improved margins in FY'23 seems to have smoothed that over. Boston Scientific has an above-average forward growth profile among larger med-techs, with multiple drivers including Watchman, ablation, structural heart, urology, and peripheral interventions.
- 02/15/2023
|
Boston Scientific (BSX) Q4 Earnings Miss, Operating Margin Up
- Boston Scientific's (BSX) organic revenues at each of its core business segments and geographies increase in the fourth quarter of 2022.
- 02/01/2023
|
Boston Scientific Corporation (BSX) Q4 2022 Earnings Call Transcript
- Boston Scientific Corporation (NYSE:BSX ) Q4 2022 Results Conference Call February 1, 2023 8:00 AM ET Company Participants Lauren Tengler - Vice President, Investor Relations Mike Mahoney - Chairman & Chief Executive Officer Dan Brennan - Executive Vice President & Chief Financial Officer Ken Stein - Chief Medical Officer Conference Call Participants Rick Wise - Stifel Robbie Marcus - JPMorgan Larry Biegelsen - Wells Fargo Joanne Wuensch - Citi Vijay Kumar - Evercore ISI Travis Steed - Bank of America Cecilia Furlong - Morgan Stanley Josh Jennings - Cowen Operator Good morning, and welcome to the Boston Scientific Fourth Quarter 2022 Earnings Call. All participants will be in listen only mode [Operator Instructions] Please note, this event is being recorded.
- 02/01/2023
|
Thermo Fisher Pops On Its Bullish Outlook As Boston Scientific Gains On Its In-Line Report
- Thermo Fisher easily beat quarterly projections, while Boston Scientific was in line. TMO stock popped Wednesday while BSX stock also rose.
- 02/01/2023
|
Boston Scientific (BSX) Lags Q4 Earnings Estimates
- Boston Scientific (BSX) delivered earnings and revenue surprises of -4.26% and 0.12%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
- 02/01/2023
|
Boston Scientific stock slides 5% premarket after profit miss
- Boston Scientific Corp. stock BSX, +0.96% slid 5% in premarket trade Wednesday, after the medical device maker missed profit estimates for the fourth quarter. The company had net income of $126 million, or 9 cents a share, up from $80 million, or 6 cents a share, in the year-earlier period.
- 02/01/2023
|
Here's Why You Should Retain Boston Scientific (BSX) Now
- Investors are optimistic about Boston Scientific (BSX) on recent acquisitions and robust performance of the WATCHMAN device.
- 01/23/2023
|
Will Boston Scientific (BSX) Beat Q4 Earnings Estimates?
- Boston Scientific (BSX) is expected to have registered strong growth in EMEA within structural heart, including TAVR, WATCHMAN, and other interventional cardiology therapies.
- 01/20/2023
|
PETQ vs. BSX: Which Stock Is the Better Value Option?
- PETQ vs. BSX: Which Stock Is the Better Value Option?
- 01/04/2023
|
Boston Scientific to Participate in J.P. Morgan Healthcare Conference and Announces Conference Call Discussing Fourth Quarter 2022 Results
- MARLBOROUGH, Mass. , Jan. 3, 2023 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) will participate in the 41st Annual J.P.
- 01/03/2023
|
Here's Why You Should Retain Boston Scientific (BSX) For Now
- Investors are optimistic about Boston Scientific (BSX), led by new strategic investments and the robust performance of the WATCHMAN device.
- 12/21/2022
|
PETQ or BSX: Which Is the Better Value Stock Right Now?
- PETQ vs. BSX: Which Stock Is the Better Value Option?
- 12/19/2022
|
What's Next For Boston Scientific Stock After An 11% Rise In A Month?
- This recent outperformance of Boston Scientific can partly be attributed to its announcement to acquire Apollo Endosurgery in a $615 million deal.
- 12/15/2022
|
Boston Scientific's (BSX) New Buyout to Expand Global Presence
- Boston Scientific's (BSX) new acquisition deal is expected to strengthen the company's presence in China.
- 12/12/2022
|
Boston Scientific: Price Correction Coming
- The company is overvalued in many ways. High debt will hamper Boston Scientific's growth.
- 12/05/2022
|
Boston Scientific's (BSX) New Buyout to Expand its Portfolio
- Boston Scientific's (BSX) latest buyout is expected to boost its Endoscopy business by adding Apollo Endosurgery's product portfolio, which includes devices used during ELS procedures.
- 11/30/2022
|
Investors Liked These 2 Stock Buyouts Tuesday
- Market performance was mixed as investors prepared for more insight on interest rates.
- 11/29/2022
|
Buy-rated Boston Scientific's $615 million takeover of Apollo Endosurgery is a positive, says Needham
- Boston Scientific Corp.'s BSX, +0.88% $615 million acquisition of Apollo Endosurgery Inc. APEN, +65.50% announced earlier is complementary to the former's endoscopy franchise, as it leverages its gastroenterologist call point while offering the potential for it to expand into surgical endoscopy and bariatric surgery, Needham analysts aid Tuesday. The deal is expected to have no material impact on Boston Scientific's 2023 per-share earnings but to boost it after that.
- 11/29/2022
|
Boston Scientific to acquire Apollo Endosurgery for $615 million in cash
- Boston Scientific Corp. BSX, -0.82% said Tuesday it has agreed to acquire Apollo Endosurgery Inc. APEN, for $10 a share, or about $615 million in cash. The news sent Apollo's stock, which closed Monday at $6, up 61% in premarket trade.
- 11/29/2022
|
Boston Scientific (BSX) Posts Positive Post-Market Study Data
- The latest PMCF study demonstrates that Boston Scientific's (BSX) ACURATE neo2 Aortic Valve System is expected to significantly improve patient outcomes.
- 11/28/2022
|
Final Trades: Salesforce, Amazon, Boston Scientific & more
- The "Halftime Report" traders give their top picks to watch for the second half.
- 11/19/2022
|
PETQ or BSX: Which Is the Better Value Stock Right Now?
- PETQ vs. BSX: Which Stock Is the Better Value Option?
- 11/16/2022
|
Is There Room For Growth In Boston Scientific Stock?
- Boston Scientific stock (NYSE: BSX) is up 6% in a month, marginally outperforming the broader S&P500 index, up 4%. The company reported its Q3 results in late October.
- 11/11/2022
|
Boston Scientific (BSX) Q3 Earnings Miss, Operating Margin Up
- Boston Scientific's (BSX) Q3 revenues reflect double-digit organic revenue growth across the majority of its businesses.
- 10/26/2022
|
Boston Scientific Corporation (BSX) Q3 2022 Earnings Call Transcript
- Boston Scientific Corporation (NYSE:BSX ) Q3 2022 Earnings Conference Call October 26, 2022 8:00 AM ET Company Participants Lauren Tengler - Vice President, Investor Relations Mike Mahoney - Chairman & Chief Executive Officer Dan Brennan - Executive Vice President & Chief Financial Officer Ian Meredith - Chief Medical Officer Ken Stein - Chief Medical Officer Conference Call Participants Robbie Marcus - JPMorgan Larry Biegelsen - Wells Fargo Joanne Wuensch - Citi Vijay Kumar - Evercore Travis Steed - Bank of America Cecilia Furlong - Morgan Stanley Rick Wise - Stifel Matthew O'Brien - Piper Jaffray Matt Taylor - Jefferies Pito Chickering - Deutsche Bank Chris Pasquale - Nephron Research Matt Miksic - Barclays Operator Good morning and welcome to the Boston Scientific Third Quarter 2022 Earnings Call. All participants will be in listen-only mode.
- 10/26/2022
|
Boston Scientific (BSX) Lags Q3 Earnings Estimates
- Boston Scientific (BSX) delivered earnings and revenue surprises of -2.27% and 1.07%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
- 10/26/2022
|
Boston Scientific Rises Despite Mixed Earnings, Light 2022 Guidance
- Boston Scientific's third-quarter earnings narrowly lagged, though sales beat. Earnings guidance missed, but BSX stock rose.
- 10/26/2022
|
Boston Scientific stock drops more than 4% after profit misses expectations but sales beat, outlook mixed
- Shares of Boston Scientific Corp. BSX, +0.78% dropped 4.4% in premarket trading Wednesday, after the medical devices company missed third-quarter profit expectations but topped on revenue, and provided a mixed full-year outlook. Net income fell to $174 million, or 12 cents a share, from $405 million, or 28 cents a share, in the year-ago period, compared with previously provided guidance for net earnings per share of 20 cents to 24 cents.
- 10/26/2022
|
Will Boston Scientific Stock Rise Post Q3 Results?
- Not only do we expect Boston Scientific to navigate well in Q3, our forecast indicates that BSX stock has ample room for growth, as discussed below.
- 10/25/2022
|
Why Boston Scientific (BSX) Could Beat Earnings Estimates Again
- Boston Scientific (BSX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
- 10/17/2022
|
Will Boston Scientific (BSX) Beat Q3 Earnings Estimates?
- Boston Scientific's (BSX) top line is likely to have improved with non-COVID elective medical procedures running in a full-fledged way in the United States and across the globe.
- 10/17/2022
|
Boston Scientific Announces Conference Call Discussing Third Quarter 2022 Results
- MARLBOROUGH, Mass. , Oct. 3, 2022 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) will webcast its conference call discussing financial results and business highlights for the third quarter ended September 30, 2022 on Wednesday, October 26, 2022 at 8:00 a.m.
- 10/03/2022
|
Boston Scientific (BSX) Benefits From New Buyouts, FX Woes Stay
- Boston Scientific's (BSX) organic growth performance is strong across all regions where most of its businesses are growing at the same pace or faster than their competitors in the respective markets.
- 09/27/2022
|
Here's Why You Should Retain Boston Scientific (BSX) For Now
- Investors are optimistic about Boston Scientific's (BSX) impressive top-line results and notable acquisitions.
- 09/20/2022
|
Boston Scientific (BSX) Grows Operationally Amid Macro Issues
- In the Asia Pacific region, Boston Scientific (BSX) grows operationally with notable performance in Japan, India and the ASEAN countries.
- 09/01/2022
|
Boston Scientific (BSX) Signs Obsidio-Acquisition Agreement
- Boston Scientific's (BSX) latest acquisition will add the FDA-approved GEM technology to its interventional oncology and embolization portfolio.
- 08/17/2022
|
Boston Scientific Announces Upcoming Conference Schedule
- MARLBOROUGH, Mass. , Aug. 16, 2022 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) will participate in two upcoming investor events.
- 08/16/2022
|
Boston Scientific: Strong Earnings Report, But Shares Are Not Cheap Yet
- The Health Care Sector ETF has beaten the S&P 500 this year, but there has been a recent relative weakness. One medical device company impressed the Street in late July with a bottom line beat and could see near-term price upside.
- 08/09/2022
|
Boston Scientific Corporation (BSX) CEO Mike Mahoney on Q2 2022 Results - Earnings Call Transcript
- Boston Scientific Corporation (NYSE:BSX ) Q2 2022 Results Conference Call July 27, 2022 8:00 AM ET Company Participants Lauren Tengler - Vice President, Investor Relations Mike Mahoney - Chairman & Chief Executive Officer Dan Brennan - Executive Vice President & Chief Financial Officer Ken Stein - Chief Medical Officer, Rhythm Management Ian Meredith - Global Chief Medical Officer Conference Call Participants Joanne Wuensch - Citi Robbie Marcus - JPMorgan Larry Biegelsen - Wells Fargo Vijay Kumar - Evercore Rick Wise - Stifel Cecilia Furlong - Morgan Stanley Travis Steed - Bank of America Pito Chickering - Deutsche Bank Josh Jennings - Cowen Richard Newitter - Truist Jayson Bedford - Raymond James Shagun Singh - RBC Operator Good morning, and welcome to the Boston Scientific Second Quarter 2022 Earnings Call. [Operator Instructions] Please note, this event is being recorded.
- 07/27/2022
|
Boston Scientific (BSX) Tops Q2 Earnings and Revenue Estimates
- Boston Scientific (BSX) delivered earnings and revenue surprises of 4.76% and 0.92%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
- 07/27/2022
|
Boston Scientific Narrowly Tops Second-Quarter Expectations; Shares Surge
- Boston Scientific narrowly topped second-quarter estimates Tuesday, but BSX stock surged higher in premarket action. The post Boston Scientific Narrowly Tops Second-Quarter Expectations; Shares Surge appeared first on Investor's Business Daily.
- 07/27/2022
|
Boston Scientific tops profit and sales expectations, but trims full-year outlook
- Boston Scientific Corp. BSX, -0.11% reported Wednesday second-quarter profit and sales that topped expectations, but trimmed its full-year outlook, saying it maintained "strong" market positions amid continued macroeconomic challenges. The medical devices company's stock was still inactive in premarket trading.
- 07/27/2022
|
MedTech Stocks' Earnings Due on Jul 27: BSX, HOLX & ALGN
- MedTech companies' results are likely to reflect a rebound in the base business. Let's see how BSX, HOLX and ALGN fare this time.
- 07/26/2022
|
What To Expect From Boston Scientific Stock Following Q2 Earnings?
- Boston Scientific (NYSE: BSX) is scheduled to report its Q2 2021 results on Wednesday, July 27. We expect the company to report revenues and earnings in line with the consensus estimates.
- 07/21/2022
|
PETQ vs. BSX: Which Stock Is the Better Value Option?
- PETQ vs. BSX: Which Stock Is the Better Value Option?
- 07/20/2022
|
What's in Store for Boston Scientific (BSX) in Q2 Earnings?
- Within the PI business of Boston Scientific (BSX), Q2 sales are expected to have been strong, banking on the strong performance of the drug-eluting franchise.
- 07/15/2022
|
Should You Buy Boston Scientific Stock At $38?
- Boston Scientific's revenue grew 13% to $12.2 billion over the last twelve months, compared to $10.7 billion in 2019, primarily led by higher sales for its peripheral interventions, endoscopy, and women's health products.
- 07/13/2022
|
What's Happening With Boston Scientific Stock?
- Boston Scientific stock (NYSE: BSX) has seen a 9% fall in a month, in line with the broader S&P500, which is down 8%.
- 07/05/2022
|
Boston Scientific Announces Conference Call Discussing Second Quarter 2022 Results
- MARLBOROUGH, Mass. , June 29, 2022 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) will webcast its conference call discussing financial results and business highlights for the second quarter ending June 30, 2022 on Wednesday, July 27, 2022 at 8:00 a.m.
- 06/29/2022
|
Boston Scientific (BSX) to Broaden Stent Portfolio With Buyout
- According to Boston Scientific (BSX), M.I.Tech's product offerings complement the company's existing stent portfolio, including the differentiated AXIOS Stent and Electrocautery Enhanced Delivery System.
- 06/16/2022
|
Boston Scientific Buys Substantial Stake In Korean MedTech Player
- Boston Scientific Corporation (NYSE: BSX) has agreed to purchase Synergy Innovation Co Ltd's majority stake (~64%) of M.I.Tech Co Ltd, a publicly-traded Korean manufacturer, and distributor of medical devices for endoscopic and urologic procedures. The deal is.
- 06/15/2022
|
Here's Why You Should Retain Boston Scientific (BSX) for Now
- Investors are optimistic about Boston Scientific's (BSX) strong organic sales and notable acquisitions.
- 06/10/2022
|
Boston Scientific (BSX) Gains from New Buyouts, FX Issue Ails
- Boston Scientific (BSX) is currently looking forward to launching its arterial and venous offerings in the second half of 2022.
- 06/06/2022
|
J&J's Interest in Boston Scientific Is Resurfacing
- Nearly three years since I wrote an article for GuruFocus speculating that Johnson & Johnson ( JNJ , Financial) might be interested in buying Boston Scientific Corp. ( BSX , Financial), rumors are percolating once again that we might see an offer soon.
- 06/01/2022
|
BSX: Boston Scientific Sports Growth At A Reasonable Price
- Healthcare stocks have beaten the S&P 500 so far this year with particular relative strength seen in Medical Device stocks. Boston Scientific features a reasonable earnings multiple, given a hearty growth outlook.
- 05/29/2022
|
Boston Scientific (BSX) Down 6.1% Since Last Earnings Report: Can It Rebound?
- Boston Scientific (BSX) reported earnings 30 days ago. What's next for the stock?
- 05/27/2022
|
Boston Scientific to Participate in Bank of America Global Healthcare Conference
- MARLBOROUGH, Mass. , May 2, 2022 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) will participate in Bank of America's Global Healthcare Conference on Thursday, May 12.
- 05/02/2022
|
Boston Scientific (BSX) Q1 Earnings Top, 2022 Revenue View Up
- Boston Scientific (BSX) registers a year-over-year improvement in organic sales, indicating a strong rebound in the legacy business from the pandemic mayhem.
- 04/27/2022
|
Boston Scientific Corporation (BSX) CEO Mike Mahoney on Q1 2022 Results - Earnings Call Transcript
- Boston Scientific Corporation (NYSE:BSX ) Q1 2022 Earnings Conference Call April 27, 2022 8:00 AM ET Company Participants Lauren Tengler - Vice President, Investor Relations Mike Mahoney - Chairman & Chief Executive Officer Dan Brennan - Executive Vice President & Chief Financial Officer Ken Stein - Chief Medical Officer Conference Call Participants Robbie Marcus - JPMorgan Rick Wise - Stifel Joanne Wuensch - Citibank Larry Biegelsen - Wells Fargo Vijay Kumar - Evercore ISI Travis Steed - Bank of America Danielle Antalffy - SVB Leerink Cecilia Furlong - Morgan Stanley Matthew O'Brien - Piper Sandler Operator Good morning, and welcome to the Boston Scientific First Quarter 2022 Earnings Call. All participants will be in listen-only mode.
- 04/27/2022
|
Boston Scientific Jumps On Upbeat Q2, FY22 Guidance
- Boston Scientific Corp (NYSE: BSX) generated net sales of $3.026 billion in Q1 FY22, beating the Wall Street estimate of $2.95 billion. Sales increased 10% Y/Y on a reported basis, 12.6% on an operational basis, and 9.7% on an organic basis, better than the management estimate of.
- 04/27/2022
|
Boston Scientific (BSX) Tops Q1 Earnings and Revenue Estimates
- Boston Scientific (BSX) delivered earnings and revenue surprises of 2.63% and 2.45%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
- 04/27/2022
|
Boston Scientific tops estimates for Q1, sending shares up 3.3% premarket
- Boston Scientific Corp. shares BSX, -4.46% rose 3.3% premarket Wednesday, after the medical device maker reported lower earnings for the first quarter than a year ago but still beat consensus estimates. The company posted net income of $97 million, or 7 cents a share, for the quarter, down from $327 million, or 23 cents a share, in the year-earlier period.
- 04/27/2022
|
What To Expect From Boston Scientific Stock Following Q1 Earnings?
- Revenues expected to be slightly above the consensus estimates Trefis estimates Boston Scientific's Q1 2022 revenues to be around $3.0 billion, slightly above the $2.9 billion consensus estimate.
- 04/26/2022
|
Final Trades: FCX, BSX, UNH & MO
- The final trades of the week. With CNBC's Melissa Lee and the Fast Money traders, Tim Seymour, Brian Kelly, Jeff Mills and Adam Parker.
- 04/22/2022
|
What's in Store for Boston Scientific (BSX) in Q1 Earnings?
- Given an innovative pipeline, expansion into faster growth markets, globalization efforts and enhanced digital capabilities, Boston Scientific (BSX) is well-positioned to register strong first quarter of 2022 results.
- 04/20/2022
|
Why Boston Scientific (BSX) Could Beat Earnings Estimates Again
- Boston Scientific (BSX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
- 04/15/2022
|
Here's Why You Should Retain Boston Scientific (BSX) For Now
- Investors are optimistic about Boston Scientific's (BSX) robust organic sales and strategic buyouts.
- 04/12/2022
|
Boston Scientific Announces Conference Call Discussing First Quarter 2022 Results
- MARLBOROUGH, Mass. , April 1, 2022 /PRNewswire/ -- Boston Scientific Corporation (NYSE:BSX) will webcast its conference call discussing financial results and business highlights for the first quarter ended March 31, 2022, on Wednesday, April 27, 2022, at 8:00 a.m.
- 04/01/2022
|
Final Trades: Amazon, FedEx, Boston Scientific
- The "Halftime Report" traders give their top picks to watch for the second half.
- 03/18/2022
|
This Software Company Is Likely To Offer Better Returns Over Boston Scientific Stock
- We think that Intuit stock, a company that specializes in financial and tax preparation software, currently is a better pick compared to medical devices maker Boston Scientific stock (NYSE: BSX), despite INTU being more expensive of the two with its P/S ratio of 11.2x, compared to 5.0x for BSX.
- 03/16/2022
|
Boston Scientific (BSX) Hurt by Price and Volume Issues
- The current headwinds around Boston Scientific (BSX) include the cost of running plants with COVID-specific measures, increased freight costs, price pressure and higher direct labor wages.
- 03/15/2022
|
Boston Scientific: Weak M&A Strategy Weighing Down Price Target
- Boston Scientific's M&A strategy has led to decreasing ROI from its acquisitions over the past 5 years from 5.97% in 2017 to 1.09% in 2021.
- 03/14/2022
|
IHI: A Standout Performer With Equally Strong Future Growth Prospects
- IHI: A Standout Performer With Equally Strong Future Growth Prospects
- 03/05/2022
|
Andreas Halvorsen Loads Up on Health Care, Tech Stocks
- Viking Global leader Andreas Halvorsen (Trades, Portfolio) disclosed his portfolio for the final quarter of 2021 last week.
- 02/22/2022
|
Riding The Stock Waves: Update On The Medical Devices Sector
- The decline from September 2021 in Medical Device stocks was healthy. Similar price structures provide confidence in coming upside.
- 02/21/2022
|
FTC approves modifications to Boston Scientific divestiture agreement
- The U.S. Federal Trade Commission said it has approved certain modifications to medical device company Boston Scientific Corp's divestiture agreements.
- 02/18/2022
|
Is Boston Scientific Stock A Good Buy At $43?
- We believe that Boston Scientific stock is a good buying opportunity at the current levels. Earlier this month the company released its Q4 earnings, which were better than our estimates.
- 02/16/2022
|
Is Boston Scientific Stock A Good Buy At $43?
- We believe that Boston Scientific stock is a good buying opportunity at the current levels. Earlier this month the company released its Q4 earnings, which were better than our estimates.
- 02/16/2022
|
Boston Scientific to Participate in 11th Annual SVB Leerink Global Healthcare Conference
- MARLBOROUGH, Mass., Feb. 14, 2022 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) will participate in SVB Leerink's 11th Annual Global Healthcare Conference on Thursday, February 17, 2022.
- 02/14/2022
|
Boston Scientific (BSX) Q4 Earnings Top Estimates, Margins Up
- Boston Scientific (BSX) registers a year-over-year improvement in organic sales, indicating a strong rebound in legacy business from pandemic mayhem.
- 02/02/2022
|
Boston Scientific Corporation (BSX) CEO Mike Mahoney on Q4 2021 Results - Earnings Call Transcript
- Boston Scientific Corporation (BSX) CEO Mike Mahoney on Q4 2021 Results - Earnings Call Transcript
- 02/02/2022
|
Boston Scientific (BSX) Q4 Earnings and Revenues Beat Estimates
- Boston Scientific (BSX) delivered earnings and revenue surprises of 2.27% and 0.91%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
- 02/02/2022
|
Medical Products Stock Earnings on Feb 2: BSX, TMO & More
- Medical Products companies' Q4 results are likely to reflect an increase in COVID-19 testing demand. Let's see how BSX, TMO, HOLX and MCK are poised ahead of their earnings releases.
- 02/01/2022
|
What To Expect From Boston Scientific Stock Following Q4 Earnings?
- Boston Scientific is scheduled to report its Q4 2021 results on Wednesday, Feb 2. We expect the company to report revenues in-line but earnings marginally below the consensus estimates, as the rise of Covid-19 cases with the spread of Omicron, likely weighed on the overall procedures volume, while.
- 02/01/2022
|
What's in Store for Boston Scientific's (BSX) Q4 Earnings?
- On a geographic basis, every Boston Scientific (BSX) market in fourth-quarter 2021 is expected to have registered broad-based growth compared with the dull fourth-quarter 2020 numbers.
- 01/26/2022
|
Boston Scientific (BSX) Hit by Procedure Deferrals Amid COVID
- Although Boston Scientific (BSX) reports margin expansion on a year-over-year basis, the decline in R&D expenses is concerning.
- 01/24/2022
|
Should You Buy Boston Scientific Stock Over Its Industry Peer?
- We think that Boston Scientific stock currently is a better pick compared to its industry peer, Medtronic stock, despite it being the more expensive of the two, trading at 5.3x trailing revenues compared to 4.4x for Medtronic. Even if we were to look at the P/EBIT ratio, BSX stock appears to be.
- 01/12/2022
|
Boston Scientific to Present New Data on Advances in Chronic Pain Care at the 2022 North American Neuromodulation Society (NANS) Meeting
- MARLBOROUGH, Mass. , Jan. 7, 2022 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) today announced key data that will be featured at the 25th North American Neuromodulation Society (NANS) annual meeting, in Orlando, Florida, on Jan.13-15, 2022.
- 01/07/2022
|
Boston Scientific to Participate in J.P. Morgan Healthcare Conference and Announces Conference Call Discussing Fourth Quarter 2021 Results
- MARLBOROUGH, Mass., Jan. 4, 2022 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) will participate in the 40th Annual J.P.
- 01/04/2022
|
4 Internet of Medical Things (IoMT) Stocks to Buy for 2022
- Stocks like Boston Scientific (BSX), Medtronic (MDT), DexCom (DXCM) and Syneos Health (SYNH) are evolving rapidly in the field of IoMT.
- 12/23/2021
|
Boston Scientific (BSX) New Buyouts Aid Amid COVID Resurgence
- Boston Scientific's (BSX) new acquisitions like Preventice, Farapulse and Lumenis Surgical, which closed in March, August and September of 2021, respectively, are contributing to its inorganic growth.
- 12/16/2021
|
This Cloud Computing Company Is A Better Pick Over Boston Scientific Stock
- We think that Veeva Systems stock (NYSE: VEEV), a cloud-computing company focused on pharmaceutical and life sciences industry applications, currently is a better pick compared to Boston Scientific stock , despite Veeva being the more expensive of the two.
- 12/03/2021
|
Here's Why You Should Retain Boston Scientific (BSX) for Now
- Investors are optimistic about Boston Scientific (BSX) owing to its solid third-quarter performance and impressive value-added acquisitions.
- 12/02/2021
|
Boston Scientific Announces Upcoming Conference Schedule
- MARLBOROUGH, Mass., Nov. 8, 2021 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) will participate in two upcoming investor conferences.
- 11/08/2021
|
4 Medical Products Stocks Poised to Beat This Earnings Season
- Amid concerns surrounding growing COVID-19 cases affecting the medical products companies' legacy business, we are optimistic about IDXX, HSIC, CGC and PODD's results this time around.
- 10/28/2021
|
Boston Scientific Corporation (BSX) CEO Mike Mahoney on Q3 2021 Results - Earnings Call Transcript
- Boston Scientific Corporation (BSX) CEO Mike Mahoney on Q3 2021 Results - Earnings Call Transcript
- 10/27/2021
|
Boston Scientific (BSX) Q3 Earnings Top Estimates, Margins Up
- Barring CRM, Boston Scientific's (BSX) organic revenues at each of its core business segments and geographies increase in Q3.
- 10/27/2021
|
Boston Scientific Q3 Earnings Comes Inline With Wall Street Expectations
- Boston Scientific Corporation (NYSE: BSX) generated net sales of $2.93 billion in Q3 of 2021, almost in line with the Wall Street estimate of $2.97 billion. Sales increased 10.3% Y/Y on a reported basis and 10.6% on an organic basis, lower than the Company's guidance of 12% - 14%.
- 10/27/2021
|
Boston Scientific (BSX) Q3 Earnings Beat Estimates
- Boston Scientific (BSX) delivered earnings and revenue surprises of 2.50% and -1.61%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
- 10/27/2021
|
Boston Scientific stock gains after profit tops expectations, while sales came up a bit short
- Shares of Boston Scientific Corp. BSX, -0.38% rose 0.4% in premarket trading Wednesday, after the medical device company reported third-quarter profit that topped expectations, but sales that came up a bit shy, while nudging up its earnings outlook and cutting its sales growth view. The company swung to net income of $405 million, or 28 cents a share, from a loss of $169 million, or 12 cents a share, in the year-ago period.
- 10/27/2021
|
What To Expect From Boston Scientific Stock In Q3?
- Boston Scientific is scheduled to report its Q3 2021 results on Wednesday, Oct 27. We expect the company to report revenues and earnings in-line with the consensus estimates, driven by a rebound in volume of procedures performed.
- 10/25/2021
|
Boston Scientific (BSX) Product Launches to Drive Q3 Earnings
- Within Urology/ Pelvic Health, Boston Scientific (BSX) is expected to have registered strong sales growth in Stone, Prostate Health and Pelvic Health franchises.
- 10/21/2021
|
3 Reasons to Hold on to Boston Scientific (BSX) Stock For Now
- Investors are optimistic about Boston Scientific (BSX) given its recent acquisitions and strength in the structural heart business.
- 10/19/2021
|
Boston Scientific's (BSX) Ranger DCB Trial Outcome Favorable
- Boston Scientific's (BSX) Ranger DCB two-year data demonstrates a constant, high rate of efficacy in patients with more complex lesion subtypes.
- 10/12/2021
|
Boston Scientific (BSX) Reports Data Backing Eluvia Stent
- The positive data demonstrated the superiority of Boston Scientific's (BSX) Eluvia stent compared to bare metal stents in treating patients with peripheral artery disease.
- 10/11/2021
|
This Stock Is Likely To Outperform Boston Scientific
- We think that Stryker stock (NYSE: SYK) currently is a better pick compared to Boston Scientific stock, despite Stryker being slightly more expensive of the two. Stryker trades at about 6.4x trailing revenues, compared to 5.7x for Boston Scientific.
- 10/07/2021
|
Why Boston Scientific (BSX) Is Buying Baylis Medical For $1.75 Billion
- Boston Scientific Corporation (NYSE: BSX) has announced that it has entered into a definitive agreement to buy Baylis Medical Company for an upfront payment of $1.75 billion. These are the details.
- 10/06/2021
|
Boston Scientific's Eluvia Drug-Eluting Vascular Stent Tops Bare Metal Stents
- Boston Scientific Corporation (NYSE: BSX) has announced data for the Eluvia Drug-Eluting Vascular Stent System (Eluvia stent) at the Vascular InterVentional Advances meeting. Data presented included one-year results from the EMINENT trial of the Eluvia stent in 775 patients.
- 10/06/2021
|
Boston Scientific Eluvia™ Drug-Eluting Vascular Stent System Exhibits Superiority Compared to Bare Metal Stents
- LAS VEGAS and MARLBOROUGH, Mass., Oct. 6, 2021 /PRNewswire/ -- Today, Boston Scientific Corporation (NYSE: BSX) announced positive data for the Eluvia™ Drug-Eluting Vascular Stent System (Eluvia stent) during a late-breaking clinical trial presentation at the Vascular InterVentional Advances (VIVA) meeting in Las Vegas.
- 10/06/2021
|
Boston Scientific Beefs Up Electrophysiology, Structural Heart Portfolio With $1.75B Baylis Deal
- Boston Scientific Corporation (NYSE: BSX) has agreed to acquire Baylis Medical Company Inc for an upfront payment of $1.75 billion. The acquisition will expand Boston Scientific's electrophysiology and structural heart product portfolios to include the radiofrequency (RF) NRG and VersaCross Transseptal Platforms and family of guidewires, sheaths, and dilators used to support left heart access.
- 10/06/2021
|
Boston Scientific Highlights Trial Data For EkoSonic System For Pulmonary Embolism
- Boston Scientific Corporation (NYSE: BSX) announced results for the EkoSonic Endovascular System at the Vascular InterVentional Advances (VIVA) meeting. Related: Boston Scientific Acquires Provider Of Thrombectomy Platform In Over $300M Deal.
- 10/06/2021
|
Boston Scientific to acquire Baylis Medical Co. for $1.75 billion
- Boston Scientific Corp. BSX, +0.07% said Wednesday it has entered an agreement to acquire Baylis Medical Co. Inc. for an upfront payment of $1.75 billion. The deal will "expand the Boston Scientific electrophysiology and structural heart product portfolios to include the radiofrequency (RF) NRG(R) and VersaCross(R) Transseptal Platforms as well as a family of guidewires, sheaths and dilators used to support left heart access," Boston Scientific said in a statement.
- 10/06/2021
|
Boston Scientific Announces Agreement to Acquire Baylis Medical Company Inc.
- MARLBOROUGH, Mass., Oct. 6, 2021 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) today announced that it has entered into a definitive agreement to acquire Baylis Medical Company Inc. for an upfront payment of $1.75 billion, subject to closing adjustments.
- 10/06/2021
|
Positive Late-breaking Clinical Trial Data for the EkoSonic™ Endovascular System Presented at VIVA21
- LAS VEGAS and MARLBOROUGH, Mass., Oct. 5, 2021 /PRNewswire/ -- Today, Boston Scientific (NYSE: BSX) announced positive results for the EkoSonic™ Endovascular System (EKOS system) during a late-breaking clinical trial presentation at the Vascular InterVentional Advances (VIVA) meeting in Las Vegas.
- 10/05/2021
|
Boston Scientific Announces Positive Late-Breaking Clinical Trial Data for the Ranger™ Drug-Coated Balloon
- LAS VEGAS and MARLBOROUGH, Mass., Oct. 5, 2021 /PRNewswire/ -- Today, Boston Scientific (NYSE: BSX) announced positive results for the Ranger™ Drug-Coated Balloon (DCB) during a late-breaking clinical trial presentation at the Vascular InterVentional Advances (VIVA) meeting in Las Vegas.
- 10/05/2021
|
Boston Scientific Announces Conference Call Discussing Third Quarter 2021 Results
- MARLBOROUGH, Mass., Oct. 4, 2021 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) will webcast its conference call discussing financial results and business highlights for the third quarter ended September 30, 2021 on Wednesday, October 27, 2021 at 8:00 a.m.
- 10/04/2021
|
MedTech Thrives on M&A Frenzy: 3 Stocks to Focus on
- MedTech stocks like Boston Scientific (BSX), Catalent (CTLT) and Baxter (BAX) are likely to solidify businesses on the back of impressive M&As.
- 09/30/2021
|
NVST or BSX: Which Is the Better Value Stock Right Now?
- NVST vs. BSX: Which Stock Is the Better Value Option?
- 09/27/2021
|
Boston Scientific: A Best Price-Positioned Medical Equipment Stock, As Seen By Market-Makers
- Boston Scientific: A Best Price-Positioned Medical Equipment Stock, As Seen By Market-Makers
- 09/23/2021
|
Boston Scientific (BSX) Strategic Buyouts Aid Amid Cost Woes
- Boston Scientific (BSX) is optimistic about its recent deal to acquire Israel-based Lumenis that develops and commercializes energy-based medical solutions.
- 09/22/2021
|
Boston Scientific's (BSX) New Buyout to Aid Clot Management
- The acquisition of Devoro Medical by Boston Scientific (BSX) is expected to advance the company's core emphasis on clot management.
- 09/22/2021
|
Boston Scientific Acquires Provider Of Thrombectomy Platform In Over $300M Deal
- Boston Scientific Corporation (NYSE: BSX) has agreed to acquire Devoro Medical Inc for over 300 million. Boston Scientific has been a strategic investor in Devoro Medical since 2019 and currently holds an equity stake of approximately 16%.
- 09/21/2021
|
Boston Scientific Announces Agreement to Acquire Devoro Medical, Inc.
- MARLBOROUGH, Mass., Sept. 21, 2021 /PRNewswire/ -- Today, Boston Scientific Corporation (NYSE: BSX) announced an agreement to acquire Devoro Medical, Inc., developer of the WOLF Thrombectomy® Platform.
- 09/21/2021
|
Late-Breaking Data Demonstrate Improved Progression-Free Survival in Patients with Metastatic Colorectal Cancer After Treatment with Boston Scientific TheraSphere™ Y-90 Glass Microspheres
- MARLBOROUGH, Mass., Sept. 20, 2021 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) announced the EPOCH clinical trial of the TheraSphere™ Y-90 Glass Microspheres (TheraSphere treatment) successfully met both primary endpoints, including progression-free survival (PFS) and hepatic progression-free survival (hPFS) of patients with metastatic colorectal cancer (mCRC) of the liver.
- 09/20/2021
|
Final Trades: Charles Schwab, Boston Scientific, Waste Management & more
- The "Halftime Report" traders give their top picks to watch for the second half.
- 09/15/2021
|
NVST vs. BSX: Which Stock Should Value Investors Buy Now?
- NVST vs. BSX: Which Stock Is the Better Value Option?
- 09/09/2021
|
Boston Scientific Announces 2021 Investor Day Meeting
- MARLBOROUGH, Mass., Sept. 9, 2021 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) will host a meeting with the investor community to review its financial goals and long-term growth strategies on Wednesday, September 22, 2021, from 8:30 a.m.
- 09/09/2021
|
Boston Scientific (BSX) New Buyout to Aid Kidney Stone Line
- Boston Scientific (BSX) shares a 20-year long relationship with Lumenis and already offers the Lumenis urology laser portfolio in the United States and Japan through a distribution arrangement.
- 09/02/2021
|
Boston Scientific Closes Acquisition Of Lumenis LTD. Surgical Business From Baring Private Equity Asia
- MARLBOROUGH, Mass. , Sept. 1, 2021 /PRNewswire/ -- Boston Scientific (NYSE: BSX) today announced the close of its acquisition of the global surgical business of Lumenis LTD.
- 09/01/2021
|
Abbott Says Amulet Superior To Boston Scientific's Watchman In Stroke Study
- Abbott Laboratories (NYSE: ABT) has announced late-breaking data from the Amulet LAA Occluder IDE trial. The head-to-head study compared Abbott's Amplatzer Amulet Left Atrial Appendage (LAA) Occluder with Boston Scientific Corporation's (NYSE: BSX) Watchman device for atrial fibrillation at an increased risk of stroke.
- 08/30/2021
|
Why Is Boston Scientific (BSX) Down 1.4% Since Last Earnings Report?
- Boston Scientific (BSX) reported earnings 30 days ago. What's next for the stock?
- 08/26/2021
|
NVST vs. BSX: Which Stock Should Value Investors Buy Now?
- NVST vs. BSX: Which Stock Is the Better Value Option?
- 08/24/2021
|
Post Market Studies Reinforce Unfavorable Risk-Benefit Profile For Boston Scientific's Vaginal Mesh
- Final results from postmarket surveillance studies of Boston Scientific Corporation's (NYSE: BSX) transvaginal mesh for pelvic organ prolapse (POP) have reinforced the FDA's unfavorable view of the benefit-risk profile. FDA said final reports from the 36-month studies found additional risks associated with transvaginal POP mesh repairs, such as mesh exposure and erosion.
- 08/17/2021
|
Boston Scientific (BSX) Just Overtook the 20-Day Moving Average
- Good things could be on the horizon when a stock surpasses the 20-day simple moving average. How should investors react?
- 08/16/2021
|
Boston Scientific's Exalt Model B Single-Use Bronchoscope Wins FDA Approval
- The FDA has given 510(k) clearance for Boston Scientific Corp's (NYSE: BSX) Exalt Model B single-use bronchoscope for use in bedside procedures within the intensive care unit and operating room. The device can be used for a wide range of bronchoscopy procedures, including secretion management, airway intubation, percutaneous tracheostomy, double-lumen endotracheal tube placement, and biopsies.
- 08/11/2021
|
Boston Scientific Receives FDA Clearance for EXALT™ Model B Single-Use Bronchoscope
- MARLBOROUGH, Mass., Aug. 10, 2021 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) today announced U.S. Food and Drug Administration (FDA) 510(k) clearance of the EXALT™ Model B Single-Use Bronchoscope, designed for use in bedside procedures within the intensive care unit (ICU) and operating room (OR).
- 08/10/2021
|
NVST or BSX: Which Is the Better Value Stock Right Now?
- NVST vs. BSX: Which Stock Is the Better Value Option?
- 08/06/2021
|
Boston Scientific Starts Trial For EkoSonic Endovascular System In Patients With Pulmonary Embolism
- Boston Scientific Corporation (NYSE: BSX) began enrollment for a clinical trial of its EkoSonic endovascular system (EKOS). Boston Scientific's HI-PEITHO trial, a collaborative research study, will compare EkoSonic in combination with anticoagulation to anticoagulation alone for treating acute, intermediate-high-risk pulmonary embolism (PE).
- 08/04/2021
|
CMS Grants Additional Reimbursement For EXALT™ Model D Single-Use Duodenoscope
- MARLBOROUGH, Mass., Aug. 2, 2021 /PRNewswire/ -- Boston Scientific (NYSE: BSX) announced that the U.S. Centers for Medicare & Medicaid Services (CMS) granted a New Technology Add-on Payment (NTAP) for single-use duodenoscopes, applicable to the EXALT™ Model D Single-Use Duodenoscope, as part of its Fiscal Year 2022 Hospital Inpatient Prospective Payment System.
- 08/02/2021
|
Will Boston Scientific Stock See Higher Levels?
- Following a solid performance in Q2, Boston Scientific raised its full year outlook for sales to increase 19-20% and adjusted earnings to be in the range of $1.58-$1.62 per share.
- 08/02/2021
|
Final Trades: Salesforce, Amazon, Boston Scientific & more
- The "Halftime Report" traders give their top picks to watch for the second half.
- 07/30/2021
|
Boston Scientific Corporation (BSX) CEO Michael Mahoney on Q2 2021 Results - Earnings Call Transcript
- Boston Scientific Corporation (BSX) CEO Michael Mahoney on Q2 2021 Results - Earnings Call Transcript
- 07/27/2021
|
Why Boston Scientific Shares Are Trading Higher Today
- Boston Scientific (NYSE:BSX) shares are trading higher after the company reported better-than-expected Q2 EPS and sales results. The company also issued FY21 EPS guidance with a midpoint above analyst estimates.
- 07/27/2021
|
Boston Scientific (BSX) Q2 Earnings Beat, 2021 Guidance Up
- Organic revenues at each of Boston Scientific's (BSX) core business segments and geographies increase in Q2.
- 07/27/2021
|
Boston Scientific (BSX) Surpasses Q2 Earnings and Revenue Estimates
- Boston Scientific (BSX) delivered earnings and revenue surprises of 8.11% and 4.41%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
- 07/27/2021
|
Boston Scientific Announces Results For Second Quarter 2021
- MARLBOROUGH, Mass., July 27, 2021 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) generated net sales of $3.077 billion during the second quarter of 2021, growing 53.6 percent on a reported basis, 49.6 percent on an operational1 basis and 52.4 percent on an organic2 basis, all compared to the prior year period.
- 07/27/2021
|
Should You Buy Boston Scientific (BSX) Ahead of Earnings?
- Boston Scientific (BSX) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
- 07/26/2021
|
What To Expect From Boston Scientific Stock In Q2?
- Boston Scientific is scheduled to report its Q2 2021 results on Tuesday, July 27. We expect Boston Scientific to report revenues and earnings in-line with the consensus estimates, driven by a rebound in demand for medical devices.
- 07/23/2021
|
Boston Scientific (BSX) Watchman FLX Sales to Aid Q2 Earnings
- Strong procedure recovery and market share gains across many of the businesses and regions are expected to have boosted Boston Scientific's (BSX) Q2 sales.
- 07/21/2021
|
Will Boston Scientific Stock Rise After A 5% Fall In A Week?
- The stock price of Boston Scientific reached its 52-week high of $44 in April this year before a recent sell-off in broader markets, which led to a 7% drop in BSX stock to levels of around $41 currently. The recent sell-off in the broader markets can be attributed to rising Covid-19 cases due to.
- 07/21/2021
|
Late-Breaking Trial Data at TVT Demonstrate Sustained Safety and Performance of WATCHMAN FLX™ Left Atrial Appendage Closure Device
- MARLBOROUGH, Mass., July 21, 2021 /PRNewswire/ -- Today, Boston Scientific (NYSE: BSX) announced positive 24-month results from the PINNACLE FLX clinical trial assessing the safety and efficacy of the next-generation WATCHMAN FLX™ Left Atrial Appendage Closure (LAAC) Device for patients with non-valvular atrial fibrillation (NVAF).
- 07/21/2021
|
Boston Scientific (BSX) Reports Next Week: Wall Street Expects Earnings Growth
- Boston Scientific (BSX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- 07/20/2021
|
How Boston Scientific Could Give You A Worry-Free Retirement
- Boston Scientific has a moat-worthy stable of innovative healthcare products and has strong profitability.
- 07/08/2021
|
NVST vs. BSX: Which Stock Should Value Investors Buy Now?
- NVST vs. BSX: Which Stock Is the Better Value Option?
- 07/01/2021
|
Boston Scientific Announces Conference Call Discussing Second Quarter 2021 Results
- MARLBOROUGH, Mass., June 29, 2021 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) will webcast its conference call discussing financial results and business highlights for the second quarter ended June 30, 2021 on Tuesday, July 27, 2021 at 8:00 a.m.
- 06/29/2021
|
Boston Scientific Elects David S. Wichmann To Board Of Directors
- MARLBOROUGH, Mass., June 24, 2021 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) announced today the election of David S.
- 06/24/2021
|
Boston Scientific Exercises Option to Acquire Farapulse, Inc.
- MARLBOROUGH, Mass., June 24, 2021 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) today announced it exercised its option to acquire the remaining shares of Farapulse, Inc. The acquisition will complement the existing Boston Scientific electrophysiology portfolio to include the FARAPULSE Pulsed Field Ablation (PFA) System – a non-thermal ablation system for the treatment of atrial fibrillation (AF) and other cardiac arrhythmias.
- 06/24/2021
|
Cardiology Space Gains Momentum in 2021: 5 Stocks to Focus on
- These cardiology device stocks Medtronic (MDT), Boston Scientific (BSX), Edwards Lifesciences (EW), Merit Medical (MMSI), BD (BDX) are expected to continue their run over the next few months.
- 06/18/2021
|
Here's Why Boston Scientific Is Undervalued At $43 Levels
- We believe that the stock price of Boston Scientific (NYSE: BSX) is undervalued at current levels of $43. BSX stock is up 65% from the levels of around $26 it was at on March 23, 2020, underperforming the broader markets with the S&P 500 rising 89% over the same period.
- 06/18/2021
|
Better Buy: Medtronic or Boston Scientific?
- Which one of these medical device makers is better poised for a breakout year?
- 06/03/2021
|
Boston Scientific (BSX) EXALT Gets CE Nod, Endoscopy Arm Grows
- The European market release of Boston Scientific's (BSX) EXALT Model B Single-Use Bronchoscope will mitigate infection risks associated with reusable imaging scopes.
- 06/02/2021
|
Boston Scientific, Gap, Molson Coors and More Tuesday Afternoon Analyst Calls
- With the trading day more than halfway over, the markets had dipped after a relatively strong start to the day.
- 05/25/2021
|
Boston Scientific Completes CE Mark for EXALT™ Model B Single-Use Bronchoscope
- Company to begin limited market release in Europe in June MARLBOROUGH, Mass., May 25, 2021 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) today announced it has completed CE Mark for the EXALT™ Model B Single-Use Bronchoscope, a single-use device designed for bedside procedures in the intensive care unit, operating room and bronchoscopy suite.
- 05/25/2021
|
Big call buying in Boston Scientific
- "Halftime Report" trader Pete Najarian spots unusual activity in the options market
- 05/24/2021
|
Boston Scientific to Participate in Bernstein's 37th Annual Strategic Decisions Conference
- MARLBOROUGH, Mass., May 24, 2021 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) will participate in Bernstein's 37th Annual Strategic Decisions Conference on Friday, June 4, 2021.
- 05/24/2021
|
Late-Breaking Registry Data at EuroPCR Congress Demonstrate Reduced Paravalvular Leak and Low Permanent Pacemaker Rates for the ACURATE neo2™ Aortic Valve System
- MARLBOROUGH, Mass., May 18, 2021 /PRNewswire/ -- Data presented at hotline and late-breaking trial sessions today at the EuroPCR 2021 congress demonstrated positive procedural performance, including low rates of paravalvular leakage (PVL) and permanent pacemaker implementation (PPI), of the Boston Scientific (NYSE: BSX) ACURATE neo2™ Aortic Valve System within the investigator-initiated Early neo2 Registry1 and ITAL-neo Registry2 studies.
- 05/18/2021
|
What's New With Boston Scientific Stock?
- The stock price of Boston Scientific has corrected 3.5% over the last five trading sessions, and the dip appears to be a good buying opportunity in our view. Not only did the company post an upbeat performance in Q1, it has seen multiple positive developments of late.
- 05/17/2021
|
Boston Scientific: Is The Expected Recovery Factored Into the Price?
- Like most medical device manufacturers, Boston Scientific Corp. ( BSX , Financial) also witnessed a slowdown in 2020 on account of the lower demand for medical devices and the deferral of elective surgeries due to the Covid-19 pandemic. The company witnessed its fair share of disruptions, but appears to be on a recovery path, delivering better-than-expected results for the first quarter.
- 05/04/2021
|
4 Medical Products Stocks Set to Beat This Earnings Season
- Rebound in base sales make us optimistic about OMI, INGN, XRAY and CNTG's results this time around.
- 05/04/2021
|
Boston Scientific Announces May Conference Schedule
- MARLBOROUGH, Mass., (May 3, 2021 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) will participate in two upcoming investor conferences.
- 05/03/2021
|
Innovation Drives Robotic-Assisted Surgery: 5 Stocks to Watch
- Rapid innovation is boosting the robotic surgery space, putting the spotlight on Johnson & Johnson (JNJ), Stryker (SYK), Boston Scientific (BSX), Intuitive Surgical (ISRG) and Asensus Surgical (ASXC).
- 05/03/2021
|
Bulls bet on Boston Scientific and Las Vegas Sands
- "Halftime Report" trader Pete Najarian spots unusual activity in the options market
- 04/30/2021
|
Boston Scientific Stock Jumps On Q1 Earnings Beat, Improved Guidance
- Boston Scientific Corporation (NYSE: BSX) Q1 sales grew by 5.9% (organically) to $2.75 billion, beating the previous guidance range between negative 3% and 3% in the quarter, better than the consensus estimate $2.62 billion. EPS of $0.37 beat the analyst consensus estimate of $0.31 versus $0.28 a year ago.
- 04/28/2021
|
Boston Scientific Corporation (BSX) CEO Michael Mahoney on Q1 2021 Results - Earnings Call Transcript
- Boston Scientific Corporation (BSX) CEO Michael Mahoney on Q1 2021 Results - Earnings Call Transcript
- 04/28/2021
|
Boston Scientific (BSX) Q1 Earnings Beat, Organic Sales Up
- Boston Scientific (BSX) registers strong sequential improvement in overall financial performance in Q1.
- 04/28/2021
|
Boston Scientific (BSX) Q1 Earnings and Revenues Surpass Estimates
- Boston Scientific (BSX) delivered earnings and revenue surprises of 23.33% and 5.30%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
- 04/28/2021
|
Boston Scientific Announces Results For First Quarter 2021
- MARLBOROUGH, Mass., April 28, 2021 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) generated net sales of $2.752 billion during the first quarter of 2021.
- 04/28/2021
|
Why Boston Scientific (BSX) Might Surprise This Earnings Season
- Boston Scientific (BSX) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
- 04/27/2021
|
Medical Product Stocks' Earnings on Apr 28: BSX, ALGN & More
- The sector's Q1 results are likely to reflect solid earnings and revenue growth on strong base business recovery.
- 04/27/2021
|
Boston Scientific's (BSX) Watchman US Sale to Aid Q1 Earnings
- Within Boston Scientific's (BSX) coronary therapies, drug-eluting stents sale continue to be a challenge from a pricing standpoint in Q1.
- 04/23/2021
|
Boston Scientific (BSX) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
- Boston Scientific (BSX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- 04/21/2021
|
Boston Scientific: Set To Climb 27%, Options Offer An Even Bigger Return
- Recent price action indicates that BSX could reach $52. An equity research firm just initiated coverage with a price target of $52.
- 04/20/2021
|
Boston Scientific Corp (BSX) EVP&Pres, Periph Intervent Jeffrey B. Mirviss Sold $1.
- EVP&Pres, Periph Intervent of Boston Scientific Corp (30-Year Financial, Insider Trades) Jeffrey B. Mirviss (insider trades) sold 28,123 shares of BSX on 04/15/2021 at an average price of $40.95 a share.
- 04/16/2021
|
Final Trades: Northrop Grumman, Boston Scientific, Nvidia & more
- The "Halftime Report" traders give their top picks to watch for the second half.
- 04/15/2021
|
AMD, Boston Scientific, Intel, Nvidia and More Thursday Afternoon Analyst Calls
- With the trading day about halfway over, the broad markets were pushing much higher with solid gains across the board.
- 04/15/2021
|
Late-Breaking Data Supports Boston Scientific's (BSX) TheraSphere
- Boston Scientific's (BSX) TheraSphere is expected to be used as a safe and effective treatment option for numerous HCC patients worldwide on the back of positive trial results.
- 03/30/2021
|
Boston Scientific Announces Conference Call Discussing First Quarter 2021 Results and Participation in Truist Securities 2021 Life Sciences Summit
- MARLBOROUGH, Mass., March 26, 2021 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) will webcast its conference call discussing financial results and business highlights for the first quarter ending March 31, 2021 on Wednesday, April 28, 2021 at 8:00 a.m.
- 03/26/2021
|
Boston Scientific (BSX) Hurt by Product Recall, Currency Woes
- Boston Scientific (BSX) currently expects its 2021 organic revenues to include a headwind of $62 million from 2020 LOTUS Edge sales.
- 03/26/2021
|
BioCardia Is Super Cheap With Multiple Shots On Goal
- BioCardia Is Super Cheap With Multiple Shots On Goal
- 03/25/2021
|
Late-Breaking Clinical Trial Data for TheraSphere™ Y-90 Glass Microspheres Demonstrates Improved Survival in Primary Liver Cancer
- MARLBOROUGH, Mass., March 25, 2021 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) announced positive data from the TARGET study of the TheraSphere™ Y-90 Glass Microspheres (TheraSphere) – a type of radioembolization comprised of millions of microscopic glass beads containing radioactive yttrium (Y-90) – during a late-breaking clinical trial presentation at the annual scientific meeting for the Society of Interventional Radiology (SIR).
- 03/25/2021
|
Boston Scientific's (BSX) TheraSphere Approved by FDA for HCC
- Boston Scientific's (BSX) TheraSphere therapy to be made accessible to more patients following the FDA's clearance.
- 03/22/2021
|
Boston Scientific Receives FDA Approval for TheraSphere™ Y-90 Glass Microspheres
- MARLBOROUGH, Mass., March 18, 2021 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) announced it has received U.S. Food and Drug Administration (FDA) approval of the TheraSphere™ Y-90 Glass Microspheres, developed for the treatment of patients with hepatocellular carcinoma (HCC).
- 03/18/2021
|
Boston Scientific (BSX) Down 2.1% Since Last Earnings Report: Can It Rebound?
- Boston Scientific (BSX) reported earnings 30 days ago. What's next for the stock?
- 03/05/2021
|
Baring Private Equity Asia Announces Agreement to Sell Lumenis' Surgical Business to Boston Scientific for USD1.07 billion
- YOKNEAM, Israel and HONG KONG, March 3, 2021 /PRNewswire/ -- Baring Private Equity Asia (BPEA) and Lumenis announced today that they have entered into a definitive agreement to sell the Lumenis Surgical Business to Boston Scientific (NYSE: BSX) in a transaction valued at USD1.07 billion,...
- 03/03/2021
|
Boston Scientific to spend $1.1 billion in cash to buy Lumentis LTD's surgical business
- Boston Scientific Corp. announced Wednesday an agreement to buy the global surgical business of Lumenis LTD for $1.07 billion in cash from Baring Private Equity Asia. The medical technology company said Lumentis's surgical business includes laser systems, fibers and accessories used for urology and otolaryngology procedures, and is expected to have 2021 sales of about $200 million.
- 03/03/2021
|
7 Stocks to Sell for March
- The market is starting to get volatile again and sector rotation is underway. Clear the decks by dumping these stocks to sell for March.
- 02/26/2021
|
Henry Schein Likely To Offer Better Returns Compared To Boston Scientific Stock
- We think that Henry Schein currently is a better pick compared to Boston Scientific. HSIC stock trades at about 0.9x trailing Revenues, compared to around 5.5x for Boston Scientific.
- 02/24/2021
|
14 AI Stocks to Stay Away From
- Whether in transportation, manufacturing or healthcare, don't touch any of these 14 AI-related stocks with a 10-foot pole. Here's why.
- 02/16/2021
|
Boston Scientific Announces February and March 2021 Conference Schedule
- MARLBOROUGH, Mass., Feb. 12, 2021 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) will participate in two upcoming investor conferences. On February 25, 2021, Dan Brennan, executive vice president and chief financial officer, and Susie Lisa, vice president, Investor Relations,...
- 02/12/2021
|
Boston Scientific (BSX) Hurt by Product Recall, Conversion
- Barring MedSurg, organic revenues at each of Boston Scientific (BSX) core segments and geographies are down in Q4 but the magnitude of this decline is lower than Q3.
- 02/09/2021
|
Boston Scientific Corporation (BSX) CEO Michael Mahoney on Q4 2020 Results - Earnings Call Transcript
- Boston Scientific Corporation (BSX) CEO Michael Mahoney on Q4 2020 Results - Earnings Call Transcript
- 02/03/2021
|
Boston Scientific (BSX) Q4 Earnings Miss, Margins Decline
- Apart from a drop in Q4 earnings and revenues drop year over year, Boston Scientific (BSX) also registers strong sequential decline in overall financial performance.
- 02/03/2021
|
Boston Scientific (BSX) Q4 Earnings and Revenues Lag Estimates
- Boston Scientific (BSX) delivered earnings and revenue surprises of -25.81% and -0.02%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
- 02/03/2021
|
Recap: Boston Scientific Q4 Earnings
- Shares of Boston Scientific (NYSE:BSX) fell 2.0% in pre-market trading after the company reported Q4 results. Quarterly Results Earnings per share decreased 50.00% year over year to $0.23, which missed the estimate of $0.31.
- 02/03/2021
|
Boston Scientific stock falls after profit and sales miss, downbeat outlook
- Shares of Boston Scientific Corp. dropped 3.2% in premarket trading Wednesday, after the medical technology company reported fourth-quarter profit and revenue that fell more than expected, and provided a downbeat first-quarter outlook. Net income fell to $138 million, or 10 cents a share, from $4.00 billion, or $2.83 a share, in the year-ago period.
- 02/03/2021
|
Boston Scientific Announces Results For Fourth Quarter And Full Year 2020
- MARLBOROUGH, Mass., Feb. 3, 2021 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) generated net sales of $2.708 billion during the fourth quarter of 2020. This represents a decline of (6.8) percent on a reported basis, (8.3) percent on an operational1 basis and (8.0) percent on...
- 02/03/2021
|
DEADLINE TODAY: The Schall Law Firm Announces it is Investigating Claims Against Boston Scientific Corporation and Encourages Investors with Losses of $100,000 to Contact the Firm
- LOS ANGELES--(BUSINESS WIRE)---- $BSX #BSX--DEADLINE TODAY: The Schall Law Firm Announces it is Investigating Claims Against Boston Scientific Corporation
- 02/02/2021
|
BSX Final Deadline Today: Rosen, National Trial Counsel, Reminds Boston Scientific Corporation Investors of Important February 2 Deadline in Securities Class Action - BSX
- New York, New York--(Newsfile Corp. - February 2, 2021) - Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Boston Scientific Corporation (NYSE: BSX) between April 24, 2019 and November 16, 2020, inclusive (the "Class Period"), of the important February 2, 2021 lead plaintiff deadline in the securities class action. The lawsuit seeks to recover damages for Boston Scientific investors under the federal securities laws.To join the Boston...
- 02/02/2021
|
BSX ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of February 2, 2021 in the Class Action Filed on Behalf of Boston Scientific Corporation Limited Shareholders
- New York, New York--(Newsfile Corp. - February 1, 2021) - The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Boston Scientific Corporation (NYSE: BSX) alleging that the Company violated federal securities laws.Class Period: April 24, 2019 and November 16, 2020Lead Plaintiff Deadline: February 2, 2021Learn more about your recoverable losses in BSX:
- 02/01/2021
|
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Boston Scientific Corporation of a Class Action Lawsuit and a Lead Plaintiff Deadline of February 2, 2021 - BSX
- New York, New York--(Newsfile Corp. - February 1, 2021) - The following statement is being issued by Levi & Korsinsky, LLP:To: All persons or entities who purchased or otherwise acquired securities of Boston Scientific Corporation (NYSE: BSX) ("Boston Scientific") between April 24, 2019 and November 16, 2020. You are hereby notified that a securities class action lawsuit has been commenced in the United States District Court for the Eastern District of New York. To...
- 02/01/2021
|
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Boston Scientific Corporation of Class Action Lawsuit and Upcoming Deadline - BSX
- NEW YORK, Jan. 31, 2021 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Boston Scientific Corporation ("Boston Scientific" or the "Company") (NYSE: BSX) and certain of its officers. The class action, filed in United States District Court for the...
- 01/31/2021
|
Final Deadline Notice: Rosen, Top Ranked National Investor Attorneys, Encourages Boston Scientific Corporation Investors with Large Losses to Secure Counsel Before Important Deadline - BSX
- New York, New York--(Newsfile Corp. - January 30, 2021) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Boston Scientific Corporation (NYSE: BSX) between April 24, 2019 and November 16, 2020, inclusive (the "Class Period"), of the important February 2, 2021 lead plaintiff deadline.SO WHAT: If you purchased Boston Scientific securities during the Class Period you may be entitled to compensation without payment of any out of...
- 01/30/2021
|
BSX Upcoming Deadline: Bronstein, Gewirtz & Grossman, LLC Reminds Boston Scientific Corporation Shareholders of Class Action and Lead Plaintiff Deadline: February 3, 2021
- New York, New York--(Newsfile Corp. - January 28, 2021) - Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Boston Scientific Corporation ("Boston Scientific" or the "Company") (NASDAQ: BSX) and certain of its officers, on behalf of shareholders who purchased or otherwise acquired Boston Scientific securities between April 24, 2019 to November 16, 2020, both dates inclusive (the "Class Period"). Such investors are encouraged to join this case...
- 01/28/2021
|
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Boston Scientific Corporation of a Class Action Lawsuit and a Lead Plaintiff Deadline of February 2, 2021 - BSX
- New York, New York--(Newsfile Corp. - January 28, 2021) - The following statement is being issued by Levi & Korsinsky, LLP:To: All persons or entities who purchased or otherwise acquired securities of Boston Scientific Corporation ("Boston Scientific") (NYSE: BSX) between April 24, 2019 and November 16, 2020. You are hereby notified that a securities class action lawsuit has been commenced in the United States District Court for the Eastern District of New York. To...
- 01/28/2021
|
Boston Scientific (BSX) LOTUS Edge Recall to Mar Q4 Earnings
- Per Boston Scientific's (BSX) October update, it has started to see strong region-wise recovery.
- 01/27/2021
|
BSX ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of February 2, 2021 in the Class Action Filed on Behalf of Boston Scientific Corporation Limited Shareholders
- New York, New York--(Newsfile Corp. - January 27, 2021) - The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Boston Scientific Corporation (NYSE: BSX) alleging that the Company violated federal securities laws.Class Period: April 24, 2019 and November 16, 2020Lead Plaintiff Deadline: February 2, 2021Learn more about your recoverable losses in BSX:
- 01/27/2021
|
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Boston Scientific Corporation of a Class Action Lawsuit and a Lead Plaintiff Deadline of February 2, 2021 - BSX
- New York, New York--(Newsfile Corp. - January 26, 2021) - The following statement is being issued by Levi & Korsinsky, LLP:To: All persons or entities who purchased or otherwise acquired securities of Boston Scientific Corporation ("Boston Scientific") (NYSE: BSX) between April 24, 2019 and November 16, 2020. You are hereby notified that a securities class action lawsuit has been commenced in the United States District Court for the Eastern District of New York. To get...
- 01/26/2021
|
BSX Upcoming Deadline: Bronstein, Gewirtz & Grossman, LLC Reminds Boston Scientific Corporation Shareholders of Class Action and Lead Plaintiff Deadline: February 3, 2021
- NEW YORK--(BUSINESS WIRE)--Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Boston Scientific Corporation ("Boston Scientific" or the "Company") (NASDAQ: BSX) and certain of its officers, on behalf of shareholders who purchased or otherwise acquired Boston Scientific securities between April 24, 2019 to November 16, 2020, both dates inclusive (the "Class Period"). Such investors are encouraged to join this case by visiting the firm's s
- 01/26/2021
|
BSX FILING DEADLINE IN 1 WEEK: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion In a Securities Class Action Lawsuit Against Boston Scientific Corporation
- New York, New York--(Newsfile Corp. - January 26, 2021) - Bernstein Liebhard, a nationally acclaimed investor rights law firm, reminds investors of the deadline to file a lead plaintiff motion in a securities class action lawsuit that has been filed on behalf of investors who purchased or acquired the securities of Boston Scientific Corporation (NYSE: BSX) ("Boston Scientific" or the "Company") from April 24, 2019 through November 16, 2020 (the "Class Period"). The...
- 01/26/2021
|
Boston Scientific's (BSX) DBS System Gets FDA's Clearance
- The latest FDA approval of Boston Scientific's (BSX) fourth-generation Vercise Genus DBS System is aimed at improving patients' quality of life.
- 01/26/2021
|
Investing in These Stocks Could Make You a Millionaire Retiree
- Amassing $1 million may be much more achievable than you think.
- 01/26/2021
|
BSX ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of February 2, 2021 in the Class Action Filed on Behalf of Boston Scientific Corporation Limited Shareholders
- New York, New York--(Newsfile Corp. - January 25, 2021) - The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Boston Scientific Corporation (NYSE: BSX) alleging that the Company violated federal securities laws.Class Period: April 24, 2019 and November 16, 2020Lead Plaintiff Deadline: February 2, 2021Learn more about your recoverable losses in BSX:
- 01/25/2021
|
Kaplan Fox Has Filed a Class Action to Recover Losses for Investors Who Purchased Boston Scientific Corporation Securities
- NEW YORK, Jan. 25, 2021 /PRNewswire/ -- Kaplan Fox & Kilsheimer LLP (www.kaplanfox.com) has filed a class action suit in the United States District Court for the District of Massachusetts against Boston Scientific Corporation ("Boston Scientific" or "BSX" or the "Company") (NYSE: BSX) and...
- 01/25/2021
|
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Boston Scientific Corporation of a Class Action Lawsuit and a Lead Plaintiff Deadline of February 2, 2021 - BSX
- New York, New York--(Newsfile Corp. - January 25, 2021) - The following statement is being issued by Levi & Korsinsky, LLP:To: All persons or entities who purchased or otherwise acquired securities of Boston Scientific Corporation ("Boston Scientific") (NYSE: BSX) between April 24, 2019 and November 16, 2020. You are hereby notified that a securities class action lawsuit has been commenced in the United States District Court for the Eastern District of New York. To get...
- 01/25/2021
|
ROSEN, TRUSTED INVESTOR COUNSEL, Reminds Boston Scientific Corporation Investors of Important Deadline in Securities Class Action; Encourages Investors with Losses Exceeding $100K to Contact Firm – BSX
- NEW YORK, Jan. 25, 2021 (GLOBE NEWSWIRE) -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Boston Scientific Corporation (NYSE: BSX) between April 24, 2019 and November 16, 2020, inclusive (the "Class Period"), of the important February 2, 2021 lead plaintiff deadline in the securities class action. The lawsuit seeks to recover damages for Boston Scientific investors under the federal securities laws.
- 01/25/2021
|
ROSEN, A TOP RANKED LAW FIRM, Reminds Boston Scientific Corporation Investors of Important February 2 Deadline in Securities Class Action; Encourages Investors with Losses Exceeding $100K to Contact Firm - BSX
- New York, New York--(Newsfile Corp. - January 23, 2021) - Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Boston Scientific Corporation (NYSE: BSX) between April 24, 2019 and November 16, 2020, inclusive (the "Class Period"), of the important February 2, 2021 lead plaintiff deadline in the securities class action. The lawsuit seeks to recover damages for Boston Scientific investors under the federal securities laws.To join the Boston...
- 01/23/2021
|
Why Boston Scientific Is Buying Preventice Solutions For $925 Million
- Boston Scientific (NYSE: BSX) recently announced that it entered into a definitive agreement to buy Preventice Solutions for $925 million. These are the details.
- 01/22/2021
|
Boston Scientific (BSX) Enhances Core Business With Buyout
- Boston Scientific's (BSX) acquisition of Preventice solutions enables the former to expand rhythm management diagnostics portfolio and abilities.
- 01/22/2021
|
Boston Scientific Receives FDA Approval For The Vercise Genus™ Deep Brain Stimulation System
- MARLBOROUGH, Mass., Jan. 22, 2021 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) has received U.S. Food and Drug Administration (FDA) approval of its fourth-generation Vercise Genus™ Deep Brain Stimulation (DBS) System. The portfolio, approved for conditional use in a magnetic...
- 01/22/2021
|
BSX ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of February 2, 2021 in the Class Action Filed on Behalf of Boston Scientific Corporation Limited Shareholders
- New York, New York--(Newsfile Corp. - January 21, 2021) - The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Boston Scientific Corporation (NYSE: BSX) alleging that the Company violated federal securities laws.Class Period: April 24, 2019 and November 16, 2020Lead Plaintiff Deadline: February 2, 2021Learn more about your recoverable losses in BSX:
- 01/21/2021
|
ROSEN, LEADING INVESTOR COUNSEL, Reminds Boston Scientific Corporation Investors of Important February 2 Deadline in Securities Class Action; Encourages Investors with Losses Exceeding $100K to Contact Firm - BSX
- NEW YORK, Jan. 21, 2021 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Boston Scientific Corporation (NYSE: BSX) between April 24, 2019 and November 16, 2020, inclusive (the "Class Period"), of the important February 2, 2021 lead...
- 01/21/2021
|
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Boston Scientific Corporation of a Class Action Lawsuit and a Lead Plaintiff Deadline of February 2, 2021 - BSX
- New York, New York--(Newsfile Corp. - January 21, 2021) - The following statement is being issued by Levi & Korsinsky, LLP:To: All persons or entities who purchased or otherwise acquired securities of Boston Scientific Corporation (NYSE: BSX) ("Boston Scientific") between April 24, 2019 and November 16, 2020. You are hereby notified that a securities class action lawsuit has been commenced in the United States District Court for the Eastern District of New York. To...
- 01/21/2021
|
Boston Scientific to acquire Preventice Solutions for $925million in cash, up to $300 million in potential milestone payments
- Boston Scientific Inc. said Thursday it has agreed to acquire privately held Preventice Solutions Inc. for an upfront payment of $925 million and up to $300 million in potential milestone payments. The company has been an investor in Preventice since 2015 and currently owns a 22% state.
- 01/21/2021
|
This Medical Device Maker Will Be Well Positioned Post COVID
- The pandemic is only a temporary setback for this diversified global manufacturer of medical devices.
- 01/21/2021
|
SHAREHOLDER ALERT; Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Boston Scientific Corporation of Class Action Lawsuit and Upcoming Deadline - BSX
- New York, New York--(Newsfile Corp. - January 20, 2021) - Pomerantz LLP announces that a class action lawsuit has been filed against Boston Scientific Corporation ("Boston Scientific" or the "Company") (NYSE: BSX) and certain of its officers. The class action, filed in United States District Court for the Eastern District of New York, and docketed under 20-cv-05894, is on behalf of a class consisting of all persons other than Defendants who purchased or...
- 01/20/2021
|
The Law Offices of Frank R. Cruz Announces the Filing of a Securities Class Action on Behalf of Boston Scientific Corporation (BSX) Investors
- LOS ANGELES, Jan. 20, 2021 /PRNewswire/ -- The Law Offices of Frank R. Cruz announces that a class action lawsuit has been filed on behalf of persons and entities that purchased or otherwise acquired Boston Scientific Corporation ("Boston Scientific" or the "Company") (NYSE: BSX)...
- 01/20/2021
|
SHAREHOLDER ALERT: BSX NERV KNDI: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines
- NEW YORK, NY / ACCESSWIRE / January 17, 2021 / The Law Offices of Vincent Wong announce that class actions have commenced on behalf of certain shareholders in the following companies. If you suffered a loss you have until the lead plaintiff deadline to request that the court appoint you as lead plaintiff.
- 01/17/2021
|
BSX ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of February 2, 2021 in the Class Action Filed on Behalf of Boston Scientific Corporation Limited Shareholders
- New York, New York--(Newsfile Corp. - January 15, 2021) - The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Boston Scientific Corporation (NYSE: BSX) alleging that the Company violated federal securities laws.Class Period: April 24, 2019 and November 16, 2020Lead Plaintiff Deadline: February 2, 2021Learn more about your recoverable losses in BSX:
- 01/15/2021
|
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Boston Scientific Corporation of a Class Action Lawsuit and a Lead Plaintiff Deadline of February 2, 2021 - BSX
- New York, New York--(Newsfile Corp. - January 15, 2021) - The following statement is being issued by Levi & Korsinsky, LLP:To: All persons or entities who purchased or otherwise acquired securities of Boston Scientific Corporation ("Boston Scientific") (NYSE: BSX) between April 24, 2019 and November 16, 2020. You are hereby notified that a securities class action lawsuit has been commenced in the United States District Court for the Eastern District of New York. To get...
- 01/15/2021
|
The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of BSX, NERV and SWI
- NEW YORK, NY / ACCESSWIRE / January 13, 2021 / The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. There is no cost to participate in the suit.
- 01/13/2021
|
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Boston Scientific Corporation of a Class Action Lawsuit and a Lead Plaintiff Deadline of February 2, 2021 - BSX
- New York, New York--(Newsfile Corp. - January 13, 2021) - The following statement is being issued by Levi & Korsinsky, LLP:To: All persons or entities who purchased or otherwise acquired securities of Boston Scientific Corporation ("Boston Scientific") (NYSE: BSX) between April 24, 2019 and November 16, 2020. You are hereby notified that a securities class action lawsuit has been commenced in the United States District Court for the Eastern District of New York. To get...
- 01/13/2021
|
Baxter Is A Better Choice Than Boston Scientific Stock
- We think that Baxter International currently is a better pick compared to Boston Scientific. BAX stock trades at about 3.6x trailing Revenues, compared to around 5.2x for Boston Scientific.
- 01/13/2021
|
BSX ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of February 2, 2021 in the Class Action Filed on Behalf of Boston Scientific Corporation Limited Shareholders
- New York, New York--(Newsfile Corp. - January 13, 2021) - The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Boston Scientific Corporation (NYSE: BSX) alleging that the Company violated federal securities laws.Class Period: April 24, 2019 and November 16, 2020Lead Plaintiff Deadline: February 2, 2021Learn more about your recoverable losses in BSX:
- 01/13/2021
|
Boston Scientific's stock sinks after downbeat sales outlook
- Shares of Boston Scientific Corp. sank 4.2% in premarket trading Tuesday, after the medical technology company provided a fourth-quarter sales outlook that was below Wall Street forecasts. The company expects to report sales for the quarter to Dec. 31 of $2.71 billion, down 6.8% from a year ago and below the FactSet consensus of $2.86 billion.
- 01/12/2021
|
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Boston Scientific Corporation of a Class Action Lawsuit and a Lead Plaintiff Deadline of February 2, 2021 - BSX
- New York, New York--(Newsfile Corp. - January 12, 2021) - The following statement is being issued by Levi & Korsinsky, LLP:To: All persons or entities who purchased or otherwise acquired securities of Boston Scientific Corporation ("Boston Scientific") (NYSE: BSX) between April 24, 2019 and November 16, 2020. You are hereby notified that a securities class action lawsuit has been commenced in the United States District Court for the Eastern District of New York. To...
- 01/12/2021
|
Boston Scientific Announces Preliminary Unaudited Sales For The Fourth Quarter And Full Year 2020
- MARLBOROUGH, Mass., Jan. 12, 2021 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) generated net sales, based upon preliminary unaudited financial information, of approximately $2.71 billion during the fourth quarter of 2020. This represents a decline of approximately (6.8)...
- 01/12/2021
|
CLASS ACTION UPDATE for BRY, BSX and SWI: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders
- NEW YORK, NY / ACCESSWIRE / January 10, 2021 / Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the court.
- 01/10/2021
|
Rosen, National Trial Lawyers, Reminds Boston Scientific Corporation Investors of Important February 2 Deadline in Securities Class Action - BSX
- New York, New York--(Newsfile Corp. - January 9, 2021) - Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Boston Scientific Corporation (NYSE: BSX) between April 24, 2019 and November 16, 2020, inclusive (the "Class Period"), of the important February 2, 2021 lead plaintiff deadline in the securities class action. The lawsuit seeks to recover damages for Boston Scientific investors under the federal securities laws.To join the Boston Scientific...
- 01/09/2021
|
Lawsuits Filed Against YY, BSX and TRIT - Jakubowitz Law Pursues Shareholders Claims
- NEW YORK, NY / ACCESSWIRE / January 7, 2021 / Jakubowitz Law announces that securities fraud class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies who purchased shares within the class periods listed below. Shareholders interested in representing the class of wronged shareholders have until the lead plaintiff deadline to petition the court.
- 01/07/2021
|
Kaplan Fox Has Filed a Class Action to Recover Losses for Investors Who Purchased Boston Scientific Corporation Securities
- NEW YORK, Jan. 6, 2021 /PRNewswire/ -- Kaplan Fox & Kilsheimer LLP (www.kaplanfox.com) has filed a class action suit in the United States District Court for the District of Massachusetts against Boston Scientific Corporation ("Boston Scientific" or "BSX" or the "Company") (NYSE: BSX) and...
- 01/06/2021
|
The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of TILE, BSX and SWI
- NEW YORK, NY / ACCESSWIRE / January 6, 2021 / The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. There is no cost to participate in the suit.
- 01/06/2021
|
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Boston Scientific Corporation of a Class Action Lawsuit and a Lead Plaintiff Deadline of February 2, 2021 - BSX
- New York, New York--(Newsfile Corp. - January 6, 2021) - The following statement is being issued by Levi & Korsinsky, LLP:To: All persons or entities who purchased or otherwise acquired securities of Boston Scientific Corporation ("Boston Scientific") (NYSE: BSX) between April 24, 2019 and November 16, 2020. You are hereby notified that a securities class action lawsuit has been commenced in the United States District Court for the Eastern District of New York. To get...
- 01/06/2021
|
UPCOMING DEADLINE ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Boston Scientific Corporation and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
- LOS ANGELES, Jan. 6, 2021 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Boston Scientific Corporation ("Boston Scientific" or "the Company") (NYSE: BSX) for violations of §§10(b) and 20(a) of the...
- 01/06/2021
|
SHAREHOLDER ALERT; Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Boston Scientific Corporation of Class Action Lawsuit and Upcoming Deadline - BSX
- New York, New York--(Newsfile Corp. - January 4, 2021) - Pomerantz LLP announces that a class action lawsuit has been filed against Boston Scientific Corporation ("Boston Scientific" or the "Company") (NYSE: BSX) and certain of its officers. The class action, filed in United States District Court for the Eastern District of New York, and docketed under 20-cv-05894, is on behalf of a class consisting of all persons other than Defendants who purchased or...
- 01/04/2021
|
Boston Scientific to Participate in J.P. Morgan Healthcare Conference and Announces Conference Call Discussing Fourth Quarter 2020 Results
- MARLBOROUGH, Mass., Jan. 4, 2021 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) will participate in the virtually held 39th Annual J.P. Morgan Healthcare Conference on Tuesday, January 12, 2021. Mike Mahoney, chairman and chief executive officer, will present at 8:20 a.m. EST....
- 01/04/2021
|
Boston Scientific Corporation: Buy This Secular Grower As Elective Procedures Rebound
- Boston Scientific Corporation: Buy This Secular Grower As Elective Procedures Rebound
- 01/04/2021
|
CLASS ACTION UPDATE for ICPT, BSX and NAK: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders
- NEW YORK, NY / ACCESSWIRE / January 3, 2021 / Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the court.
- 01/03/2021
|
SHAREHOLDER ALERT; Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Boston Scientific Corporation of Class Action Lawsuit and Upcoming Deadline - BSX
- NEW YORK, Jan. 3, 2021 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Boston Scientific Corporation ("Boston Scientific" or the "Company") (NYSE: BSX) and certain of its officers. The class action, filed in United States District Court for the...
- 01/03/2021
|
Firestone: Be careful that what you're buying hasn't moved too far ahead in anticipation of a reopen
- Karen Firestone of Aureus Asset Management discusses whether investors can still take advantage of further gains in a mix of growth and "re-opening" stocks going into early 2021.
- 12/30/2020
|
ROSEN, RESPECTED INVESTOR COUNSEL Reminds Boston Scientific Corporation Investors of the Important February 2 Deadline in Securities Class Action; Encourages Investors with Losses in Excess of $100K to Contact the Firm - BSX
- NEW YORK, Dec. 29, 2020 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Boston Scientific Corporation (NYSE: BSX) between April 24, 2019 and November 16, 2020, inclusive (the "Class Period"), of the important February 2, 2021 lead...
- 12/29/2020
|
SHAREHOLDER ALERT; Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Boston Scientific Corporation of Class Action Lawsuit and Upcoming Deadline - BSX
- New York, New York--(Newsfile Corp. - December 26, 2020) - Pomerantz LLP announces that a class action lawsuit has been filed against Boston Scientific Corporation ("Boston Scientific" or the "Company") (NYSE: BSX) and certain of its officers. The class action, filed in United States District Court for the Eastern District of New York, and docketed under 20-cv-05894, is on behalf of a class consisting of all persons other than Defendants who purchased or...
- 12/26/2020
|
BSX ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of February 2, 2021 in the Class Action Filed on Behalf of Boston Scientific Corporation Limited Shareholders
- New York, New York--(Newsfile Corp. - December 23, 2020) - The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Boston Scientific Corporation (NYSE: BSX) alleging that the Company violated federal securities laws.Class Period: April 24, 2019 and November 16, 2020Lead Plaintiff Deadline: February 2, 2021Learn more about your recoverable losses in BSX:
- 12/23/2020
|
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Boston Scientific Corporation of a Class Action Lawsuit and a Lead Plaintiff Deadline of February 2, 2021 - BSX
- New York, New York--(Newsfile Corp. - December 22, 2020) - The following statement is being issued by Levi & Korsinsky, LLP:To: All persons or entities who purchased or otherwise acquired securities of Boston Scientific Corporation ("Boston Scientific") (NYSE: BSX) between April 24, 2019 and November 16, 2020. You are hereby notified that a securities class action lawsuit has been commenced in the United States District Court for the Eastern District of New York. To...
- 12/22/2020
|
The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of YY, BSX and NAK
- NEW YORK, NY / ACCESSWIRE / December 22, 2020 / The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. There is no cost to participate in the suit.
- 12/22/2020
|
BSX ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of February 2, 2021 in the Class Action Filed on Behalf of Boston Scientific Corporation Limited Shareholders
- New York, New York--(Newsfile Corp. - December 22, 2020) - The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Boston Scientific Corporation (NYSE: BSX) alleging that the Company violated federal securities laws.Class Period: April 24, 2019 and November 16, 2020Lead Plaintiff Deadline: February 2, 2021Learn more about your recoverable losses in BSX:
- 12/22/2020
|
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Boston Scientific Corporation of a Class Action Lawsuit and a Lead Plaintiff Deadline of February 2, 2021 - BSX
- New York, New York--(Newsfile Corp. - December 21, 2020) - The following statement is being issued by Levi & Korsinsky, LLP:To: All persons or entities who purchased or otherwise acquired securities of Boston Scientific Corporation ("Boston Scientific") (NYSE: BSX) between April 24, 2019 and November 16, 2020. You are hereby notified that a securities class action lawsuit has been commenced in the United States District Court for the Eastern District of New York. To get...
- 12/21/2020
|
SHAREHOLDER ALERT; Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Boston Scientific Corporation of Class Action Lawsuit and Upcoming Deadline – BSX
- NEW YORK, Dec. 19, 2020 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Boston Scientific Corporation (“Boston Scientific” or the “Company”) (NYSE: BSX) and certain of its officers. The class action, filed in United States District Court for the Eastern District of New York, and docketed under 20-cv-05894, is on behalf of a class consisting of all persons other than Defendants who purchased or otherwise, acquired Boston Scientific securities between April 24, 2019 and November 16, 2020, both dates inclusive (the “Class Period”), seeking to recover damages caused by Defendants' violations of the federal securities laws and to pursue remedies under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 (the “Exchange Act”) and Rule 10b-5 promulgated thereunder, against the Company and certain of its top officials.
- 12/19/2020
|
BOSTON SCIENTIFIC CORPORATION CLASS ACTION ALERT: Wolf Haldenstein Adler Freeman & Herz LLP reminds investors that a securities class action lawsuit has been filed in the United States District Court for the Eastern District of New York against Boston Sci
- LEAD PLAINTIFF DEADLINE IS FEBRUARY 2, 2021
- 12/18/2020
|
Andreas Halvorsen's Top 5 Health Care Positions as of the 3rd Quarter
- According to current portfolio statistics, a Premium feature of GuruFocus, the top five health care positions in Andreas Halvorsen (Trades, Portfolio)'s equity portfolio as of the third quarter are Adaptive Biotechnologies Corp. (NASDAQ:ADPT), Centene Corp. (NYSE:CNC), BridgeBio Pharma Inc. (NASDAQ:BBIO), Boston Scientific Corp. (NYSE:BSX) and Thermo Fisher Scientific Inc. (NYSE:TMO). This week, Halvorsen revealed a slight reduction to his Adaptive Biotechnologies position according to GuruFocus Real-Time Picks, which is also a Premium feature.
- 12/17/2020
|
The Law Offices of Frank R. Cruz Announces the Filing of a Securities Class Action on Behalf of Boston Scientific Corporation (BSX) Investors
- LOS ANGELES, Dec. 17, 2020 /PRNewswire/ -- The Law Offices of Frank R. Cruz announces that a class action lawsuit has been filed on behalf of persons and entities that purchased or otherwise acquired Boston Scientific Corporation ("Boston Scientific" or the "Company") (NYSE: BSX)...
- 12/17/2020
|
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Boston Scientific Corporation of a Class Action Lawsuit and a Lead Plaintiff Deadline of February 2, 2021 - BSX
- New York, New York--(Newsfile Corp. - December 16, 2020) - The following statement is being issued by Levi & Korsinsky, LLP:To: All persons or entities who purchased or otherwise acquired securities of Boston Scientific Corporation ("Boston Scientific") (NYSE: BSX) between April 24, 2019 and November 16, 2020. You are hereby notified that a securities class action lawsuit has been commenced in the United States District Court for the Eastern District of New York. To get...
- 12/16/2020
|
Rosen, A Leading Investor Rights Law Firm, Reminds Boston Scientific Corporation Investors of the Important Deadline in Securities Class Action; Encourages Investors with Losses in Excess of $100K to Contact the Firm - BSX
- New York, New York--(Newsfile Corp. - December 16, 2020) - Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Boston Scientific Corporation (NYSE: BSX) between April 24, 2019 to November 16, 2020, inclusive (the "Class Period"), of the important February 2, 2021 lead plaintiff deadline in the securities class action. The lawsuit seeks to recover damages for Boston Scientific investors under the federal securities laws.To join the Boston Scientific...
- 12/16/2020
|
Kaplan Fox Files Class Action to Recover Losses for Investors Who Purchased Boston Scientific Securities
- NEW YORK, Dec. 16, 2020 (GLOBE NEWSWIRE) -- Kaplan Fox & Kilsheimer LLP ( www.kaplanfox.com ) has filed a class action suit in the United States District Court for the District of Massachusetts against Boston Scientific Corporation (“Boston Scientific” or “BSX” or the “Company”) (NYSE: BSX) and certain of its executives.
- 12/16/2020
|
BSX Shareholder Alert: Bronstein, Gewirtz & Grossman, LLC Reminds Boston Scientific Corporation Shareholders of Class Action and Lead Plaintiff Deadline: February 3, 2021
- NEW YORK--(BUSINESS WIRE)--Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Boston Scientific Corporation ("Boston Scientific" or the "Company") (NYSE: BSX) and certain of its officers, on behalf of shareholders who purchased or otherwise acquired Boston Scientific securities between April 24, 2019 to November 16, 2020, both dates inclusive (the "Class Period"). Such investors are encouraged to join this case by visiting the firm's sit
- 12/16/2020
|
BSX ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of February 2, 2021 in the Class Action Filed on Behalf of Boston Scientific Corporation Limited Shareholders
- New York, New York--(Newsfile Corp. - December 16, 2020) - The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Boston Scientific Corporation (NYSE: BSX) alleging that the Company violated federal securities laws.Class Period: April 24, 2019 and November 16, 2020Lead Plaintiff Deadline: February 2, 2021Learn more about your recoverable losses in BSX:
- 12/16/2020
|
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Boston Scientific Corporation of a Class Action Lawsuit and a Lead Plaintiff Deadline of February 2, 2021 - BSX
- New York, New York--(Newsfile Corp. - December 15, 2020) - The following statement is being issued by Levi & Korsinsky, LLP:To: All persons or entities who purchased or otherwise acquired securities of Boston Scientific Corporation ("Boston Scientific") (NYSE: BSX) between April 24, 2019 and November 16, 2020. You are hereby notified that a securities class action lawsuit has been commenced in the the United States District Court for the Eastern District of New York. To...
- 12/15/2020
|
SHAREHOLDER ALERT; Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Boston Scientific Corporation of Class Action Lawsuit and Upcoming Deadline - BSX
- New York, New York--(Newsfile Corp. - December 14, 2020) - Pomerantz LLP announces that a class action lawsuit has been filed against Boston Scientific Corporation ("Boston Scientific" or the "Company") (NYSE: BSX) and certain of its officers. The class action, filed in United States District Court for the Eastern District of New York, and docketed under 20-cv-05894, is on behalf of a class consisting of all persons other than Defendants who purchased or...
- 12/14/2020
|
Boston Scientific Announces Stipulation Of Dismissal Of Nevro Corporation's Patent Infringement Case In California
- MARLBOROUGH, Mass., Dec. 14, 2020 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) today announced that a stipulation of dismissal has been filed in the Nevro Corporation (NYSE: NVRO) patent infringement case against Boston Scientific in the United States District Court for the...
- 12/14/2020
|
BSX ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of February 2, 2021 in the Class Action Filed on Behalf of Boston Scientific Corporation Limited Shareholders
- New York, New York--(Newsfile Corp. - December 14, 2020) - The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Boston Scientific Corporation (NYSE: BSX) alleging that the Company violated federal securities laws.Class Period: April 24, 2019 and November 16, 2020Lead Plaintiff Deadline: February 2, 2021Learn more about your recoverable losses in BSX:
- 12/14/2020
|
Deadline Reminder: Law Offices of Howard G. Smith Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Boston Scientific Corporation (BSX)
- BENSALEM, Pa.--(BUSINESS WIRE)---- $BSX #CLASSACTION--Deadline Reminder: Law Offices of Howard G. Smith Reminds Investors of Deadline in Class Action Lawsuit Against Boston Scientific Corporation (BSX)
- 12/14/2020
|
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Boston Scientific Corporation of a Class Action Lawsuit and a Lead Plaintiff Deadline of February 2, 2021 - BSX
- New York, New York--(Newsfile Corp. - December 14, 2020) - The following statement is being issued by Levi & Korsinsky, LLP:To: All persons or entities who purchased or otherwise acquired securities of Boston Scientific Corporation ("Boston Scientific") (NYSE: BSX) between April 24, 2019 and November 16, 2020. You are hereby notified that a securities class action lawsuit has been commenced in the United States District Court for the Eastern District of New York. To get...
- 12/14/2020
|
SHAREHOLDER ALERT; Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Boston Scientific Corporation of Class Action Lawsuit and Upcoming Deadline – BSX
- NEW YORK, Dec. 13, 2020 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Boston Scientific Corporation (“Boston Scientific” or the “Company”) (NYSE: BSX) and certain of its officers. The class action, filed in United States District Court for the Eastern District of New York, and docketed under 20-cv-05894, is on behalf of a class consisting of all persons other than Defendants who purchased or otherwise, acquired Boston Scientific securities between April 24, 2019 and November 16, 2020, both dates inclusive (the “Class Period”), seeking to recover damages caused by Defendants' violations of the federal securities laws and to pursue remedies under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 (the “Exchange Act”) and Rule 10b-5 promulgated thereunder, against the Company and certain of its top officials.
- 12/13/2020
|
BSX STOCK DEADLINE: Zhang Investor Law Reminds Investors with Losses of the Deadline in Securities Class Action Lawsuit Against Boston Scientific Corporation– BSX
- NEW YORK, Dec. 11, 2020 (GLOBE NEWSWIRE) -- Zhang Investor Law announces a class action lawsuit on behalf of shareholders who bought shares of Boston Scientific Corporation (NYSE: BSX) between April 24, 2019 and November 16, 2020, inclusive (the “Class Period”).
- 12/11/2020
|
BSX ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of February 2, 2021 in the Class Action Filed on Behalf of Boston Scientific Corporation Limited Shareholders
- New York, New York--(Newsfile Corp. - December 10, 2020) - The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Boston Scientific Corporation (NYSE: BSX) alleging that the Company violated federal securities laws.Class Period: April 24, 2019 and November 16, 2020Lead Plaintiff Deadline: February 2, 2021Learn more about your recoverable losses in BSX:
- 12/10/2020
|
BOSTON SCIENTIFIC SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Reminds Investors with Losses in Excess of $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Boston Scientific Corporation - BSX
- New Orleans, Louisiana--(Newsfile Corp. - December 10, 2020) - Kahn Swick & Foti, LLC ("KSF") and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until February 2, 2021 to file lead plaintiff applications in a securities class action lawsuit against Boston Scientific Corporation (NYSE: BSX), if they purchased the Company's securities between April 24, 2019 and November 16, 2020, inclusive (the "Class Period"). This action is...
- 12/10/2020
|
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Boston Scientific Corporation of a Class Action Lawsuit and a Lead Plaintiff Deadline of February 2, 2021 - BSX
- New York, New York--(Newsfile Corp. - December 10, 2020) - The following statement is being issued by Levi & Korsinsky, LLP:To: All persons or entities who purchased or otherwise acquired securities of Boston Scientific Corporation ("Boston Scientific") (NYSE: BSX) between April 24, 2019 and November 16, 2020. You are hereby notified that a securities class action lawsuit has been commenced in the the United States District Court for the Eastern District of New York. To...
- 12/10/2020
|
ROSEN, GLOBAL INVESTOR COUNSEL, Reminds Boston Scientific Corporation Investors of the Important Deadline in Securities Class Action; Encourages Investors with Losses in Excess of $100K to Contact the Firm – BSX
- NEW YORK--(BUSINESS WIRE)--Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Boston Scientific Corporation (NYSE: BSX) between April 24, 2019 to November 16, 2020, inclusive (the "Class Period"), of the important February 2, 2021 lead plaintiff deadline in the securities class action. The lawsuit seeks to recover damages for Boston Scientific investors under the federal securities laws. To join the Boston Scientific class action, go to http://www.rosenle
- 12/10/2020
|
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Boston Scientific Corporation of a Class Action Lawsuit and a Lead Plaintiff Deadline of February 2, 2021 - BSX
- New York, New York--(Newsfile Corp. - December 9, 2020) - The following statement is being issued by Levi & Korsinsky, LLP:To: All persons or entities who purchased or otherwise acquired securities of Boston Scientific Corporation ("Boston Scientific") (NYSE: BSX) between April 24, 2019 and November 16, 2020. You are hereby notified that a securities class action lawsuit has been commenced in the the United States District Court for the Eastern District of New York. To...
- 12/09/2020
|
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Boston Scientific Corporation and Encourages Investors with Losses of $100,000 to Contact the Firm
- LOS ANGELES--(BUSINESS WIRE)---- $BSX #BSX--INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Boston Scientific Corporation.
- 12/09/2020
|
BSX ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of February 2, 2021 in the Class Action Filed on Behalf of Boston Scientific Corporation Limited Shareholders
- New York, New York--(Newsfile Corp. - December 9, 2020) - The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Boston Scientific Corporation (NYSE: BSX) alleging that the Company violated federal securities laws.Class Period: April 24, 2019 and November 16, 2020Lead Plaintiff Deadline: February 2, 2021Learn more about your recoverable losses in BSX:
- 12/09/2020
|
INVESTOR ACTION ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Boston Scientific Corporation and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
- Los Angeles, California--(Newsfile Corp. - December 9, 2020) - The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Boston Scientific Corporation (NYSE: BSX) ("Boston Scientific" or "the Company") for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.Investors who purchased the Company's securities between April 24, 2019 and November...
- 12/09/2020
|
ROSEN, A LEADING LAW FIRM, Announces Filing of Securities Class Action Lawsuit Against Boston Scientific Corporation; Encourages Investors with Losses in Excess of $100K to Contact the Firm - BSX
- New York, New York--(Newsfile Corp. - December 8, 2020) - Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of Boston Scientific Corporation (NYSE: BSX) between April 24, 2019 to November 16, 2020, inclusive (the "Class Period"). The lawsuit seeks to recover damages for Boston Scientific investors under the federal securities laws.To join the Boston Scientific class action, go to...
- 12/08/2020
|
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Boston Scientific Corporation of a Class Action Lawsuit and a Lead Plaintiff Deadline of February 2, 2021 - BSX
- New York, New York--(Newsfile Corp. - December 8, 2020) - The following statement is being issued by Levi & Korsinsky, LLP:To: All persons or entities who purchased or otherwise acquired securities of Boston Scientific Corporation (NYSE: BSX) ("Boston Scientific") between April 24, 2019 and November 16, 2020. You are hereby notified that a securities class action lawsuit has been commenced in the the United States District Court for the Eastern District of New York....
- 12/08/2020
|
INVESTOR ALERT: Law Offices of Howard G. Smith Announces the Filing of a Securities Class Action on Behalf of Boston Scientific Corporation (BSX) Investors
- BENSALEM, Pa.--(BUSINESS WIRE)---- $BSX #CLASSACTION--INVESTOR ALERT: Law Offices of Howard G. Smith Announces Filing of Securities Class Action on Behalf of Boston Scientific Corporation (BSX) Investors
- 12/08/2020
|
BSX SHAREHOLDER DEADLINE: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion In a Securities Class Action Lawsuit Against Boston Scientific Corporation
- NEW YORK, Dec. 08, 2020 (GLOBE NEWSWIRE) -- Bernstein Liebhard, a nationally acclaimed investor rights law firm, reminds investors of the deadline to file a lead plaintiff motion in a securities class action lawsuit that has been filed on behalf of investors who purchased or acquired the securities of Boston Scientific Corporation ("Boston Scientific" or the "Company") (NYSE: BSX) from April 24, 2019 through November 16, 2020 (the "Class Period"). The lawsuit filed in the United States District Court for the Eastern District of New York alleges violations of the Securities Exchange Act of 1934.
- 12/08/2020
|
SHAREHOLDER ACTION NOTICE: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Boston Scientific Corporation and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
- LOS ANGELES--(BUSINESS WIRE)---- $BSX #BSX--SHAREHOLDER ACTION NOTICE: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Boston Scientific Corporation.
- 12/08/2020
|
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces the Filing of a Securities Class Action on Behalf of Boston Scientific Corporation (BSX) Investors
- LOS ANGELES--(BUSINESS WIRE)---- $BSX #CLASSACTION--Glancy Prongay & Murray, a Leading Law Firm, Announces Filing of Securities Class Action on Behalf of Boston Scientific Corporation (BSX) Investors
- 12/08/2020
|
ROSEN, RESPECTED INVESTOR COUNSEL, Announces Filing of Securities Class Action Lawsuit Against Boston Scientific Corporation; Encourages Investors with Losses in Excess of $100K to Contact the Firm - BSX
- NEW YORK, Dec. 7, 2020 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of Boston Scientific Corporation (NYSE: BSX) between April 24, 2019 to November 16, 2020, inclusive (the...
- 12/07/2020
|
SHAREHOLDER ALERT; Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Boston Scientific Corporation of Class Action Lawsuit and Upcoming Deadline – BSX
- NEW YORK, Dec. 07, 2020 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Boston Scientific Corporation (“Boston Scientific” or the “Company”) (NYSE: BSX) and certain of its officers. The class action, filed in United States District Court for the Eastern District of New York, and docketed under 20-cv-05894, is on behalf of a class consisting of all persons other than Defendants who purchased or otherwise, acquired Boston Scientific securities between April 24, 2019 and November 16, 2020, both dates inclusive (the “Class Period”), seeking to recover damages caused by Defendants' violations of the federal securities laws and to pursue remedies under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 (the “Exchange Act”) and Rule 10b-5 promulgated thereunder, against the Company and certain of its top officials.
- 12/07/2020
|
SHAREHOLDER ACTION REMINDER: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Boston Scientific Corporation and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
- Los Angeles, California--(Newsfile Corp. - December 7, 2020) - The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Boston Scientific Corporation ("Boston Scientific" or "the Company") (NYSE: BSX) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.Investors who purchased the Company's securities between April 24, 2019 and November 16,...
- 12/07/2020
|
The Law Offices of Frank R. Cruz Announces Investigation of Boston Scientific Corporation (BSX) on Behalf of Investors
- LOS ANGELES--(BUSINESS WIRE)---- $BSX #classaction--The Law Offices of Frank R. Cruz announces an investigation of Boston Scientific Corporation (“Boston Scientific” or the “Company”) (NYSE: BSX) on behalf of investors concerning the Company's possible violations of federal securities laws. If you are a shareholder who suffered a loss, click here to participate. On November 17, 2020, Boston Scientific announced a worldwide recall of all unused inventory of the LOTUS Edge Aortic Valve System, a transcatheter aortic v
- 12/07/2020
|
BOSTON SCIENTIFIC SHAREHOLDER ALERT by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Reminds Investors With Losses in Excess of $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Boston Scientific Corporation - BSX
- NEW ORLEANS--(BUSINESS WIRE)--Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until February 2, 2021 to file lead plaintiff applications in a securities class action lawsuit against Boston Scientific Corporation (NYSE: BSX), if they purchased the Company's securities between April 24, 2019 and November 16, 2020, inclusive (the “Class Period”). This action is pending in the United States District Cour
- 12/07/2020
|
BSX INVESTOR ALERT: Bernstein Liebhard LLP Announces that a Securities Class Action Lawsuit Has Been Filed Against Boston Scientific Corporation
- NEW YORK, Dec. 7, 2020 /PRNewswire/ -- Bernstein Liebhard, a nationally acclaimed investor rights law firm, announces that a securities class action lawsuit has been filed on behalf of investors who purchased or acquired the securities of Boston Scientific Corporation ("Boston Scientific"...
- 12/07/2020
|
SHAREHOLDER ACTION ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Boston Scientific Corporation and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
- LOS ANGELES--(BUSINESS WIRE)---- $BSX #BSX--SHAREHOLDER ACTION ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Boston Scientific Corporation.
- 12/07/2020
|
INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Boston Scientific Corporation (BSX) on Behalf of Investors
- BENSALEM, Pa.--(BUSINESS WIRE)---- $BSX #CLASSACTION--INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Boston Scientific Corporation (BSX) on Behalf of Investors
- 12/07/2020
|
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Boston Scientific Corporation (BSX) on Behalf of Investors
- LOS ANGELES--(BUSINESS WIRE)---- $BSX #CLASSACTION--Glancy Prongay & Murray LLP, Leading Securities Fraud Law Firm, Announces Investigation of Boston Scientific Corporation (BSX) on Behalf of Investors
- 12/07/2020
|
Boston Scientific - Looking Past The TAVR Setbacks
- Addressing the elephant in the room - recent setbacks in TAVR. BSX has a premium Medical Devices portfolio that is likely to continue to grow above market in the medium term.
- 12/07/2020
|
ROSEN, A TOP RANKED LAW FIRM, Announces Filing of Securities Class Action Lawsuit Against Boston Scientific Corporation – BSX
- NEW YORK--(BUSINESS WIRE)--Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of Boston Scientific Corporation (NYSE: BSX) between April 24, 2019 to November 16, 2020, inclusive (the "Class Period"). The lawsuit seeks to recover damages for Boston Scientific investors under the federal securities laws. To join the Boston Scientific class action, go to http://www.rosenlegal.com/cases-register-2002.html or ca
- 12/07/2020
|
Pomerantz Law Firm Announces the Filing of a Class Action against Boston Scientific Corporation and Certain Officers - BSX
- NEW YORK, Dec. 5, 2020 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Boston Scientific Corporation ("Boston Scientific" or the "Company") (NYSE: BSX) and certain of its officers. The class action, filed in United States District Court for the...
- 12/05/2020
|
Pomerantz Law Firm Announces the Filing of a Class Action against Boston Scientific Corporation and Certain Officers - BSX
- NEW YORK, Dec. 4, 2020 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Boston Scientific Corporation ("Boston Scientific" or the "Company") (NYSE: BSX) and certain of its officers. The class action, filed in United States District Court for the...
- 12/04/2020
|
3 Under-Loved Biotech Stocks to Buy for Profits Into 2021
- Biotech stocks are vulnerable to headlines, but these three have too much potential to ignore. Own them for a swing trade into 2021.
- 12/03/2020
|
Boston Scientific sells BTG specialty pharma business to SERB affiliates for $800 million in cash
- Boston Scientific Corp. said Tuesday it is selling its BTG Specialty Pharmaceuticals business to Stark International Lux S.A.R.L. and SERB SAS, both affiliates of specialty pharma group SERB, for $800 million in cash.
- 12/01/2020
|
Boston Scientific Signs Definitive Agreement to Divest BTG Specialty Pharmaceuticals Business
- MARLBOROUGH, Mass., Dec. 1, 2020 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) today announced that it has entered into a definitive agreement with Stark International Lux S.A.R.L., and SERB SAS, affiliates of SERB, a European specialty pharmaceutical group, to sell its BTG...
- 12/01/2020
|
Boston Scientific's Stock Down 10%, What Comes Next?
- Here is an interesting fact. While most stocks have been climbing, Boston Scientific's stock is doing something different.
- 11/25/2020
|
Boston Scientific to Participate in Evercore ISI 2020 Healthcare Conference
- MARLBOROUGH, Mass., Nov. 23, 2020 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) is scheduled to participate in the 2020 Evercore ISI HealthCONx Conference on December 1. Mike Mahoney, chairman and chief executive officer, and Susie Lisa, vice president, Investor Relations will...
- 11/23/2020
|
Investor Alert: Kaplan Fox Continues To Investigate Boston Scientific Corporation (BSX)
- NEW YORK, Nov. 20, 2020 /PRNewswire/ -- Kaplan Fox & Kilsheimer LLP (www.kaplanfox.com) has been investigating potential claims against Boston Scientific Corporation (NYSE: BSX) ("BSX" or the "Company") for violations of the federal securities laws. BSX's Lotus Edge is a transcatheter...
- 11/20/2020
|
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Boston Scientific Corporation - BSX
- NEW YORK, Nov. 18, 2020 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Boston Scientific Corporation ("Boston Scientific" or the "Company") (NYSE: BSX). Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext....
- 11/18/2020
|
New Product Launches And Attractive Valuation To Drive Boston Scientific Stock Higher
- Despite a 47% rise since the March lows, at the current price of around $38 per share we believe Boston Scientific stock, has more room for growth in the near term. BSX stock has rallied from $26 to $38 off the recent bottom compared to the S&P which moved 60% over the same period, with the.
- 11/17/2020
|
Boston Scientific Announces November 2020 Conference Schedule
- MARLBOROUGH, Mass., Nov. 5, 2020 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) will participate in two upcoming virtual investor conferences. On November 12, 2020, Meghan Scanlon, senior vice president and president, Urology and Pelvic Health, and Susie Lisa, vice president,...
- 11/05/2020
|
Boston Scientific Receives FDA Approval for the Ranger™ Drug-Coated Balloon
- MARLBOROUGH, Mass., Nov. 2, 2020 /PRNewswire/ -- Boston Scientific (NYSE: BSX) announced it has received U.S. Food and Drug Administration (FDA) approval of the Ranger™ Drug-Coated Balloon, developed for the treatment of patients with peripheral artery disease (PAD) in the superficial...
- 11/02/2020
|
Boston Scientific Corporation (BSX) CEO Michael Mahoney on Q3 2020 Results - Earnings Call Transcript
- Boston Scientific Corporation (BSX) CEO Michael Mahoney on Q3 2020 Results - Earnings Call Transcript
- 10/28/2020
|
Boston Scientific Announces Results For Third Quarter 2020
- MARLBOROUGH, Mass., Oct. 28, 2020 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) generated sales of $2.659 billion during the third quarter of 2020. This represents a decline of (1.8) percent on a reported basis, (2.5) percent on an operational1 basis and (5.7) percent on an...
- 10/28/2020
|
Cardiovascular Interventional Devices Market Developments, Competitive Analysis, Forecasts 2026
- Oct 09, 2020 (Market Insight Reports) --
Global Cardiovascular Interventional Devices Market Research Report 2020 begins with an overview of the Market and...
- 10/09/2020
|
Interventional Radiology Market Size, Growth, Trends, Company Analysis and Forecast 2020 to 2030
- Oct 08, 2020 (Profound via COMTEX) --
InsightSLICE report, titled Global Interventional Radiology Market Size, Share, Growth, Trends, Company Analysis and...
- 10/08/2020
|
Colesterolo LDL: L’acido bempedoico (NILEMDO®) riduce significativamente il colesterolo nei pazienti con ipercolesterolemia familiare. L’analisi presentata all’EAS2020
- L’acido bempedoico (NILEMDO®) ha dimostrato riduzioni significative del colesterolo nelle persone con la forma più comune di ipercolesterolemia famili
- 10/08/2020
|
Interventional Radiology Market Emerging Trends, Revenue Estimation, Global Size and Forecast Report to 2025
- Oct 07, 2020 (Heraldkeepers) --
The Interventional Radiology Market is segmented on the lines of its product, procedure, application and regional. Based on...
- 10/07/2020
|
Global Cardiology Defibrillators Devices Market PESTEL Analysis and Phenomenal Growth(2020-2029)| Biotronik, Boston Scientific Corporation, Cardiac Science Corporation
- Sep 30, 2020 (WiredRelease via Comtex) --
The latest research report provides a complete assessment of the Global Cardiology Defibrillators Devices market...
- 09/30/2020
|
Tracking Ole Andreas Halvorsen's Viking Global Portfolio - Q2 2020 Update
- Halvorsen's 13F portfolio value increased from $19.21B to $23.14B. The number of positions increased from 64 to 71.
- 09/11/2020
|
Interventional Cardiology & Peripheral Vascular Devices Market Report 2020: Manufacturers, Countries, Type and Application, Global Forecast To 2025
- Sep 10, 2020 (Heraldkeepers) --
Interventional cardiology offers with catheter-based totally technologies for the remedy of structural heart sicknesses. The...
- 09/10/2020
|
Wall Street Breakfast: The Week Ahead
- Listen on the go! A daily podcast of Wall Street Breakfast will be available by 8:00 a.m. on Seeking Alpha, iTunes, Stitcher and Spotify.
- 09/06/2020
|
Stocks To Watch: Tech Reboots And Eyes On Lululemon, Peloton & GameStop
- Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning.
- 09/05/2020
|
Tracking Larry Robbins' Glenview Capital Management Portfolio - Q2 2020 Update
- Glenview Capital Management's 13F portfolio value decreased from $3.68B to $3.63B this quarter. The number of positions decreased from 44 to 43.
- 09/04/2020
|
Interventional Cardiology & Peripheral Vascular Devices Market Forecast Revised in a New Big Market Research Report as COVID-19 Projected to Hold a Massive Impact on Sales in 2019
- Aug 28, 2020 (Heraldkeepers) --
Interventional cardiology offers with catheter-based totally technologies for the remedy of structural heart sicknesses. The...
- 08/28/2020
|
NILEMDO® Delivers Significant Cholesterol Lowering in Addition to Statin Therapy Which is Maintained During 2.5 Years of Treatment
- Daiichi Sankyo Europe GmbH (hereafter, ‘Daiichi Sankyo’) today announced that NILEMDO® (bempedoic acid) has demonstrated consistent tolerability and s
- 08/28/2020
|
Allscripts Continuing to Lead in Physician Practice Market With Series of New Wins
- Allscripts ambulatory business has seen increasing momentum with 18 new physician practices selecting Allscripts (Nasdaq: MDRX) this year for ambulato
- 08/27/2020
|
Rhythm Pharmaceuticals (NASDAQ:RYTM) Stock Rating Lowered by Zacks Investment Research
- Rhythm Pharmaceuticals (NASDAQ:RYTM) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a research report issued on Wednesday, Zacks.com reports. According to Zacks, “Rhythm Pharmaceuticals, Inc. is a biopharmaceutical company. It focused on the development and commercialization of peptide therapeutics for the treatment of rare genetic deficiencies which result […]
- 08/26/2020
|
COVID-19 Pandemic Impact on Global Interventional Spine Devices Market 2020-2024 | Technavio
- The Global Interventional Spine Devices Market will grow by USD 2.31 bn during 2020-2024
- 08/26/2020
|
Boston Scientific Co. (NYSE:BSX) Shares Bought by Steward Partners Investment Advisory LLC
- Steward Partners Investment Advisory LLC raised its stake in shares of Boston Scientific Co. (NYSE:BSX) by 33.6% in the second quarter, according to its most recent 13F filing with the SEC. The fund owned 15,348 shares of the medical equipment provider’s stock after buying an additional 3,856 shares during the period. Steward Partners Investment Advisory […]
- 08/22/2020
|
Tracking David Tepper's Appaloosa Management Portfolio - Q2 2020 Update
- David Tepper’s 13F portfolio value increased from $3.27B to $5.76B this quarter. Appaloosa added AT&T while increasing Alibaba Group Holdings during the quarter.
- 08/20/2020
|
Boston Scientific's Voraxaze's MAA Accepted by EMA for Review
- Boston Scientific's (BSX) business arm's MMA for Voraxaze (glucarpidase) accepted by EMA for review.
- 08/18/2020
|
BTG Specialty Pharmaceuticals announces the European Medicines Agency has accepted for review a marketing authorisation application for Voraxaze®
- BTG Specialty Pharmaceuticals, a division of Boston Scientific (NYSE:BSX), today announced the European Medicines Agency (EMA) has accepted for review a Marketing Authorisation Application (MAA) for Voraxaze® (glucarpidase). BTG Specialty Pharmaceuticals is seeking marketing authorization of Voraxaze® for the treatment of adults and children (from 28 days of age) at risk of methotrexate toxicity due to delayed methotrexate elimination.
- 08/17/2020
|
Boston Scientific For The Long Term
- Boston Scientific faces many headwinds in Q3 and Q4 2020 because the pandemic has dramatically curtailed its operations and reduced the demand for its products.
- 08/13/2020
|
Global Pacemakers Market Analysis and Forecast Model 2015-2030: Epidemiology-Based Indications With Procedure Volumes - ResearchAndMarkets.com
|
Viking Global Investors Trims Technology Company Holdings in 2nd Quarter
- Amazon, Netflix, Alphabet, Facebook among largest sales Continue reading...
- 08/10/2020
|
PQ Bypass Will Present Important DETOUR2 Study Update During AMP Virtual Conference 2020
- PQ Bypass to share update on DETOUR2 Clinical Trial at Amputation Prevention Symposium
- 08/10/2020
|
Insider Selling: Boston Scientific Co. (NYSE:BSX) EVP Sells 2,385 Shares of Stock
- Boston Scientific Co. (NYSE:BSX) EVP David A. Pierce sold 2,385 shares of the business’s stock in a transaction on Monday, August 3rd. The shares were sold at an average price of $38.69, for a total value of $92,275.65. Following the transaction, the executive vice president now owns 7,016 shares of the company’s stock, valued at […]
- 08/09/2020
|
3 Top Healthcare Stocks to Buy in August | The Motley Fool
- New products mean solid revenue may be ahead for these companies.
- 08/08/2020
|
Insights on the Global Flexible Endoscopes Market 2020-2024 | COVID-19 Analysis, Drivers, Restraints, Opportunities and Threats | Technavio
- The Global Flexible Endoscopes Market will grow by USD 1.75 bn during 2020-2024
- 08/07/2020
|
Charting a solid August start: S&P 500, Nasdaq stage latest summer breakouts
- Technically speaking, the U.S. benchmarks’ bigger-picture backdrop remains bullish amid a solid August start, writes Michael Ashbaugh.
- 08/04/2020
|
Edwards Lifesciences Shows Surprising Resilience, And TAVR Remains A Growth Market (NYSE:EW)
- TAVR procedures were surprisingly resilient in the second quarter, driving a large revenue and profit beat for Edwards.
- 08/04/2020
|
Outlook on the Worldwide Intensive Care Unit (ICU) Equipment Market to 2025 - Featuring Nihon Kohden, Resmed & Stryker Among Others - ResearchAndMarkets.com
|
Analysts Conflicted on These Healthcare Names: Zoetis (NYSE: ZTS) and Boston Scientific (NYSE: BSX) - Markets
- Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Zoetis (ZTS –
- 08/03/2020
|
SVB Leerink Weighs in on Boston Scientific Co.’s Q3 2020 Earnings (NYSE:BSX)
- Boston Scientific Co. (NYSE:BSX) – Equities research analysts at SVB Leerink raised their Q3 2020 earnings estimates for shares of Boston Scientific in a report issued on Thursday, July 30th. SVB Leerink analyst D. Antalffy now expects that the medical equipment provider will post earnings per share of $0.28 for the quarter, up from their […]
- 08/03/2020
|
First Quadrant L P CA Sells 8,898 Shares of Boston Scientific Co. (NYSE:BSX)
- First Quadrant L P CA trimmed its position in shares of Boston Scientific Co. (NYSE:BSX) by 39.0% during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 13,902 shares of the medical equipment provider’s stock after selling 8,898 shares during the period. First Quadrant L […]
- 08/01/2020
|
Did Business Growth Power Boston Scientific's (NYSE:BSX) Share Price Gain of 125%?
- When you buy a stock there is always a possibility that it could drop 100%. But when you pick a company that is really...
- 07/30/2020
|
Coronavirus update: U.S. death toll climbs above 150,000, and White House task force says 21 states are in the ‘red zone’
- The U.S. death toll from the coronavirus illness COVID-19 climbed above 150,000 on Wednesday, and the White House Task Force created to manage the pandemic...
- 07/29/2020
|
Boston Scientific (BSX) Q2 Earnings Top, Margins Decline
- This time too Boston Scientific (BSX) refrains from providing any update on the full-year guidance.
- 07/29/2020
|
Boston Scientific Corporation (BSX) CEO Michael Mahoney on Q2 2020 Results - Earnings Call Transcript
- Boston Scientific Corporation. (NYSE:BSX) Q2 2020 Results Earnings Conference Call July 29, 2020, 08:00 AM ET Company Participants Susan Lisa - Vice President, Investor Relations Michael Mahoney - Chairman and Chief Executive Officer Daniel Brennan - Executive Vice President and Chief Financial Officer Conference Call Participants Robert Hopkins - Bank of America Merrill Lynch David Lewis - Morgan Stanley Larry Biegelsen - Wells Fargo Robert Marcus - JPMorgan Rick Wise - Stifel Vijay Kumar - Evercore ISI Matthew Taylor - UBS Joanne Wuensch - Citibank Presentation Operator Ladies and gentlemen, thank you for standing by and welcome to the Boston Scientific Second Quarter 2020 Earnings Conference Call.
- 07/29/2020
|
Boston Scientific Earnings Top; Medical Device Giant Rises
- Boston Scientific earnings were positive on adjusted basis. Analysts expected the medical device giant to report a loss. BSX stock rose modestly.
- 07/29/2020
|
Boston Scientific's Debt Overview
- Shares of Boston Scientific Inc. (NYSE: BSX) moved higher by 7.76% in the past three months. Before we understand the importance of debt, let's look at how much debt Boston Scientific has.Boston Scientific's Debt Based on Boston Scientific's financial statement as of May 6, 2020, long-term debt is at $9.33 billion and current debt is at $1.00 billion, amounting to $10.34 billion in total debt. Adjusted for $370.00 million in cash-equivalents, the company's net debt is at $9.96 billion.Investors look at the debt-ratio to understand how much financial leverage a company has. Boston Scientific has $30.11 billion in total assets, therefore making the debt-ratio 0.34. Generally speaking, a debt-ratio more than 1 means that a large portion of debt is funded by assets. As the debt-ratio increases, so the does the risk of defaulting on loans, if interest rates were to increase. Different industries have different thresholds of tolerance for debt-ratios. For example, a debt ratio of 25% might be higher for one industry, whereas normal for another.Why Debt Is Important Debt is an important factor in the capital structure of a company, and can help it attain growth. Debt usually has a relatively lower financing cost than equity, which makes it an attractive option for executives.However, interest-payment obligations can have an adverse impact on the cash-flow of the company. Equity owners can keep excess profit, generated from the debt capital, when companies use the debt capital for its business operations.See more from Benzinga * Recap: Boston Scientific Q2 Earnings(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
- 07/29/2020
|
Boston Scientific (BSX) Tops Q2 Earnings and Revenue Estimates
- Boston Scientific (BSX) delivered earnings and revenue surprises of 300.00% and 22.07%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
- 07/29/2020
|
Recap: Boston Scientific Q2 Earnings
- Shares of Boston Scientific (NYSE:BSX) moved higher by 0.6% in pre-market trading after the company reported Q2 results.Quarterly Results Earnings per share were down 79.49% year over year to $0.08, which beat the estimate of ($0.03).Revenue of $2,003,000,000 declined by 23.87% year over year, which beat the estimate of $1,710,000,000.Looking Ahead Earnings guidance hasn't been issued by the company for now.Revenue guidance hasn't been issued by the company for now.Conference Call Details Date: Jul 29, 2020View more earnings on BSXTime: 08:00 AMET Webcast URL: https://www.webcaster4.com/Webcast/Page/514/35543Price Action 52-week high: $46.6252-week low: $24.10Price action over last quarter: Up 2.19%Company Profile Boston Scientific produces less-invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, cardiac rhythm management, catheter-directed ultrasound imaging, structural heart disease, upper gastrointestinal tract tests, interventional oncology, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for nearly half of the firm's total sales.See more from Benzinga * Spotify Technology: Q2 Earnings Insights * Eaton: Q2 Earnings Insights * Recap: TE Connectivity Q3 Earnings(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
- 07/29/2020
|
Boston Scientific swings to loss and sales fall, but remain ahead of estimates
- Boston Scientific Corp. shares rose 2.7% in premarket trade Wednesday, after the maker of medical devices reported a loss and sales decline for its second quarter, but remained well ahead of estimates. The company said it had a net loss of $153 million, or 11 cents a share, in the quarter, after income of $154 million, or 11 cents a share, in the year-earlier period. Adjusted per-share earnings came to 8 cents, ahead of the FactSet consensus for a loss of 3 cents per share. Sales fell to $2.003 billion from $2.631 billion, but were also ahead of the $1.727 billion FactSet consensus. Sales fell at each of the company's divisions, with medical surgical sales down 29.6%, rhythm and neuro down 33.2% and cardiovascular sales down 18.7%. Shares have fallen 15% in the year to date, while the S&P 500 has fallen 0.4%.
- 07/29/2020
|
Boston Scientific swings to loss as medical device sales sink
|
Only 4% of Companies Reveal the Racial Makeup of Their Companies. Investors Are Pushing to Change That.
- Only 4% of companies disclose data, which makes it hard to measure progress.
- 07/27/2020
|
Global Drug Eluting Balloons (DEBs) Market Analysis Highlights the Impact of COVID-19 2020-2024| Growing Demand for Cath Labs to Boost Market Growth | Technavio
- The Global Drug Eluting Balloons (DEBs) Market will grow by $ 476.64 mn during 2020-2024
- 07/27/2020
|
Acutus Medical Files For IPO For Commercialization Push
- Acutus Medical has filed to raise $75 million in a U.S. IPO, although the final figure may differ.
- 07/23/2020
|
Deferred Procedures to Mar Boston Scientific (BSX) Q2 Earnings
- With lockdowns continuing through all three months of the second quarter, Boston Scientific (BSX) is expected to have faced a more dreadful time.
- 07/23/2020
|
Earnings Preview: Boston Scientific (BSX) Q2 Earnings Expected to Decline
- Boston Scientific (BSX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- 07/22/2020
|
The Daily Biotech Pulse: Aurinia's Kidney Inflammation Drug Filing Accepted For Review, Intuitive Surgical's Q2 Beat
- Scaling The Peaks(Biotech Stocks Hitting 52-week Highs July 21) * ABIOMED, Inc. (NASDAQ: ABMD) * Assembly Biosciences Inc (NASDAQ: ASMB) * Bio-Rad Laboratories, Inc. (NYSE: BIO) * Beigene Ltd (NASDAQ: BGNE) * BioLife Solutions Inc (NASDAQ: BLFS) * BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) * Brainstorm Cell Therapeutics Inc (NASDAQ: BCLI) * Catalent Inc (NYSE: CTLT) * CTI BioPharma Corp (NASDAQ: CTIC) * GENMAB A/S/S ADR (NASDAQ: GMAB) * Heat Biologics Inc (NASDAQ: HTBX) * Hologic, Inc. (NASDAQ: HOLX) * Horizon Therapeutics PLC (NASDAQ: HZNP) * Immunomedics, Inc. (NASDAQ: IMMU) * Intuitive Surgical, Inc. (NASDAQ: ISRG) * Ligand Pharmaceuticals Inc. (NASDAQ: LGND) * Natera Inc (NASDAQ: NTRA) * Novo Nordisk A/S (NYSE: NVO) * Opko Health Inc. (NASDAQ: OPK)(moved in reaction to an announcement it will offer COVID-19 diagnostics testing to the NFL) * ResMed Inc. (NYSE: RMD) * Retrophin Inc (NASDAQ: RTRX) * Trevena Inc (NASDAQ: TRVN) * Twist Bioscience Corp (NASDAQ: TWST) * Veracyte Inc (NASDAQ: VCYT) * West Pharmaceutical Services Inc. (NYSE: WST) * Zoetis Inc (NYSE: ZTS)Down In The Dumps (Biotech Stocks Hitting 52-week Lows July 21) * ALX Oncology Holdings Inc (NASDAQ: ALXO) (IPOed Friday) * Biofrontera AG (NASDAQ: BFRA) * Nkarta Inc (NASDAQ: NKTX) * Pandion Therapeutics Holdco LLC (NASDAQ: PAND) (IPOed Friday) * RENALYTIX AI ADR (NASDAQ: RNLX) (IPOed Friday) * Tricida Inc (NASDAQ: TCDA)Stocks In Focus Aurinia Announces FDA Acceptance of NDA For Kidney Inflammation Drug With Priority Review Aurinia Pharmaceuticals Inc (NASDAQ: AUPH) said the FDA has accepted the filing of its NDA for voclosporin, as a potential treatment for lupus nephritis, a serious inflammation of the kidneys caused by the autoimmune disease systemic lupus erythematosus. The FDA has granted Priority Review for the application, and has assigned a PDUFA target action date of Jan. 22, 2021.The stock advanced 9.12% to $15.80 in after-hours trading.Biogen Appoints Iqvia Executive as New CFO Biogen Inc (NASDAQ: BIIB) announced the appointment of Michael McDonnell as EVP and CFO, effective Aug. 15, replacing the incumbent Jeffrey Capello. McDonnell is currently serving as CFO of Iqvia Holdings Inc (NYSE: IQV).FDA To Hold an Adcom Review of Mesoblast's BLA For Acute GvHD Drug Mesoblast limited (NASDAQ: MESO) said the Oncologic Drugs Advisory Committee of the FDA has scheduled a meeting Aug. 13 to review data supporting its BLA for the approval of Ryoncil for the treatment of steroid-refractory acute graft versus host disease in children.The BLA has a PDUFA action date of Sept. 30.Boston Scientific Announces FDA Nod For Device to Reduce Risk of Stroke Boston Scientific Corporation (NYSE: BSX) said it has received FDA approval for the WATCHMAN FLX Left Atrial Appendage Closure Device.View more earnings on IBBThe device is indicated to reduce the risk of stroke in patients with non-valvular atrial fibrillation who need an alternative to oral anticoagulation therapy by permanently closing off the left atrial appendage.The company said it is planning an immediate limited commercial launch in the U.S.In pre-market trading Wednesday, the stock was adding 2.05% to $38.25.Intuitive Surgical Q2 Beats Estimates Intuitive Surgical, Inc. (NASDAQ: ISRG) reported a 22% decline in second-quarter revenues to $852 million, while its non-GAAP net income per share fell from $3.25 to $1.11. Analysts, on average, had estimated earnings of 63 cents per share on revenues of $664.96 million.Offerings CASI Pharmaceuticals Inc (NASDAQ: CASI) said it has commenced an underwritten public offering to issue shares of its common stock. All of the shares of common stock in the offering will be sold by the company.The stock was slipping 9.42% to $2.02 in pre-market trading Wednesday.On The Radar Clinical Readouts Zynerba Pharmaceuticals Inc (NASDAQ: ZYNE) said it will present an overview of its Zygel development program in Fragile X syndrome and additional caregiver-reported data from its 14-week pivotal CONNECT-FX trial during the 17th NFXF International Fragile X Conference Research Roundup. The presentation is scheduled to take place at 3:45 pm ET. The company reported results from the study on June 30, showing the study did not meet the primary and secondary endpoints.Earnings Biogen (before the market open)See more from Benzinga * The Daily Biotech Pulse: Opko Wins CDC Contract, Novartis Lowers Guidance, Pieris Study Placed On Partial Clinical Hold * Credit Suisse Upgrades Gilead On Remdesivir Commercial Opportunity * The Daily Biotech Pulse: 2 IPOs, Nabriva Pneumonia Drug Gets Canadian Regulatory Nod, PhaseBio Doses First COVID-19 Trial Patient(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
- 07/22/2020
|
Empirical Finance LLC Raises Stock Position in Boston Scientific Co. (NYSE:BSX)
- Empirical Finance LLC boosted its position in shares of Boston Scientific Co. (NYSE:BSX) by 14.3% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 9,161 shares of the medical equipment provider’s stock after acquiring an additional 1,145 shares during […]
- 07/22/2020
|
Tributary Capital Management LLC Buys 1,250 Shares of Boston Scientific Co. (NYSE:BSX)
- Tributary Capital Management LLC boosted its stake in Boston Scientific Co. (NYSE:BSX) by 10.9% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 12,750 shares of the medical equipment provider’s stock after purchasing an additional 1,250 shares during the quarter. Tributary […]
- 07/22/2020
|
Episode Four – The Heart of a Ballerina | Direct2DellEMC
- Lindsay Davis’ childhood was consumed with dancing. The aspiring ballerina had her sights set on attending Julliard. After that, the sky was the limit.
- 07/22/2020
|
Boston Scientific Scores FDA Green Light For New LAAC Heart Device
- Medical tech giant Boston Scientific Corporation (BSX) has announced that it has received U.S. Food and Drug Administration (FDA) approval for its
- 07/22/2020
|
Boston Scientific Receives FDA Approval for Next-Generation WATCHMAN FLX™ Left Atrial Appendage Closure Device
- Boston Scientific Corporation (NYSE: BSX) announced it has received U.S. Food and Drug Administration (FDA) approval for the WATCHMAN FLX™ Left Atrial Appendage Closure (LAAC) Device.
- 07/21/2020
|
Tax Free? 41 Big And Profitable U.S. Companies Paid No Tax
- You likely just filed your taxes and even paid some. You might wonder how some S&P 500 companies didn't pay a dime.
- 07/21/2020
|
Soligenix Issues Corporate Update - Highlights Important Catalysts for Second Half of 2020
- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, today issued an update letter from its President and Chief Executive Officer, Dr. Christopher J. Schaber. The content of this letter is provided below.
- 07/20/2020
|
Exchange Traded Concepts LLC Increases Stake in Boston Scientific Co. (NYSE:BSX)
- Exchange Traded Concepts LLC increased its holdings in Boston Scientific Co. (NYSE:BSX) by 121.0% in the second quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 9,676 shares of the medical equipment provider’s stock after purchasing an additional 5,298 shares during the period. Exchange Traded Concepts LLC’s holdings in […]
- 07/18/2020
|
Cramer Weighs In On Beyond Meat, Boston Scientific And More
- On CNBC's "Mad Money Lightning Round," Jim Cramer said that the Beyond Meat Inc (NASDAQ: BYND) franchise is good and he likes the stock.Cramer can't recommend Scorpio Tankers Inc. (NYSE: STNG). He is looking for solid blue-chip stocks.Crowdstrike Holdings Inc (NASDAQ: CRWD) is trading lower because people are buying stocks that are going to do better if the economy opens, explained Cramer. It seems the market thinks these stay-at-home stocks have reached their peak, but Cramer is not so sure.Cramer wouldn't sell Boston Scientific Corporation (NYSE: BSX) because it is one of the best medical device companies out there. He prefers Medtronic PLC (NYSE: MDT).Datadog Inc (NASDAQ: DDOG) is a high-multiple stock and it's due to a little bit of a hit, said Cramer. He would wait for a pullback.See more from Benzinga * Cramer Shares His Thoughts On Sirius XM, Nokia And More * Cramer Weighs In On Beyond Meat, Canopy Growth, Penn National And More(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
- 07/16/2020
|
Is Boston Scientific Stock a Buy? | The Motley Fool
- Newly released products will drive revenue growth, but will they benefit shareholders?
- 07/15/2020
|
Boston Scientific Mulls Billion-Dollar Snake Venom Sale -Report
- Medical devices giant Boston Scientific Corp. (BSX) is reportedly considering selling its specialty pharmaceutical business focused on snake venom treatments.According to people with knowledge of the matter, the deal could be worth as much as $1 billion, reports Bloomberg. The publisher’s sources- who asked not to be identified- said that BSX is currently working with advisers on the potential sale. A final decision has yet to be made.Boston Scientific snapped up the niche business as part of its $4 billion BTG acquisition in 2019. Under the terms of the transaction, holders of BTG common shares received 840 pence in cash per share.BTG’s products include CroFab, a sheep-derived antivenin for crotalid envenomation, which occurs from the bite of snakes from the Crotalidae family, such as the rattle snake and copperhead snake.It is the only treatment approved by the US regulatory body for all North American pit viper snakebites in adult and pediatric patients- and according to BSX it has already been used to treated over 50,000 patients since its 2000 approval.Shares in BSX traded up 2% in Tuesday’s trading, taking the stock’s year-to-date loss to 22%. Nonetheless analysts have a bullish Strong Buy consensus on Boston Scientific’s outlook, with an average analyst price target of $44 (25% upside potential). (See Boston Scientific stock analysis on TipRanks).“BSX’s solid execution on its pipeline and acquisitions have delivered best in class sales growth and helped to diversify the company from slower end markets” commented Oppenheimer analyst Steven Lichtman recently. But he added: “Near-term pressure will be felt down the P&L; from COVID-19, though BSX has offsets in its underlying pipeline and high out-patient mix.”Related News: IMV Pops 134% In Pre-Market On “Rapid Progress” Of Covid-19 Vaccine Development Abbott Labs, Edwards Lifesciences Settle Heart Device Patent Disputes Akebia Initiates Vadadustat Study In Covid-19 Patients More recent articles from Smarter Analyst: * Walmart Leads $1.2B Funding Round For Flipkart’s E-Commerce Biz * Boeing Reports 60 Canceled Orders For The 737 Max In June * Delta Posts $2.8B Quarterly Loss, Cuts Summer Flights Amid Rise In Covid-19 Cases * Moderna Soars 16% As Covid-19 Vaccine Shows Strong Immune Response
- 07/15/2020
|
UnitedHealth Group Continues Efforts to Combat COVID-19, Reports Second Quarter Performance
- During the second quarter of 2020, UnitedHealth Group (NYSE: UNH) expanded its COVID-19 response efforts, proactively supporting patients, customers,
- 07/15/2020
|
Boston Scientific Puts Snake Venom Unit Up for Sale
- (Bloomberg) -- Boston Scientific Corp. is exploring a sale of its specialty pharmaceutical business focused on treatments for snake venom, which could fetch close to $1 billion, according to people with knowledge of the matter.The Marlborough, Massachusetts-based medical device maker is working with advisers on the potential sale, said the people, who asked to not be identified because the matter isn’t public. No final decision has been made and Boston Scientific could opt to keep the business, they said.A spokesperson for Boston Scientific declined to comment.Boston Scientific’s shares were little changed at $34.49 at 10:29 a.m. in New York, giving the company a market value of about $49.3 billion.It acquired the business in its $4.2 billion takeover of BTG Plc last year. The company is retaining the other parts of BTG’s portfolio, including liver and kidney cancer treatments.For more articles like this, please visit us at bloomberg.comSubscribe now to stay ahead with the most trusted business news source.©2020 Bloomberg L.P.
- 07/14/2020
|
IFM Investors Pty Ltd Cuts Holdings in Boston Scientific Co. (NYSE:BSX)
- IFM Investors Pty Ltd lessened its position in shares of Boston Scientific Co. (NYSE:BSX) by 25.3% in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 103,204 shares of the medical equipment provider’s stock after selling 34,915 shares during the period. […]
- 07/14/2020
|
Global $1.5B Cardiac Mapping Market, 2020 to 2025 - ResearchAndMarkets.com
|
Why These Top Medical Device Stocks Have Fallen by Double Digits So Far in 2020
- Shares of medical device makers Becton Dickinson (NYSE: BDX), Boston Scientific (NYSE: BSX), and Medtronic (NYSE: MDT) fell by double-digit percentages in the first six months of 2020, according to data provided by S&P; Global Market Intelligence. BD's shares slid 12%, Medtronic's were down 19.2%, and Boston Scientific's tumbled 22.4% during the six-month period, trailing the S&P; 500, which was only down a modest 4%. All three companies are diversified manufacturers of hundreds of different pieces of medical equipment and devices, both high- and low-tech.
- 07/11/2020
|
Were Hedge Funds Right About Piling Into Boston Scientific Corporation (BSX)?
- We know that hedge funds generate strong, risk-adjusted returns over the long run, which is why imitating the picks that they are collectively bullish on can be a profitable strategy for retail investors. With billions of dollars in assets, professional investors have to conduct complex analyses, spend many resources and use tools that are not […]
- 07/08/2020
|
Should You Buy Boston Scientific At $35?
- Despite a 38% rise since the March 23 lows of this year, at the current price of around $35 per share we believe Boston Scientific looks attractive and it has more room for growth. Boston Scientific stock has rallied from $26 to $36 off the recent bottom compared to the S&P which moved 40%...
- 07/08/2020
|
uLab Systems Announces CEO & CFO in Preparation for Aligner Launch
- uLab Systems Announces CEO & CFO in Preparation for Aligner Launch
- 07/07/2020
|
Innovation Inc: The telemedicine push and how the digital era will impact businesses and consumers
|
$10.5 Billion Neurostimulation Devices Market Assessment 2020-2026 - ResearchAndMarkets.com
|
Boston Scientific's (BSX) ICM System Receives FDA Approval
- Boston Scientific's (BSX) new ICM System gets the FDA's nod, thus paving way for better detection and treatment of arrhythmias.
- 07/03/2020
|
Global $6.3 Bn Pain Management Devices Market and Competition Analysis 2016-2026 - ResearchAndMarkets.com
|
Boston Scientific Co. (NYSE:BSX) Shares Acquired by Axa
- Axa grew its holdings in Boston Scientific Co. (NYSE:BSX) by 14.1% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 1,168,594 shares of the medical equipment provider’s stock after acquiring an additional 144,678 shares during the period. Axa owned […]
- 07/02/2020
|
MGC Pharmaceuticals : COVID-19 Clinical Trial Site Expansion into India | MarketScreener
|
FDx Advisors Inc. Sells 6,787 Shares of Boston Scientific Co. (NYSE:BSX)
- FDx Advisors Inc. trimmed its position in shares of Boston Scientific Co. (NYSE:BSX) by 39.4% during the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 10,436 shares of the medical equipment provider’s stock after selling 6,787 shares during the quarter. FDx Advisors Inc.’s holdings […]
- 07/01/2020
|
Flow Diversion Aneurysm Treatment Market 2020-2024 | Improvements in Detection of UIAs to Boost Growth | Technavio
- The Global Flow Diversion Aneurysm Treatment Market will grow by USD 1.64 bn during 2020-2024
- 07/01/2020
|
How Dedric & Krystal Polite are Building a Real Estate Empire | | IT Business Net
- LOS ANGELES, CA / ACCESSWIRE / June 30, 2020 / Dedric and Krystal Polite have come together as an absolute power couple in the world of business and real estate. With both Dedric and Krystal having ba
- 06/30/2020
|
Boston Scientific Announces Conference Call Discussing Second Quarter 2020 Financial Results
- Boston Scientific Corporation (NYSE: BSX) will webcast its conference call discussing financial results and business highlights for the second quarter ended June 30, 2020 on Wednesday, July 29, 2020 at 8:00 a.m. EDT. The call will be hosted by Mike Mahoney, chairman and chief executive officer, and Dan Brennan, executive vice president and chief financial officer. The company will issue a news release announcing financial results for the second quarter on Wednesday, July 29, 2020, prior to the conference call.
- 06/30/2020
|
A Growing List of Professional Sports Organizations, Businesses, Schools and Others Are Using VenueScreen’s Thermal Imaging Cameras and CDC- and HIPAA-Based Protocols
- Milestone: 350,000 Already Screened to Help Ensure Safe Work and Public PlacesMINNEAPOLIS & ST. PAUL, Minn. — As states reopen work and public places, a Twin Cities-based company is helpi…
- 06/30/2020
|
Worldwide Nerve Repair and Regeneration Market to 2025 - Featuring Abbott Laboratories, Baxter & Medtronic Among Others - ResearchAndMarkets.com
|
Cardiac Implantable Electronic Device Market to Surpass US$ 38,027.8 Million Globally by End of 2027, Says CMI
|
Boston Scientific Receives FDA 510(k) Clearance for the LUX-Dx™ Insertable Cardiac Monitor System
- Boston Scientific (NYSE: BSX) has received U.S. Food and Drug Administration (FDA) 510(k) clearance for the LUX-Dx™ Insertable Cardiac Monitor (ICM) System, a new, long-term diagnostic device implanted in patients to detect arrhythmias associated with conditions such as atrial fibrillation (AF), cryptogenic stroke and syncope.
- 06/29/2020
|
Cardiac Implantable Electronic Device Market to Surpass US$ 38,027.8 Million Globally by End of 2027, Says CMI
- Cardiac implantable electronic device market valued at US$ 22,576.22 million in 2020 and is expected to grow at CAGR of 7.7%.
- 06/29/2020
|
For Boston Scientific, a ‘most difficult year’ - The Boston Globe
- CEO Mike Mahoney, in his most detailed public remarks about how he is steering Boston Scientific through its biggest crisis since he became CEO in 2011, said the pandemic hasn’t been the only extraordinary challenge. The turmoil in Minneapolis also affected its employees.
- 06/28/2020
|
‘What can I do?’: 19 Black and brown business leaders want to drive a movement to end racial inequities - The Boston Globe
- The New Commonwealth Racial Equity and Social Justice Fund expects to begin issuing out grants in a few months to organizations working on racial equity and social justice matters.
- 06/28/2020
|
Global Stable Isotope Labeled Compounds Market, By Compounds, By Application, By Substances, By Indication, By Method, By End-User, By Region, Forecast & Opportunities, 2025
- This report is 80% complete and can be delivered within three working days post order confirmation and will include the latest impact analysis of Covid-19 in 2020 and forecast. Global Stable Isotope Labeled Compounds Market, By Compounds (Carbon (13C), Nitrogen(15N), Deuterium, Oxygen(18O), Others), By Application (Diagnosis, Drug Discovery, Imaging, Sterilization, Others), By Substances (Nucleic Acids, Amino Acids, Drugs/Metabolites, Fatty Acids /Lipids, NMR Solvents and Others), By Indication (Cardiology, Neurology, Inflammation, Metabolic disease and Others), By Method (Chemical, Cell-culturing), By End-User (Pharmaceutical and Biotechnology Companies, Academic Institute and Others), By Region, Forecast & Opportunities, 2025
- 06/26/2020
|
Cryosa Completes $8.25 Million in Series A-2 Funding for Further Development of Breakthrough, Minimally Invasive Treatment for Obstructive Sleep Apnea | | IT Business Net
- MEDICAL ALLEY, Minn.--(BUSINESS WIRE)--Minnesota medical device startup Cryosa completed its Series A-2 funding, raising $8.25 million to further develop its breakthrough therapies for obstructive sle
- 06/25/2020
|
Bipartisan Campaign Calls For Spring Cleaning Commissions - ValueWalk
- Our launch petition calls for "spring cleaning commissions" to recommend simplified codes to replace the bureaucratic tangle
- 06/25/2020
|
Stifel Nicolaus Reiterates Buy Rating for Boston Scientific (NYSE:BSX)
- Boston Scientific (NYSE:BSX)‘s stock had its “buy” rating reaffirmed by research analysts at Stifel Nicolaus in a report released on Wednesday, TipRanks reports. They presently have a $45.00 price target on the medical equipment provider’s stock. Stifel Nicolaus’ target price points to a potential upside of 32.94% from the company’s previous close. Several other equities […]
- 06/25/2020
|
Insights & Forecast with Potential Impact of COVID-19 - Artificial Organs Market 2020-2024 | Increasing Prevalence of Chronic Disorders to Boost Growth | Technavio
- The Global Artificial Organs Market will grow by $ 11.07 bn during 2020-2024
- 06/25/2020
|
The Global Cardiac Rhythm Management Market is expected to grow from USD 15,462.44 Million in 2019 to USD 23,862.41 Million by the end of 2025 at a Compound Annual Growth Rate (CAGR) of 7.49%
- Market Segmentation & Coverage: This research report categorizes the Cardiac Rhythm Management to forecast the revenues and analyze the trends in each of the following sub-markets:
- 06/24/2020
|
Why Sales Network Hosts First Annual, Why Sales Leadership Retreat June 25 – 26, 2020
- Founder Joyce Johnson Creates Growth Opportunities for Entrepreneurs to Pivot during the Pandemic
- 06/23/2020
|
Toshiba nomeia lista de candidatos a diretores altamente qualificada e emite carta pública para acionistas
- Toshiba Corporation (TOKYO:6502) anunciou hoje a nomeação de 11 de seus atuais diretores para reeleição ao Conselho de Administração na Assembleia Ger
- 06/23/2020
|
Toshiba nomina una lista de candidatos a directores altamente calificados; emite una carta pública para los accionistas
- Toshiba Corporation (TOKYO: 6502) anunció hoy la nominación de 11 de sus actuales directores para reelección al Directorio en la Asamblea General Ordi
- 06/22/2020
|
Zacks: Brokerages Anticipate Boston Scientific Co. (NYSE:BSX) Will Post Quarterly Sales of $1.62 Billion
- Wall Street brokerages expect Boston Scientific Co. (NYSE:BSX) to post sales of $1.62 billion for the current quarter, Zacks Investment Research reports. Seven analysts have issued estimates for Boston Scientific’s earnings, with the highest sales estimate coming in at $1.80 billion and the lowest estimate coming in at $1.31 billion. Boston Scientific reported sales of […]
- 06/21/2020
|
The Global Catheter Market is expected to grow from USD 2,717.06 Million in 2019 to USD 4,026.91 Million by the end of 2025 at a Compound Annual Growth Rate (CAGR) of 6.77%
- Market Segmentation & Coverage: This research report categorizes the Catheter to forecast the revenues and analyze the trends in each of the following sub-markets: On the basis of Product Type, the Catheter Market is studied across Cardiovascular, Intravenous, Neurovascular, and Urology.
- 06/20/2020
|
Job Openings In SoCal: Businesses Hiring Amid Coronavirus
- As unemployment remains high across California, many companies are still looking to hire.
- 06/19/2020
|
Deep Brain Stimulation Devices Market to Exhibit a CAGR of 11.6% by 2026; Rising Geriatric Population to Enable Expansion, states Fortune Business Insights™
- The global deep brain stimulation devices market size is expected to reach USD 1,676.8 million by 2026, exhibiting a CAGR of 11.6% during the forecast
- 06/19/2020
|
North American PTCA Balloon Catheters Market, Forecast to 2028 - ResearchAndMarkets.com
|
Global Market Outlook for the Fractional Flow Reserve Market to 2025, Featuring Key Players Opsens Medical, Abbott, Boston Scientific, GE Healthcare and Siemens Healthcare - ResearchAndMarkets.com
|
Bad News for Women: “The Altis Sling…Performance is Consistent with…Predicate Devices”
- Does the Altis sling, like other mini-slings, reduce the risk of obturator and pudendal neuralgia when compared to TVT-O or TOTs?
- 06/17/2020
|
Global Markets for Catheters, Needles and Cannulas (2017-2028): Major Trends, Leading Players, Supply Chain Analysis, Future Strategies - ResearchAndMarkets.com
|
DarioHealth (NASDAQ:DRIO) Receives News Impact Score of -3.53
- News articles about DarioHealth (NASDAQ:DRIO) have been trending very negative recently, according to InfoTrie Sentiment Analysis. InfoTrie identifies positive and negative press coverage by analyzing more than 6,000 news and blog sources in real time. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five […]
- 06/16/2020
|
Acessa Health Adds Three Executives to Leadership Team
- Acessa Health Inc. is proud to announce the addition of three new executive team members.
- 06/16/2020
|
Soligenix Inc. : Set To Leverage Its Milestone Filled 2019 Toward A Transformational 2020; Chief Scientific Officer Featured In PharmaVOICE Podcast | MarketScreener
|
Yogi Adityanath’s UP govt provides 51 lakh jobs under MGNREGA; tops race against job crisis
- UP government has given employment to 51 lakh workers under MGNREGA and under the rural job guarantee scheme, the state government is likely to employ over 10 lakh more workers by next week.
- 06/15/2020
|
Catheter Market Size is Projected to Witness 8.8% CAGR in Near Future: P&S Intelligence
- Around the world, the volume of interventional radiology procedures is rising, on account of being less invasive than conventional, open medical procedures,
- 06/15/2020
|
Which Stock Will Bounce Back Best: Medtronic or Boston Scientific? | The Motley Fool
- The pandemic has slowed sales for the two medical device companies. Which stock is ready to rise when medical procedures return?
- 06/14/2020
|
Industry Report: Vagus Nerve Stimulator Market Size to grow at 11.40% CAGR by 2027
- Jun 12, 2020 (Market Insight Reports) --
Selbyville, Delaware According to Market Study Report, VAGUS NERVE STIMULATOR Market provides a comprehensive...
- 06/12/2020
|
COVID-19 Impact on Wearable Medical Device Market Size, Applications, Future Trends, Share Analysis, Growth Insights and Industry Dynamics By 2023
- Jun 11, 2020 (MarketersMedia via COMTEX) --
Wearable Medical Device Market: Type (Activity Monitors, Smart Watches, Smart Clothing, Patches), Device Type...
- 06/12/2020
|
Cardiac Pacemakers Market Analysis as per the Latest COVID-19 Impact
- Jun 11, 2020 (Heraldkeepers) --
New York, June 11, 2020:You will get latest updated report as per the COVID-19 Impact on this industry. Our updated reports...
- 06/11/2020
|
Boston Scientific's Single-Use Duodenoscope Gets TPT Class Nod
- Boston Scientific's (BSX) EXALT Model D Single-Use Duodenoscope, approved for a TPT payment class by the CMS, will aid Medicare beneficiaries to enjoy the benefits of new and innovative devices.
- 06/11/2020
|
Electrophysiology Market Share, Growth to amass around US $6.5 billion by 2025
- Jun 11, 2020 (Market Insight Reports) --
Selbyville, Delaware According to Market Study Report, Has Added A New Report On Electrophysiology Market That...
- 06/11/2020
|
Human Enhancement Market Complete Market Research Report with Detailed Analysis 2019 & Forecast to 2030
- Jun 11, 2020 (Market Insight Reports) --
United States, There was a time when imaging that a person with disability, including the inability to hear, see,...
- 06/11/2020
|
Minimally Invasive & Non-Invasive Medical Imaging and Visualization Systems Market Outlook, 2020-2027 - ResearchAndMarkets.com
|
Patent Filings Roundup: WSOU Entity Leads Sustained Spike in District Court Filings, Sandoz Takes a Shot at Novo Nordisk’s Insulin treatment
- District court filings remained unusually high this week (97), with 40 Patent Trial and Appeal Board (PTAB) cases filed (one Covered Business Method, one Post Grant Review, and 38 Inter Partes Reviews).
- 06/10/2020
|
Buy Boston Scientific (BSX) Stock for Turbulent Times
- Diamond Hill Capital recently released its Q1 2020 Investor Letter, a copy of which you can download below. The Diamond Hill Small Cap Fund posted a return of -36.17% for the quarter, underperforming its benchmark, the Russell 2000 Index which returned -30.61% in the same quarter. You should check out Diamond Hill Capital's top 5 […]
- 06/10/2020
|
$10+ Billion Worldwide Electrosurgical Devices Market to 2027 - Impact of COVID-19 - ResearchAndMarkets.com
|
Worldwide Pain Management Devices Market to 2026 - Growth Opportunities In Emerging Markets - ResearchAndMarkets.com
|
BioTelemetry: Still Undervalued Despite Pandemic Headwinds (NASDAQ:BEAT)
- BioTelemetry presents a strong investment case despite being in danger of finally breaking a cycle of 30+ consecutive quarters of top line revenue growth. In fa
- 06/08/2020
|
BOSTON SCIENTIFIC CORP : Change in Directors or Principal Officers, Financial Statements and Exhibits (form 8-K) | MarketScreener
|
Tracking Ole Andreas Halvorsen's Viking Global Portfolio - Q1 2020 Update
- Halvorsen's 13F portfolio value decreased from $21.35B to $19.21B. The number of positions decreased from 66 to 64. Viking Global increased Comcast, Fidelity Na
- 06/08/2020
|
Boston Scientific Receives Approval for Medicare Transitional Pass-Through Payment for the EXALT Model D Single-Use Duodenoscope
|
Boston Scientific : Receives Medicare Transitional Pass-Through Payment for the EXALT™ Model D Single-Use Duodenoscope | MarketScreener
|
Boston Scientific Receives Medicare Transitional Pass-Through Payment for the EXALT™ Model D Single-Use Duodenoscope
- Boston Scientific (NYSE: BSX) today announced that the Centers for Medicare & Medicaid Services (CMS) has approved its application for a transitional pass-through (TPT) payment category to describe single-use endoscopes, including the EXALT™ Model D Single-Use Duodenoscope, under the Medicare hospital outpatient prospective payment system (OPPS). The intent of TPT payment is to facilitate Medicare beneficiary access to the advantages of new and innovative devices by allowing for adequate payment for these new devices while the necessary cost data is collected to incorporate the costs for these devices into the procedure Ambulatory Payment Classifications (APC) rate.
- 06/08/2020
|
Global Endoscopy Devices Market (2020 to 2025) - Industry Analysis, Market Size, Share, Trends, Application Analysis, Growth and Forecast - ResearchAndMarkets.com
|
COVID-19 Impact and Recovery Analysis - Endoscopic Closure Devices Market 2020-2024 | Growing Demand for MI Procedures to Boost Growth | Technavio
- The Global Endoscopic Closure Devices Market will grow by $ 482.04 mn during 2020-2024
- 06/04/2020
|
Boston Scientific (BSX) Launches Monitoring Tool Post FDA Nod
- Boston Scientific (BSX) introduces tool for local measurement and visualization of tissue response to RF ablation treatment in the United States.
- 06/03/2020
|
Electro-Diagnostic Devices Market Analysis as per the Latest COVID-19 Impact
- Jun 03, 2020 (Heraldkeepers) --
New York, June 3, 2020:You will get latest updated report as per the COVID-19 Impact on this industry. Our updated reports...
- 06/03/2020
|
COVID-19 Impact Cholesterol Management Devices Market
- Jun 03, 2020 (Heraldkeepers) --
New York, June 3, 2020: You will get latest updated report as per the COVID-19 Impact on this industry. Our updated reports...
- 06/03/2020
|
Global Telemonitoring Systems Market 2020-2025 - The COVID-19 Pandemic Has Resulted in a Surge in Demand for Telemonitoring Systems to Tackle Postponed Surgery Appointments - ResearchAndMarkets.com
|
Prostate Laser Surgery Market Growth Analysis By Olympus Europa SE & Co. KG, Limmer Laser GmbH, Urologix, LLC, Boston Scientific Corporation
- Jun 02, 2020 (CDN Newswire via Comtex) --
In this Prostate Laser Surgery Market report, competitor strategies are also analysed in regard of their recent...
- 06/02/2020
|
Boston Scientific Corporation (BSX) Management Presents at Jefferies 2020 Virtual Healthcare Conference (Transcript)
- Boston Scientific Corporation (NYSE:BSX) Jefferies 2020 Virtual Healthcare Conference Call June 2, 2020 08:00 ET Company Participants Joe Fitzgerald - President
- 06/02/2020
|
New Preferred Stock IPOs, May 2020
- Thirteen new preferred stocks were introduced during May offering an average annual coupon of 6.1 percent. There are currently 122 high-quality preferred stocks
- 06/02/2020
|
Aspiration And Biopsy Needles Market Clinical Demand, Production, Key Players and Forecast till 2026 : CONMED Corporation, Medtronic Plc, Olympus, Becton Dickinson
- Jun 02, 2020 (Market Insight Reports) --
Latest Industry Research Report On global Aspiration And Biopsy NeedlesMarket Research Report 2020 in-depth analysis...
- 06/02/2020
|
Minimally Invasive Devices Market Current Trends, Segmentation, Key Players and Analysis 2026
- Jun 01, 2020 (AmericaNewsHour) -- Kenneth Research has published a detailed report on Minimally Invasive Devices Market which has been categorized by market...
- 06/01/2020
|
